Optic IconOptic Logo
|
SearchCollectionsBenchmarks
Indication

Multiple Myeloma

Aliases
Recurrent Multiple Myeloma, Recurrent Plasma Cell Myeloma, Refractory Multiple Myeloma, Refractory Plasma Cell Myeloma

910 clinical trials

655 products

73 drugs

1 abstract

Clinical trial
A Phase IB Multicenter, Open-label Study To Determine The Recommended Dose And Regimen Of Durvalumab (MEDI4736) Either As Monotherapy or In Combination With Pomalidomide (POM) With Or Without Low-Dose Dexamethasone (DEX) In Subjects With Relapsed And Refractory Multiple Myeloma (RRMM)
Status: Active (not recruiting), Estimated PCD: 2018-11-23
Product
Durvalumab
Product
Pomalidomide
Product
Dexamethasone
Product
NMS-03597812
Clinical trial
ELRANATAMAB POST TRIAL ACCESS: AN OPEN-LABEL, SINGLE-ARM STUDY FOR PARTICIPANTS WITH MULTIPLE MYELOMA CONTINUING FROM PFIZER-SPONSORED ELRANATAMAB CLINICAL STUDIES
Status: Recruiting, Estimated PCD: 2031-02-22
Clinical trial
A Phase I Dose Escalation Study of NMS-03597812, a PERK Inhibitor, in Adult Patients With Relapsed or Refractory Multiple Myeloma
Status: Recruiting, Estimated PCD: 2024-06-01
Product
NMS-03597812 + Dexamethasone
Clinical trial
International, Multi-center, Open-label, Treatment Extension Study in Patients With Multiple Myeloma Who Are Still Benefitting From Isatuximab-based Therapy Following Completion of a Phase 1, 2, or 3 Parental Study
Status: Recruiting, Estimated PCD: 2026-09-21
Product
Lenalidomide
Product
ACY-1215
Product
Isatuximab
Product
Cemiplimab
Clinical trial
A Phase 1B/2 Multi-Center, Open Label, Dose-Escalation Study to Determine the Maximum Tolerated Dose, Safety, and Efficacy of ACY-1215 (RICOLINOSTAT) in Combination With Pomalidomide and Low-Dose Dexamethasone in Patients With Relapsed and Refractory Multiple Myeloma
Status: Active (not recruiting), Estimated PCD: 2024-02-29
Product
Elranatamab
Product
Daratumumab
Product
Velcade
Clinical trial
A Randomized, Multicenter, Open-label, Phase 3 Study to Compare Daratumumab, Bortezomib, and Dexamethasone (DVd) vs Bortezomib and Dexamethasone (Vd) in Chinese Subjects With Relapsed or Refractory Multiple Myeloma
Status: Active (not recruiting), Estimated PCD: 2019-10-07
Product
Zimberelimab
Product
Isatuximab IV
Clinical trial
A Phase 1/1b Study to Evaluate the Safety and Tolerability of AB308 in Combination With AB122 in Participants With Advanced Malignancies
Status: Active (not recruiting), Estimated PCD: 2025-01-01
Product
AB308
Clinical trial
Expanded Access to Venetoclax
Status:
Product
Venetoclax
Product
Carfilzomib
Clinical trial
A Phase 2 Study of Daratumumab Subcutaneous (Dara-SC) Administration in Combination With Carfilzomib and Dexamethasone (DKd) Compared With Carfilzomib and Dexamethasone (Kd) in Participants With Multiple Myeloma Who Have Been Previously Treated With Daratumumab to Evaluate Daratumumab Retreatment
Status: Terminated, Estimated PCD: 2022-10-24
Product
Dara-SC
Clinical trial
A Phase 3, Multicenter, Randomized, Open Label Study of Venetoclax and Dexamethasone Compared With Pomalidomide and Dexamethasone in Subjects With t(11;14)-Positive Relapsed or Refractory Multiple Myeloma
Status: Active (not recruiting), Estimated PCD: 2026-02-25
Product
Standard of Care
Clinical trial
A Phase 1 Study of The Safety and Tolerability of COM902 in Subjects With Advanced Malignancies
Status: Recruiting, Estimated PCD: 2024-12-30
Product
Bela
Clinical trial
A Phase 1/2 Open-label, Multicentre, Dose Escalation and Expansion Study to Investigate the Safety, Tolerability, and Clinical Activity of Belantamab as Monotherapy and in Combination With Other Treatments in Participants With Multiple Myeloma
Status: Recruiting, Estimated PCD: 2027-09-29
Product
Belamaf
Product
COM902
Product
COM902 in combination with COM701
Clinical trial
An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) in Combination With Lenalidomide and Dexamethasone (IRD) in Patients With Multiple Myeloma Previously Receiving a Bortezomib-Based Induction Regimen (US MM-6)
Status: Active (not recruiting), Estimated PCD: 2026-11-30
Product
zevor-cel
Clinical trial
Open Label, Multi-center, Phase 1b/2 Clinical Trial to Evaluate the Safety and Efficacy of Autologous CAR BCMA T Cells (CT053) in Patients With Relapsed and/or Refractory Multiple Myeloma (LUMMICAR STUDY 2)
Status: Active (not recruiting), Estimated PCD: 2024-12-31
Product
Belantamab mafodotin
Product
Pom/dex
Clinical trial
A Phase III, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of Single Agent Belantamab Mafodotin Compared to Pomalidomide Plus Lowdose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) (DREAMM 3)
Status: Active (not recruiting), Estimated PCD: 2022-09-12
Product
Ixazomib
Product
lenalidomide
Clinical trial
A Dose Escalation, Safety, Pharmacokinetic, Pharmacodynamic and Preliminary Efficacy Study of SAR650984 (Isatuximab) Administered Intravenously in Combination With Bortezomib - Based Regimens in Adult Patients With Newly Diagnosed Multiple Myeloma Non Eligible for Transplantation or No Intent for Immediate Transplantation
Status: Completed, Estimated PCD: 2022-01-28
Product
cyclophosphamide
Product
dexamethasone
Product
bb2121
Clinical trial
Characterization of Corneal Epithelial Changes in Participants Treated With Belantamab Mafodotin (GSK2857916)
Status: Terminated, Estimated PCD: 2022-11-21
Product
bortezomib
Clinical trial
A Phase II Trial of Daratumumab, Lenalidomide and Dexamethasone (DRd) in Combination With Selinexor for Patients With Newly Diagnosed Multiple Myeloma
Status: Recruiting, Estimated PCD: 2026-05-31
Clinical trial
A Multicenter, Randomized, Open-label Phase 2 Study Evaluating the Safety and Efficacy of Three Different Regimens of Oral Panobinostat in Combination With Subcutaneous Bortezomib and Oral Dexamethasone in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma Who Have Been Previously Exposed to Immunomodulatory Agents
Status: Completed, Estimated PCD: 2019-10-18
Product
AEVI-007
Clinical trial
Open Label, Multicenter, Long-Term Follow-Up Study for Subjects Treated With P-BCMA-101
Status: Active (not recruiting), Estimated PCD: 2032-08-01
Clinical trial
A Multicenter Phase 2 Study to Evaluate Subcutaneous Daratumumab in Combination With Standard Multiple Myeloma Treatment Regimens
Status: Active (not recruiting), Estimated PCD: 2020-08-12
Clinical trial
Study of EOS884448 Alone, and in Combination With Iberdomide With or Without Dexamethasone, in Participants With Relapsed or Refractory Multiple Myeloma
Status: Terminated, Estimated PCD: 2023-11-29
Product
Iberdomide
Clinical trial
First-in-Human Study of the BCL-2 Inhibitor ABBV-453 in Biomarker-Selected Subjects With Relapsed or Refractory Multiple Myeloma
Status: Recruiting, Estimated PCD: 2026-08-28
Product
Prednisone
Clinical trial
A Phase 2, Multicenter Study to Determine the Efficacy and Safety of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma
Status: Completed, Estimated PCD: 2023-12-20
Product
EOS884448
Product
COM902 + COM701
Clinical trial
A Randomized, Phase 3, Open Label Study Evaluating Subcutaneous Versus Intravenous Administration of Isatuximab in Combination With Pomalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM)
Status: Recruiting, Estimated PCD: 2024-05-23
Clinical trial
A Phase 1 First in Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 224 in Subjects With Relapsed or Refractory Multiple Myeloma
Status: Completed, Estimated PCD: 2018-11-30
Product
Pomalyst
Product
AMG 224
Clinical trial
A Phase 2, Open-Label, Multicenter Study of BMS-986393, a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma (QUINTESSENTIAL)
Status: Recruiting, Estimated PCD: 2026-10-02
Clinical trial
A Multicenter, Open-Label, Dose-Escalation Phase 1b Study of AEVI-007 in Subjects With Relapsed or Refractory Multiple Myeloma
Status: Completed, Estimated PCD: 2022-03-30
Clinical trial
A Phase 1 Study of ANV419 as Monotherapy, and ANV419 in Combination With Daratumumab or With Lenalidomide Plus Low-Dose Dexamethasone, in Patients With Relapsed or Refractory Multiple Myeloma (OMNIA-2)
Status: Terminated, Estimated PCD: 2023-07-12
Product
Selinexor
Clinical trial
A Phase II, Open Label, Randomized, Two-Arm Study to Investigate the Efficacy and Safety of Two Doses of the Antibody Drug Conjugate GSK2857916 in Participants With Multiple Myeloma Who Had 3 or More Prior Lines of Treatment, Are Refractory to a Proteasome Inhibitor and an Immunomodulatory Agent and Have Failed an Anti-CD38 Antibody (DREAMM 2)
Status: Active (not recruiting), Estimated PCD: 2019-06-21
Product
KQ-2003
Clinical trial
A Phase I Trial of Selinexor, Ruxolitinib and Methylprednisolone for Patients With Relapsed/Refractory Multiple Myeloma
Status: Not yet recruiting, Estimated PCD: 2027-04-01
Clinical trial
A Double-Blind, Randomized Clinical Study of the Efficacy and Safety of Monotherapy With BCD-264 and Darzalex® in Subjects With Relapsed and Refractory Multiple Myeloma
Status: Recruiting, Estimated PCD: 2025-01-01
Product
Darzalex
Product
Ruxolitinib
Product
Methylprednisolone
Clinical trial
A Phase 1/2a Study to Evaluate the Safety, Tolerability, Preliminary Efficacy, and Pharmacokinetic Characterization of KQ-2003 for Patients With Relapsed/Refractory Multiple Myeloma
Status: Recruiting, Estimated PCD: 2026-03-31
Product
BMS-986393
Clinical trial
DREAMM 7: A Multicenter, Open-Label, Randomized Phase III Study to Evaluate the Efficacy and Safety of the Combination of Belantamab Mafodotin, Bortezomib, and Dexamethasone (B-Vd) Compared With the Combination of Daratumumab, Bortezomib and Dexamethasone (D-Vd) in Participants With Relapsed/Refractory Multiple Myeloma
Status: Active (not recruiting), Estimated PCD: 2023-10-02
Clinical trial
Phase I, Open Label, Study of B-cell Maturation Antigen (BCMA)-Directed CAR-T Cells in Adult Patients With Multiple Myeloma
Status: Active (not recruiting), Estimated PCD: 2026-02-19
Product
PHE885
Clinical trial
A Phase 1 Study of SG301 in Subjects With Hematological Malignancies
Status: Active (not recruiting), Estimated PCD: 2024-06-30
Product
CC-92328
Product
BCD-264
Clinical trial
Comparative Effectiveness of Elranatamab (PF-06863135) in Clinical Study C1071003 Versus Standard of Care (SOC) in Real-World (RW) External Control Arms in Patients With Triple-Class Refractory (TCR) Multiple Myeloma (MM)
Status: Completed, Estimated PCD: 2023-07-12
Product
Standard of care
Clinical trial
A Multicenter, Phase 1b, Open-label Study of ABBV-383 Administered Subcutaneously in Subjects With Relapsed or Refractory Multiple Myeloma
Status: Not yet recruiting, Estimated PCD: 2027-02-14
Product
ABBV-383
Clinical trial
A Phase 1, Multi-center, Open-label, Dose Finding Study of CC-92328 in Subjects With Relapsed and/or Refractory Multiple Myeloma
Status: Active (not recruiting), Estimated PCD: 2025-07-01
Product
SG301
Clinical trial
A Phase 1/2, Open-Label, Multicenter Study of INCB000928 Administered as a Monotherapy in Participants With Anemia Due to Myelodysplastic Syndromes or Multiple Myeloma
Status: Active (not recruiting), Estimated PCD: 2024-09-21
Product
Panobinostat
Product
Bortezomib
Product
INCB000928
Product
COM902 + COM701 + Pembrolizumab
Product
Rimiducid
Product
ANV419
Product
Melphalan
Product
UTAA17
Clinical trial
Single-arm, Open-label, Early-stage Clinical Study of UTAA17 Injection in the Treatment of Relapsed/Refractory Multiple Myeloma
Status: Recruiting, Estimated PCD: 2027-04-01
Product
ABBV-453
Clinical trial
Open-Label, Multicenter, Phase 1 Study to Assess the Safety of P-BCMA-ALLO1 in Subjects With Relapsed / Refractory Multiple Myeloma (MM)
Status: Recruiting, Estimated PCD: 2027-12-01
Product
P-BCMA-ALLO1 CAR-T cells
Clinical trial
LUMT1A22, Phase 1 Study of BAFF CAR T Cells (LMY-920) for Treatment of Relapsed or Refractory Myeloma (LMY-920-002)
Status: Recruiting, Estimated PCD: 2025-07-31
Clinical trial
A Dose Escalation and Expansion Study of ABBV-383 in Combination With Anti-Cancer Regimens for the Treatment of Patients With Relapsed/Refractory Multiple Myeloma
Status: Recruiting, Estimated PCD: 2028-11-29
Clinical trial
A Phase I Study of FT576 as Monotherapy and in Combination With Daratumumab in Subjects With Relapsed/Refractory Multiple Myeloma
Status: Recruiting, Estimated PCD: 2024-09-01
Product
Fludarabine
Product
Bendamustine
Product
Autologous CAR-T cell therapy
Clinical trial
A PHASE 1/2, OPEN-LABEL, MULTICENTER STUDY TO EVALUATE A DOSING REGIMEN WITH TWO STEP-UP PRIMING DOSES AND LONGER DOSING INTERVALS OF ELRANATAMAB (PF-06863135) MONOTHERAPY IN PARTICIPANTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
Status: Active (not recruiting), Estimated PCD: 2023-06-15
Product
Nirogacestat
Clinical trial
A Phase 2 Study of Venetoclax in Combination With Isatuximab and Dexamethasone for Relapsed/Refractory Multiple Myeloma Patients With t(11;14)
Status: Not yet recruiting, Estimated PCD: 2026-03-31
Product
Cyclophosphamide
Product
TQB2934
Product
JNJ-79635322
Product
Descartes-25
Clinical trial
Phase I/IIa Study of Descartes-25 in Patients With Relapsed/Refractory Multiple Myeloma
Status: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
A Phase 2, Multi-cohort, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma and in Subjects With Clinical High-Risk Multiple Myeloma (KarMMa-2)
Status: Recruiting, Estimated PCD: 2025-07-31
Product
Talquetamab
Clinical trial
A Phase I Clinical Trial Evaluating the Tolerance and Pharmacokinetics of TQB2934 for Injection in Multiple Myeloma Subjects
Status: Recruiting, Estimated PCD: 2024-10-01
Clinical trial
A Phase I/II Study of Isatuximab (Anti-CD38 mAb) Administered as a Single Agent in Japanese Patients With Relapsed and Refractory Multiple Myeloma
Status: Completed, Estimated PCD: 2018-07-31
Clinical trial
Phase 1, First-in-Human, Dose Escalation Study of JNJ-79635322, a Trispecific Antibody, in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated AL Amyloidosis
Status: Recruiting, Estimated PCD: 2025-04-18
Product
Lenalomide
Product
ION251
Clinical trial
A Phase 1 First-in-human Dose-escalation and Dose-expansion Study of BMF-219, an Oral Covalent Menin Inhibitor, in Adult Patients With Acute Leukemia (AL), Diffuse Large B-cell Lymphoma (DLBCL), Multiple Myeloma (MM), and Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL)
Status: Recruiting, Estimated PCD: 2024-12-31
Clinical trial
A Phase 1 Study of ION251 Administered by Intravenous Infusion to Patients With Relapsed/Refractory Multiple Myeloma
Status: Active (not recruiting), Estimated PCD: 2024-01-01
Product
FT576
Clinical trial
A Phase I/II, Randomized, Open-label Platform Study Utilizing a Master Protocol to Study Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Anti-Cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) - DREAMM 5
Status: Recruiting, Estimated PCD: 2026-02-24
Product
Feladilimab
Clinical trial
Treatment of Patients With Relapsed/Refractory Multiple Myeloma With Ruxolitinib, Methylprednisolone and Lenalidomide: Using Changes in Serum B-Cell Maturation Antigen (BCMA) or International Multiple Working Group (IMWG) Criteria to Determine Disease Progression in Order to Add Lenalidomide to Those Failing the Ruxolitinib/Methylprednisolone Combination
Status: Not yet recruiting, Estimated PCD: 2026-05-01
Product
GSK3174998
Product
Dostarlimab
Clinical trial
A Phase 1, Multicenter, Open-Label Study of CC-95266 in Subjects With Relapsed and/or Refractory Multiple Myeloma
Status: Active (not recruiting), Estimated PCD: 2025-06-07
Product
CC-95266
Clinical trial
ELRANATAMAB (PF-06863135) MONOTHERAPY EXPANDED ACCESS PROTOCOL FOR TREATMENT OF PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA WHO ARE REFRACTORY TO AT LEAST ONE PROTEASOME INHIBITOR, ONE IMMUNOMODULATORY DRUG AND ONE ANTI-CD38 ANTIBODY AND HAVE NO ACCESS TO OTHER COMPARABLE/ALTERNATIVE THERAPY
Status:
Product
BMF-219
Clinical trial
A Phase III, Randomized, Placebo-Controlled, Multi-Centre Study Evaluating the Safety, Tolerability and Efficacy of Combination Treatment of BL-8040 and G-GSF as Compared to Placebo and G-CSF for the Mobilization of Hematopoietic Stem Cells for Autologous Transplantation in Subjects With Multiple Myeloma - The GENESIS Study
Status: Active (not recruiting), Estimated PCD: 2020-12-22
Product
Placebo
Product
BL-8040
Clinical trial
An Open-label, Phase 2 Study Treating Subjects With First or Second Relapse of Multiple Myeloma With Carfilzomib, Pomalidomide, and Dexamethasone (KPd)
Status: Active (not recruiting), Estimated PCD: 2022-11-30
Clinical trial
A Phase 1b Open-label Study to Evaluate the Safety and Tolerability of Intravenous Modakafusp Alfa as Part of Combination Therapy in Adult Patients With Multiple Myeloma
Status: Active (not recruiting), Estimated PCD: 2025-07-24
Product
Modakafusp
Clinical trial
A Multicenter, Phase 1b, Open-label Study to Evaluate Dose Optimization Measures and Safety of ABBV-383 in Subjects With Relapsed or Refractory Multiple Myeloma
Status: Recruiting, Estimated PCD: 2026-07-12
Clinical trial
A Prospective, Non-interventional, Multinational, Observational Study With Isatuximab in Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM)
Status: Recruiting, Estimated PCD: 2026-02-23
Clinical trial
A Phase 2b, Open-label Study of Selinexor Plus Low-dose Dexamethasone (Sd) in Patients With Penta-refractory Multiple Myeloma (MM), Selinexor and Bortezomib Plus Low-dose Dexamethasone (SVd) in Patients With Triple-class Refractory MM, and Selinexor and Pomalidomide Plus Low-dose Dexamethasone (SPd) in Patients With Relapsed Refractory MM.
Status: Recruiting, Estimated PCD: 2024-06-30
Product
Maplirpacept
Clinical trial
A PHASE I, OPEN LABEL STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND PHARMACOKINETICS OF TTI-622 (PF-07901801), A SINGLE AGENT IN JAPANESE PARTICIPANTS WITH RELAPSED OR REFRACTORY LYMPHOMA
Status: Active (not recruiting), Estimated PCD: 2024-07-10
Clinical trial
A Phase 3 Study to Evaluate Zimberelimab (AB122) Combined With AB154 in Front-Line, PD-L1-High, Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Status: Active (not recruiting), Estimated PCD: 2024-08-31
Product
anitocabtagene-autoleucel
Product
ARC-T Plus Anti-BCMA SparX
Clinical trial
A Phase Ⅰ/Ⅱ Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of MBS314 Injection in Patients With Relapsed/Refractory Multiple Myeloma.
Status: Recruiting, Estimated PCD: 2026-02-01
Product
CT071
Clinical trial
An Open-Label, Multicenter, Phase 1b Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Regimens for the Treatment of Subjects With Multiple Myeloma
Status: Completed, Estimated PCD: 2019-01-31
Clinical trial
A Phase 1/2 Open Label Study to Evaluate the Safety and Efficacy of CT071, an Autologous Anti-GPRC5D CAR T, in Relapsed/Refractory Multiple Myeloma (RRMM) or Relapsed/Refractory Primary Plasma Cell Leukemia (RRpPCL)
Status: Not yet recruiting, Estimated PCD: 2027-06-15
Product
MBS314
Clinical trial
A Randomized, Open-label, Phase 3 Study Comparing Carfilzomib, Dexamethasone, and Daratumumab to Carfilzomib and Dexamethasone for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma
Status: Completed, Estimated PCD: 2019-07-14
Product
Thalidomide
Product
Acetaminophen
Product
Diphenhydramine
Product
Montelukast
Clinical trial
A PHASE 1B/2, OPEN LABEL UMBRELLA STUDY OF ELRANATAMAB (PF-06863135), A B-CELL MATURATION ANTIGEN (BCMA) CD3 BISPECIFIC ANTIBODY, IN COMBINATION WITH OTHER ANTI-CANCER TREATMENTS IN PARTICIPANTS WITH MULTIPLE MYELOMA
Status: Recruiting, Estimated PCD: 2025-08-16
Clinical trial
A Phase 3, Randomized, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Alnuctamab Compared to Standard of Care Regimens in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) - ALUMMINATE RRMM
Status: Not yet recruiting, Estimated PCD: 2025-11-16
Clinical trial
An Open-Label, Multicenter, Phase 2 Study of Iopofosine I 131 (CLR 131) in Patients With Relapsed or Refractory (R/R) Select B-Cell Malignancies (CLOVER-1) and Expansion Cohort in Patients With Waldenstrom Macroglobulinemia (CLOVER-WaM)
Status: Recruiting, Estimated PCD: 2024-11-30
Product
Triplet combination of COM902 + COM701 + Pembrolizumab
Product
AMG 176
Clinical trial
A Global, Open-Label, Multicenter, Phase 1/2 Study of the Safety and Dose Escalation of BAX 888, an Adeno-Associated Virus Serotype 8 (AAV8) Vector Expressing B-Domain Deleted Factor VIII (BDD-FVIII) in Severe Hemophilia A Subjects Administered a Single Intravenous Infusion
Status: Active (not recruiting), Estimated PCD: 2025-04-24
Product
Itraconazole
Product
Iopofosine I 131
Product
Modakafusp alfa
Clinical trial
A Phase 1/2 Open-label Study to Investigate the Safety and Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of Modakafusp Alfa (TAK-573) as a Single Agent in Patients With Relapsed Refractory Multiple Myeloma
Status: Active (not recruiting), Estimated PCD: 2024-03-19
Product
Elranatamab + Lenalidomide + Dexamethasone
Product
Azacitidine
Clinical trial
AN OPEN-LABEL, PHASE 1 STUDY EVALUATING THE PHARMACOKINETICS, SAFETY AND ANTI-TUMOR ACTIVITY OF PF-07901801 (TTI-622) MONOTHERAPY IN CHINESE PARTICIPANTS WITH ADVANCED HEMATOLOGIC MALIGNANCIES
Status: Recruiting, Estimated PCD: 2025-02-26
Clinical trial
An Expanded Access Program for Elotuzumab in Combination With Lenalidomide Plus Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma in Japan
Status:
Product
PF-06863135
Clinical trial
MAGNETISMM-1 A PHASE I, OPEN LABEL STUDY TO EVALUATE THE SAFETY, PHARMACOKINETIC, PHARMACODYNAMIC AND CLINICAL ACTIVITY OF ELRANATAMAB (PF-06863135), A B-CELL MATURATION ANTIGEN (BCMA) - CD3 BISPECIFIC ANTIBODY, AS A SINGLE AGENT AND IN COMBINATION WITH IMMUNOMODULATORY AGENTS IN PATIENTS WITH RELAPSED/REFRACTORY ADVANCED MULTIPLE MYELOMA (MM)
Status: Completed, Estimated PCD: 2024-01-19
Product
PF-06863135 + lenalidomide
Product
Elotuzumab
Product
PF-06863135 + Dexamethasone
Product
PF-06863135 + Pomalidomide
Clinical trial
A Phase 1 Open-Label, Multi-Center First in Human Study of TnMUC1-Targeted Genetically-Modified Chimeric Antigen Receptor T Cells in Patients With Advanced TnMUC1-Positive Solid Tumors and Multiple Myeloma
Status: Terminated, Estimated PCD: 2022-12-02
Product
CART-TnMUC1
Clinical trial
A Phase 3, Multicenter, Randomized, Open Label Study of ABBV-383 Compared With Standard Available Therapies in Subjects With Relapsed or Refractory Multiple Myeloma (3L+ RRMM Monotherapy Study)
Status: Not yet recruiting, Estimated PCD: 2027-12-06
Clinical trial
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
Status: Active (not recruiting), Estimated PCD: 2025-05-27
Product
CART-BCMA
Product
G-CSF
Clinical trial
A Phase 3 Randomized, Open-label, Multicenter Study Assessing the Clinical Benefit of Isatuximab (SAR650984) in Combination With Bortezomib (Velcade®), Lenalidomide and Dexamethasone Versus Bortezomib, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
Status: Active (not recruiting), Estimated PCD: 2026-04-05
Product
P-BCMA-ALLO1
Clinical trial
A PHASE 1B, OPEN-LABEL STUDY OF ELRANATAMAB IN COMBINATION WITH IBERDOMIDE IN PARTICIPANTS WITH RELAPSED REFRACTORY MULTIPLE MYELOMA
Status: Recruiting, Estimated PCD: 2027-04-10
Clinical trial
MAGNETISMM-6: AN OPEN-LABEL, 2-ARM, MULTICENTER, RANDOMIZED PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ELRANATAMAB (PF-06863135) + DARATUMUMAB + LENALIDOMIDE VERSUS DARATUMUMAB + LENALIDOMIDE + DEXAMETHASONE IN TRANSPLANT-INELIGIBLE PARTICIPANTS WITH NEWLY-DIAGNOSED MULTIPLE MYELOMA
Status: Recruiting, Estimated PCD: 2028-03-31
Clinical trial
Comparative Effectiveness of Elranatamab (PF 06863135) in Clinical Study C1071003 Versus Standard of Care (SOC) in Real-World (RW) External Control Arms in Patients With Triple-Class Refractory (TCR) Multiple Myeloma (MM)
Status: Completed, Estimated PCD: 2022-11-04
Clinical trial
An Open-label Phase I/IIa Study to Evaluate the Safety and Efficacy of CCS1477 as Monotherapy and in Combination in Patients With Advanced Haematological Malignancies.
Status: Recruiting, Estimated PCD: 2025-06-30
Clinical trial
A Phase I/II Single Arm Open-Label Study to Explore Safety and Clinical Activity of GSK2857916 Administered in Combination With Pembrolizumab in Subjects With Relapsed/Refractory Multiple Myeloma (DREAMM 4)
Status: Completed, Estimated PCD: 2021-10-18
Product
Pembrolizumab
Clinical trial
An Open-label, Multicenter, Dose Escalation Phase 1b Study to Assess the Safety and Pharmacokinetics of Subcutaneous Delivery of Daratumumab With the Addition of Recombinant Human Hyaluronidase (rHuPH20) for the Treatment of Subjects With Relapsed or Refractory Multiple Myeloma
Status: Completed, Estimated PCD: 2017-12-13
Product
Recombinant Human Hyaluronidase
Clinical trial
Phase 3 Study Comparing Daratumumab, Bortezomib and Dexamethasone (DVd) vs Bortezomib and Dexamethasone (Vd) in Subjects With Relapsed or Refractory Multiple Myeloma
Status: Completed, Estimated PCD: 2016-01-11
Clinical trial
A RANDOMIZED, 2-ARM, PHASE 3 STUDY OF ELRANATAMAB (PF-06863135) VERSUS LENALIDOMIDE IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA AFTER UNDERGOING AUTOLOGOUS STEM-CELL TRANSPLANTATION
Status: Recruiting, Estimated PCD: 2027-08-04
Product
WVT078
Clinical trial
A Phase I, Open-label, Multicenter, Study of WVT078 in Subjects With Relapsed and/or Refractory Multiple Myeloma
Status: Active (not recruiting), Estimated PCD: 2024-11-29
Product
MIK665
Product
Linvoseltamab
Product
Cilta-cel
Product
CFT7455
Clinical trial
A Phase 1/2 Open-Label Multi-Center Study to Characterize the Safety and Tolerability of CFT7455 in Subjects With Relapsed/Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma
Status: Recruiting, Estimated PCD: 2025-09-07
Clinical trial
A Multicenter, Open-label, Phase I/II Study to Investigate the Safety and Tolerability of SyB L-0501RI (Bendamustine Hydrochloride for Injection) Administered As an Intravenous (IV) Rapid Infusion Over 10 Minutes
Status: Completed, Estimated PCD: 2020-09-09
Clinical trial
A Phase III Randomized, Controlled, Multicenter, Open-label Study of ATG-010, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)
Status: Active (not recruiting), Estimated PCD: 2024-07-15
Product
CC-99712
Clinical trial
A Phase 1, Multicenter, Open-label, Dose Finding Study of CC-99712, a BCMA Antibody-Drug Conjugate, in Subjects With Relapsed and Refractory Multiple Myeloma
Status: Active (not recruiting), Estimated PCD: 2024-08-23
Product
VELCADE
Clinical trial
A Phase I Clinical Trial to Evaluate CART-BCMA in Patients With Relapsed and/or Refractory Multiple Myeloma
Status: Active (not recruiting), Estimated PCD: 2022-07-31
Product
Melflufen
Product
Alnuctamab
Clinical trial
Incidence of Hyperpigmentation in Black Patients With Multiple Myeloma Treated With Immunomodulatory Drugs
Status: Active (not recruiting), Estimated PCD: 2024-04-30
Clinical trial
A Single-center, Prospective, Single-arm Clinical Study of All-trans Retinoic Acid in Combination With a KPD Regimen for the Treatment of Refractory/Relapsed Multiple Myeloma (MM)
Status: Recruiting, Estimated PCD: 2025-12-31
Product
All-trans Retinoic Acid
Clinical trial
MAGNETISMM-3 AN OPEN-LABEL, MULTICENTER, NON-RANDOMIZED PHASE 2 STUDY OF ELRANATAMAB (PF-06863135) MONOTHERAPY IN PARTICIPANTS WITH MULTIPLE MYELOMA WHO ARE REFRACTORY TO AT LEAST ONE PROTEASOME INHIBITOR, ONE IMMUNOMODULATORY DRUG AND ONE ANTI-CD38 ANTIBODY
Status: Active (not recruiting), Estimated PCD: 2022-06-17
Product
VOB560
Clinical trial
A Phase Ib, Multicenter Study of VOB560 in Combination With MIK665 in Patients With Relapsed/Refractory Non-Hodgkin Lymphoma, Relapsed/Refractory Acute Myeloid Leukemia, or Relapsed/Refractory Multiple Myeloma.
Status: Active (not recruiting), Estimated PCD: 2024-08-02
Product
CC-220
Clinical trial
Phase 1/2 FIH Study of REGN5458 (Anti-BCMA x Anti-CD3 Bispecific Antibody) in Patients With Relapsed or Refractory Multiple Myeloma
Status: Recruiting, Estimated PCD: 2032-05-04
Clinical trial
A Phase I/II, Open-label, Multicenter Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of Anti-GPRC5D CAR-T Cell Product (OriCAR-017) in Subjects With Relapsed/Refractory Multiple Myeloma.
Status: Recruiting, Estimated PCD: 2026-12-12
Product
Autologous CAR-T cell therapy expressing the BAFF-ligand
Clinical trial
A Phase 1b/2a Multicenter, Open-label, Dose-escalation Study to Determine the Maximum Tolerated Dose, Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of CC-220 as Monotherapy and in Combination With Other Treatments in Subjects With Multiple Myeloma
Status: Active (not recruiting), Estimated PCD: 2024-04-30
Product
Belantamab Mafodotin
Product
BMS-986405
Product
Isatuximab SC
Product
WHG626
Product
Lymphodepleting Therapy
Clinical trial
A Safety and Efficacy Study of JNJ-68284528 (Ciltacabtagene Autoleucel) Out-of-Specification (OOS) for Commercial Release in Patients With Multiple Myeloma
Status: Completed, Estimated PCD: 2023-11-30
Clinical trial
A Randomized, Controlled, Open-label, Phase 3 Study of Melflufen/Dexamethasone Compared With Pomalidomide/Dexamethasone for Patients With Relapsed Refractory Multiple Myeloma Who Are Refractory to Lenalidomide
Status: Terminated, Estimated PCD: 2021-02-03
Product
IMiD treatment
Product
IMiD
Product
Systemic therapy
Product
Elranatamab + Nirogacestat
Clinical trial
First-in-human, Open-label Phase 1/2 Study to Investigate Safety and Efficacy of SAR445514, an NKcell Engager (NKCE) Targeting B-cell Maturation Antigen (BCMA) in Monotherapy in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) and in Relapsed/Refractory Light-chain Amyloidosis (RRLCA)
Status: Recruiting, Estimated PCD: 2026-04-29
Product
SAR445514
Product
CCS1477
Product
PF-06863135 monotherapy
Product
PF-06863135 + Lenalidomide
Product
OriCAR-017
Product
SVd
Product
Vd
Clinical trial
Empliciti® (Elotuzumab) Post-Marketing Surveillance Study for Patients With Multiple Myeloma in Taiwan
Status: Recruiting, Estimated PCD: 2025-06-30
Clinical trial
A Phase I/II, Randomized, Open-label Platform Study Utilizing a Master Protocol to Study Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Anti-Cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)-DREAMM5. Sub-study 1 - Belantamab Mafodotin and aOX40 (GSK3174998) in Combination
Status: Terminated, Estimated PCD: 2023-01-09
Product
DARZALEX
Product
Cevostamab
Clinical trial
A Phase I/II, Open-Label, Multi-Cohort Study to Evaluate the Efficacy and Safety of Cevostamab in Prior B Cell Maturation Antigen-Exposed Patients With Relapsed/Refractory Multiple Myeloma
Status: Recruiting, Estimated PCD: 2027-02-26
Product
Tocilizumab
Clinical trial
A Phase 3, Randomized, Controlled, Open-label Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination With VMP (D-VMP), in Subjects With Previously Untreated Multiple Myeloma Who Are Ineligible for High-dose Therapy
Status: Active (not recruiting), Estimated PCD: 2017-11-21
Clinical trial
A Phase 2, Open-Label, Multi-Center Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
Status: Active (not recruiting), Estimated PCD: 2027-06-22
Clinical trial
A Phase 3 Randomized, Multicenter Study of Subcutaneous vs. Intravenous Administration of Daratumumab in Subjects With Relapsed or Refractory Multiple Myeloma
Status: Completed, Estimated PCD: 2019-06-27
Clinical trial
An Open-Label, Multicenter, Phase Ib Trial Evaluating the Safety, Pharmacokinetics, and Activity of the Combination of Cevostamab and Elranatamab in Patients With Relapsed or Refractory Multiple Myeloma
Status: Recruiting, Estimated PCD: 2026-07-31
Product
EZM0414
Clinical trial
A Multi-center, Open-label, Phase 1b Study to Assess the Pharmacokinetics, Safety, and Efficacy of Subcutaneous and Intravenous Isatuximab (SAR650984) in Combination With Pomalidomide and Dexamethasone, in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)
Status: Completed, Estimated PCD: 2024-03-27
Product
pomalidomide
Product
HLX15
Clinical trial
A Platform Study Evaluating the Safety and Efficacy of Multiple Treatments in Patients With Multiple Myeloma
Status: Recruiting, Estimated PCD: 2026-03-16
Clinical trial
An Open-Label, Multicenter, Phase Ib Trial Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab as Monotherapy and Cevostamab Plus Pomalidomide and Dexamethasone or Cevostamab Plus Daratumumab and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
Status: Recruiting, Estimated PCD: 2024-09-11
Clinical trial
Continuing Treatment for Subjects Who Have Participated in a Prior Protocol Investigating Elotuzumab
Status: Active (not recruiting), Estimated PCD: 2024-06-28
Product
Nivolumab
Clinical trial
A Phase 2 Multi-Arm Study of Magrolimab Combinations in Patients With Relapsed/Refractory Multiple Myeloma
Status: Active (not recruiting), Estimated PCD: 2024-12-01
Product
LBL-034
Clinical trial
A Single-arm, Open-label, Phase 2 Study Evaluating Subcutaneous Administration of Isatuximab, Administered by an On Body Delivery System, in Combination With Weekly Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma (RRMM)
Status: Not yet recruiting, Estimated PCD: 2027-01-08
Product
Mezigdomide
Clinical trial
A Phase 1b/2a, Multicenter, Open-label Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Alnuctamab in Combination With Mezigdomide in Participants With Relapsed and/or Refractory Multiple Myeloma
Status: Recruiting, Estimated PCD: 2032-02-13
Clinical trial
A Phase 3 Randomized, Open Label, Multicenter Study of Isatuximab (SAR650984) in Combination With Lenalidomide and Dexamethasone Versus Lenalidomide and Dexamethasone in Patients With High-risk Smoldering Multiple Myeloma
Status: Active (not recruiting), Estimated PCD: 2030-11-11
Clinical trial
An Exploratory Phase 1b/2a Multicenter, Open-Label, Novel-Novel Combination Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of CC-92480 (BMS-986348) in Novel Therapeutic Combinations in Participants With Relapsed or Refractory Multiple Myeloma
Status: Recruiting, Estimated PCD: 2026-10-12
Product
Tazemetostat
Product
BMS-986158
Clinical trial
Randomized, Open Label, Multicenter Study Assessing The Clinical Benefit Of Isatuximab Combined With Carfilzomib (Kyprolis®) And Dexamethasone Versus Carfilzomib With Dexamethasone In Patients With Relapse And/Or Refractory Multiple Myeloma Previously Treated With 1 to 3 Prior Lines
Status: Active (not recruiting), Estimated PCD: 2022-01-14
Product
carfilzomib
Clinical trial
A Phase I Open-label, Dose Escalation Study to Investigate the Safety, Tolerability, Pharmacokinetics, Immunogenicity and Clinical Activity of the Antibody Drug Conjugate GSK2857916 in Chinese Participants With Relapsed/Refractory Multiple Myeloma Who Have Failed At Least Two Lines of Previous Treatment, Containing an Alkylator, a Proteasome Inhibitor and an Immunomodulatory Agent
Status: Completed, Estimated PCD: 2022-12-30
Product
Dara
Clinical trial
A Phase 1/1b, Open-Label, Multi-Center, Two-Part Study of SETD2 Inhibitor EZM0414 in Subjects With Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Status: Recruiting, Estimated PCD: 2024-12-30
Product
Isatuximab SAR650984
Product
SIM0500
Clinical trial
A Phase I Study to Compare the Pharmacokinetic Characteristics, Safety, Tolerability, and Immunogenicity (Randomized, Double-blind, Parallel Controlled) of HLX15 With Daratumumab Injection in Healthy Chinese Male Subjects
Status: Active (not recruiting), Estimated PCD: 2024-03-16
Product
Magrolimab
Product
TJ202
Product
Lenalidomide and Dexamethasone
Clinical trial
A Phase 3, Randomized, Open-label, Parallel-controlled, Multi-center Study Comparing TJ202, Lenalidomide and Dexamethasone vs. Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma Who Received at Least 1 Prior Line of Treatment
Status: Active (not recruiting), Estimated PCD: 2024-05-31
Clinical trial
An Open-Label, Multicenter, Phase I Trial Evaluating the Safety and Pharmacokinetics of Escalating Doses of Cevostamab (BFCR4350A) in Patients With Relapsed or Refractory Multiple Myeloma
Status: Recruiting, Estimated PCD: 2025-12-31
Clinical trial
Phase 1/2 Study of Linvoseltamab (Anti-BCMA X Anti-CD3 Bispecific Antibody) in Previously Untreated Patients With Symptomatic Multiple Myeloma
Status: Recruiting, Estimated PCD: 2035-11-02
Clinical trial
An Open-Label, Multicenter Phase 1b Study Investigating the Safety of TAK-079 in Combination With Backbone Regimens for the Treatment of Patients With Newly Diagnosed Multiple Myeloma and for Whom Stem Cell Transplantation Is Not Planned as Initial Therapy
Status: Active (not recruiting), Estimated PCD: 2025-02-23
Product
Placebo + G-CSF
Product
TAK-079
Clinical trial
A Phase 1, Multicenter, Open-label Study to Evaluate the Safety and Preliminary Efficacy of BMS-986393 in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma and Determine the Recommended Dose for Each Add-on Investigational Component
Status: Recruiting, Estimated PCD: 2028-08-01
Clinical trial
A Phase I First-in-human, Open-label Trial to Investigate the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of SIM0500, A Humanized GPRC5D-BCMA-CD3 Tri-specific Antibody, in Participants With Relapsed or Refractory Multiple Myeloma
Status: Not yet recruiting, Estimated PCD: 2026-06-30
Clinical trial
A Randomized, Phase 2, Open Label Study Evaluating Subcutaneous Administration of Isatuximab in Combination With Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma (RRMM)
Status: Recruiting, Estimated PCD: 2024-10-14
Clinical trial
A Multicenter, Open-label, Phase I/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of LBL-034 in Patients With Relapsed/Refractory Multiple Myeloma
Status: Recruiting, Estimated PCD: 2026-10-20
Clinical trial
A Phase 1/2a Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of Modakafusp Alfa in Combination With Daratumumab Subcutaneous in Patients With Relapsed or Refractory Multiple Myeloma
Status: Active (not recruiting), Estimated PCD: 2025-03-04
Product
Modakafusp Alfa
Clinical trial
A Double-Blind, Randomized, Placebo-Controlled, Single Ascending Dose Study to Investigate the Pharmacokinetic Profile of Oral AB680 in Healthy Volunteers
Status: Completed, Estimated PCD: 2021-09-22
Product
CC-92480
Product
Trametinib
Clinical trial
A Phase 1b-2, Open-Label Study of JNJ-68284528, A Chimeric Antigen Receptor T-Cell (CAR-T) Therapy Directed Against BCMA in Subjects With Relapsed or Refractory Multiple Myeloma
Status: Completed, Estimated PCD: 2022-08-23
Clinical trial
A Phase 1, Open-label, Dose Finding Study of CC-93269, a BCMA x CD3 T Cell Engaging Antibody, in Subjects With Relapsed and Refractory Multiple Myeloma
Status: Recruiting, Estimated PCD: 2029-06-30
Clinical trial
A Randomized, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation (KarMMa-9)
Status: Recruiting, Estimated PCD: 2031-03-27
Clinical trial
A Study of the Pharmacokinetics of Melphalan During Treatment With Melflufen and Dexamethasone in Patients With Relapsed Refractory Multiple Myeloma and Impaired Renal Function
Status: Terminated, Estimated PCD: 2021-12-22
Clinical trial
A Phase I Open Label First in Human Dose Escalation of the Immunoproteasome Inhibitor M3258 as a Single Agent and Expansion Study of M3258 in Combination With Dexamethasone in Participants With Relapsed Refractory Multiple Myeloma
Status: Terminated, Estimated PCD: 2021-04-01
Product
M3258
Clinical trial
A Phase 3, Two-stage, Randomized, Multi-center, Controlled, Open-label Study Comparing Iberdomide Maintenance to Lenalidomide Maintenance Therapy After Autologous Stem Cell Transplantation (ASCT) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) (EXCALIBER-Maintenance)
Status: Recruiting, Estimated PCD: 2029-03-15
Product
Clarithromycin
Clinical trial
Descartes-15 for Patients With Relapsed/Refractory Multiple Myeloma
Status: Recruiting, Estimated PCD: 2026-12-01
Clinical trial
Open Label, Phase I/II Clinical Trial to Evaluate the Safety and Efficacy of Fully Human Anti-BCMA Chimeric Antibody Receptor Autologous T Cell （CAR T）in Patients With Relapsed and/or Refractory Multiple Myeloma (LUMMICAR STUDY 1)
Status: Active (not recruiting), Estimated PCD: 2024-12-31
Product
UCARTCS1A
Clinical trial
A Phase I Study of Single-centre, Open-label Clinical Trial to Evaluate HG146 Capsule in the Treatment of Relapsed and Refractory Multiple Myeloma
Status: Terminated, Estimated PCD: 2022-09-28
Clinical trial
A Phase 1/2 Study to Evaluate Safety, Pharmacokinetics and Efficacy of Isatuximab in Combination With Cemiplimab in Patients With Relapsed/Refractory Multiple Myeloma
Status: Completed, Estimated PCD: 2023-04-05
Clinical trial
A Pilot Study Examining Selinexor's Ability to Overcome Resistance in Multiple Myeloma Patients Who Are Refractory to Lenalidomide-containing Therapy.
Status: Recruiting, Estimated PCD: 2023-12-29
Clinical trial
An Open-Label, Randomized Phase 3 Trial of Combinations of Nivolumab, Pomalidomide and Dexamethasone in Relapsed and Refractory Multiple Myeloma
Status: Completed, Estimated PCD: 2022-03-09
Clinical trial
A Phase 1 Study of Subcutaneous Delivery of JNJ-54767414 (Daratumumab) in Japanese Participants With Relapsed or Refractory Multiple Myeloma
Status: Completed, Estimated PCD: 2017-11-01
Clinical trial
Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity and Preliminary Effectiveness of QLS32015 Injection in Patients With Relapsed or Refractory Multiple Myeloma
Status: Recruiting, Estimated PCD: 2024-12-31
Product
NEX-20A
Clinical trial
Teclistamab US Expanded Access Treatment Protocol for Patients With Relapsed or Refractory Multiple Myeloma
Status:
Clinical trial
A Phase 1/2 Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Subjects With Relapsed or Refractory Multiple Myeloma
Status: Completed, Estimated PCD: 2021-11-29
Clinical trial
Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Selinexor (KPT-330), Carfilzomib, and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma Previously Treated With a Proteasome Inhibitor and an Immunomodulatory Drug
Status: Withdrawn, Estimated PCD: 2017-06-01
Clinical trial
A Phase 3 Randomized, Controlled, Open-label Study of Selinexor, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)
Status: Active (not recruiting), Estimated PCD: 2020-02-18
Clinical trial
A Phase Ib/II Study of CBM.BCMA Chimeric Antigen Receptor T Cell Product (C-CAR088) for Treating Patients With Relapsed or Refractory Multiple Myeloma
Status: Recruiting, Estimated PCD: 2024-07-01
Clinical trial
A Single Ascending Dose Pilot Study to Assess the Safety, Tolerability and Pharmacokinetics of NEX-20A Given as a Subcutaneous Prolonged-release Injection to Healthy Male Subjects
Status: Completed, Estimated PCD: 2023-09-26
Clinical trial
A Randomized, Multicenter, Phase 3 Study Comparing Carfilzomib, Lenalidomide, and Dexamethasone (CRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects With Relapsed Multiple Myeloma
Status: Completed, Estimated PCD: 2014-06-16
Product
LOXO-338
Product
Pirtobrutinib
Clinical trial
Phase 1b/2, Multicenter, Open-label Study of Oprozomib and Dexamethasone, in Combination With Lenalidomide or Oral Cyclophosphamide in Patients With Newly Diagnosed Multiple Myeloma
Status: Terminated, Estimated PCD: 2019-09-23
Clinical trial
A Phase 1 Study of KTX-1001, an Oral, First-In-Class, Selective, and Potent MMSET Catalytic Inhibitor That Suppresses H3K36me2 in Patients With Relapsed and Refractory Multiple Myeloma
Status: Recruiting, Estimated PCD: 2024-12-01
Product
Oprozomib
Clinical trial
A Phase 3, Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Pomalidomide, Bortezomib and Low-Dose Dexamethasone Versus Bortezomib and Low-Dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
Status: Completed, Estimated PCD: 2022-05-09
Clinical trial
A Randomized Open-Label Phase 1/2 Study of INCB001158 Combined With Subcutaneous (SC) Daratumumab, Compared to Daratumumab SC, in Participants With Relapsed or Refractory Multiple Myeloma
Status: Terminated, Estimated PCD: 2022-04-05
Product
Cobimetinib
Clinical trial
A Phase Ib/II Study of Cobimetinib Administered as Single Agent and in Combination With Venetoclax, With or Without Atezolizumab, in Patients With Relapsed and Refractory Multiple Myeloma
Status: Completed, Estimated PCD: 2021-05-18
Clinical trial
Study Evaluating Safety and Efficacy of BCMA-Targeted Prime CAR-T Cell in Patients With Relapsed/Refractory Multiple Myeloma
Status: Recruiting, Estimated PCD: 2023-12-31
Product
NKTR-255
Clinical trial
A Phase 1, Open-label, Multi-center, Dose Escalation and Dose Expansion Study of NKTR-255 in Relapsed or Refractory Hematological Malignancies
Status: Completed, Estimated PCD: 2023-04-24
Clinical trial
A Phase 1/2 Study of Weekly Carfilzomib in Combination With Dexamethasone for Progressive Multiple Myeloma
Status: Completed, Estimated PCD: 2016-07-22
Clinical trial
Clinical Study on the Safety and Efficacy of SENL103 Autologous T Cell Injection in the Treatment of Recurrent or Refractory Plasma Cell Blood Tumors
Status: Recruiting, Estimated PCD: 2025-08-01
Clinical trial
A Phase Ⅱ Clinical Study Evaluating the Efficacy and Safety of Human BCMA Targeted T Cells Injection Therapy for Relapsed/Refractory Multiple Myeloma
Status: Recruiting, Estimated PCD: 2025-07-31
Clinical trial
A Phase I Study of Human Placental Hematopoietic Stem Cell Derived Natural Killer Cells (CYNK 001) in Multiple Myeloma Patients Following Autologous Stem Cell Transplant in the Front-line Setting.
Status: Active (not recruiting), Estimated PCD: 2023-01-31
Product
SGN-40
Product
Rituximab
Clinical trial
An Open-Label, Phase Ib, Dose-Escalation Study of the Safety and Pharmacology of the Anti-CD40 Monoclonal Antibody SGN-40 Administered in Combination With Bortezomib (Velcade®, PS-341) in Patients With Relapsed or Refractory Multiple Myeloma
Status: Completed, Estimated PCD: 2010-04-08
Clinical trial
Prospective, Multicenter, Non-interventional Study to Evaluate Patient and Healthcare Provider Satisfaction of Daratumumab Use in the Treatment of First-line Daratumumab, Lenalidomide, Dexamethasone (DRd) Multiple Myeloma Patients as Per Routine Clinical Practice in Germany Depending on Application Route (sc or iv)
Status: Active (not recruiting), Estimated PCD: 2024-09-30
Clinical trial
A Phase 1, Open-Label, Multicenter, Dose-Escalation Study of PRT1419 in Patients With Relapsed/Refractory Hematologic Malignancies
Status: Completed, Estimated PCD: 2022-03-21
Product
HPN217
Product
Melphalan flufenamide
Clinical trial
A Single Arm, Open-Label, Phase 2 Study of Melflufen in Combination With Dexamethasone in Patients With Relapsed Refractory Multiple Myeloma Who Are Refractory to Pomalidomide and/or an Anti-CD38 Monoclonal Antibody
Status: Completed, Estimated PCD: 2020-10-22
Clinical trial
A Phase 1, Open-Label, Multicenter, Study of mRNA-2736 in Patients With Relapsed or Refractory Multiple Myeloma
Status: Withdrawn, Estimated PCD: 2026-05-27
Product
AO-176
Clinical trial
A Phase 1/2, Dose Escalation Safety and Tolerability Study of AO-176 as Monotherapy and in Combination With Bortezomib and Dexamethasone in Adults With Relapsed or Refractory Multiple Myeloma
Status: Completed, Estimated PCD: 2022-08-05
Clinical trial
A Phase 2 Study of Weekly 70 mg/m2 Carfilzomib for Multiple Myeloma Patients Refractory to 27 mg/m2 Carfilzomib
Status: Terminated, Estimated PCD: 2020-09-21
Clinical trial
An Open-Label Phase 1/2a Study of the Safety and Efficacy of Melflufen and Dexamethasone in Combination With Either Bortezomib or Daratumumab in Patients With Relapsed or Relapsed-Refractory Multiple Myeloma
Status: Terminated, Estimated PCD: 2022-02-02
Clinical trial
A Phase 1/2, Multicenter, Dose-Escalation and Expansion Study of Combination Therapy With Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Subjects With Relapsed or Refractory Multiple Myeloma
Status: Active (not recruiting), Estimated PCD: 2025-08-28
Clinical trial
A Phase 1a/1b Dose-Escalation and Expansion Trial of TTI-622 in Patients With Advanced Hematologic Malignancies, Including Lymphoma, Leukemia, and Multiple Myeloma
Status: Active (not recruiting), Estimated PCD: 2024-09-11
Clinical trial
A Phase IIa, Multi-center, Dose-finding Study to Evaluate Safety and Efficacy for Prevention of Oral Mucositis and PK of MIT-001 in Patients With Lymphoma or Multiple Myeloma Receiving Conditioning Chemotherapy Followed by Auto HSCT
Status: Recruiting, Estimated PCD: 2023-10-31
Product
Lemzoparlimab
Clinical trial
A Phase 1b, Dose Escalation and Expansion Study of Lemzoparlimab With or Without Dexamethasone and in Combination With Anti-Myeloma Regimens for the Treatment of Patients With Relapsed/Refractory Multiple Myeloma
Status: Terminated, Estimated PCD: 2022-06-24
Product
Farydak
Clinical trial
A Phase Ib/II Open-Label Study of APG-2575 in Combination With Novel Therapeutic Regimens in Subjects With Relapsed or Refractory Multiple Myeloma and Immunoglobin Light Chain Amyloidosis
Status: Recruiting, Estimated PCD: 2024-09-01
Clinical trial
A Phase I Study to Evaluate the Safety and Immunogenicity of 3D189 in Patients With Hematologic Malignancies
Status: Active (not recruiting), Estimated PCD: 2024-05-01
Clinical trial
A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation
Status: Completed, Estimated PCD: 2019-08-12
Product
APG-2575
Product
3D189
Product
Idecabtagene vicleucel
Clinical trial
An Open Label, Randomized Phase 2 Trial of Pomalidomide/Dexamethasone With or Without Elotuzumab in Relapsed and Refractory Multiple Myeloma (ELOQUENT-3)
Status: Completed, Estimated PCD: 2018-01-17
Product
COVID-19 Vaccine
Clinical trial
A Phase 2 Randomized, Multi-center Study of GEO-CMO4S1 (SARS-CoV-2 Vaccine) Versus mRNA SARS-CoV-2 Vaccine in Patients Post Cellular Therapy for Hematological Malignancies
Status: Recruiting, Estimated PCD: 2025-03-31
Product
IMNOVID
Clinical trial
A Randomized, Open-label, Multicenter, Multiphase Study of JNJ-63723283, an Anti-PD-1 Monoclonal Antibody, Administered in Combination With Daratumumab, Compared With Daratumumab Alone in Subjects With Relapsed or Refractory Multiple Myeloma
Status: Completed, Estimated PCD: 2018-10-24
Clinical trial
A Phase 3, Randomized, Open Label Trial of Lenalidomide/Dexamethasone With or Without Elotuzumab in Subjects With Previously Untreated Multiple Myeloma
Status: Completed, Estimated PCD: 2019-10-01
Clinical trial
A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) Plus Low-Dose Dexamethasone (Sd) in Patients With Multiple Myeloma Previously Treated With Lenalidomide, Pomalidomide, Bortezomib, Carfilzomib, and an Anti-CD38 Monoclonal Antibody (mAb) Daratumumab, and Refractory to Prior Treatment With Glucocorticoids, an Immunomodulatory Agent, a Proteasome Inhibitor, and an the Anti-CD38 mAb Daratumumab
Status: Completed, Estimated PCD: 2019-07-26
Product
Tinostamustine
Clinical trial
A Phase 2, Multi-center, Single-arm Study of TJ202 Combined With Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma Who Received at Least 2 Prior Lines of Treatment
Status: Active (not recruiting), Estimated PCD: 2023-01-28
Product
JNJ-68284528
Product
COM902 (RDFE)
Product
Forimtamig
Clinical trial
An Open-Label, Randomized Phase IB/II Study Evaluating Safety, Tolerability, and Clinical Activity of Forimtamig-Based Treatment Combinations in Participants With Relapsed or Refractory Multiple Myeloma
Status: Recruiting, Estimated PCD: 2027-06-10
Clinical trial
A PHASE 1B/2, OPEN-LABEL STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS, PHARMACODYNAMICS, AND EFFICACY OF ELRANATAMAB (PF-06863135) IN CHINESE PARTICIPANTS WITH MULTIPLE MYELOMA WHO ARE REFRACTORY TO AT LEAST ONE PROTEASOME INHIBITOR, ONE IMMUNOMODULATORY DRUG AND ONE ANTI-CD38 ANTIBODY (TRIPLE-CLASS REFRACTORY MM)
Status: Active (not recruiting), Estimated PCD: 2023-08-06
Product
Placebo +G-CSF
Clinical trial
A Phase 1 Study of bb21217, an Anti-BCMA CAR T Cell Drug Product, in Relapsed and/or Refractory Multiple Myeloma
Status: Completed, Estimated PCD: 2022-12-02
Clinical trial
A Multi-Center, Phase 1/2, Open-Label Study of Selinexor (KPT- 330), Lenalidomide, and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma
Status: Withdrawn, Estimated PCD: 2018-01-01
Product
CC-93269
Clinical trial
Protocol for Transgene Service Assay
Status: Recruiting, Estimated PCD: 2038-10-06
Product
Lisocabtagene maraleucel
Product
CAR-T cell therapy expressing BAFF-ligand
Clinical trial
A Phase 1, Open-Label Study of the Safety, Tolerability, and Preliminary Clinical Activity of Allogeneic Invariant Natural Killer T (iNKT) Cells (agenT-797) in Subjects With Relapsed/Refractory Multiple Myeloma
Status: Completed, Estimated PCD: 2023-01-13
Clinical trial
A Phase 1b Open-label Study Evaluating the Safety and Pharmacokinetics of Subcutaneous AMG 701 for the Treatment of Relapsed or Refractory Multiple Myeloma (ProxiMMity-1)
Status: Withdrawn, Estimated PCD: 2025-08-02
Product
AMG 701
Clinical trial
A Phase I Study to Evaluate the Pharmacokinetics and Safety of Belantamab Mafodotin Monotherapy in Participants With Relapsed and/or Refractory Multiple Myeloma (RRMM) Who Have Normal and Varying Degrees of Impaired Renal Function (DREAMM 12)
Status: Recruiting, Estimated PCD: 2025-03-07
Clinical trial
A Multi-Center, Open Label Phase 1/2 Study of CYT-0851 in Patients With Relapsed/Refractory B-Cell Malignancies and Advanced Solid Tumors
Status: Active (not recruiting), Estimated PCD: 2024-07-30
Clinical trial
AN OPEN-LABEL, 3-ARM, MULTICENTER, RANDOMIZED PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ELRANATAMAB (PF-06863135) MONOTHERAPY AND ELRANATAMAB + DARATUMUMAB VERSUS DARATUMUMAB + POMALIDOMIDE + DEXAMETHASONE IN PARTICIPANTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST 1 PRIOR LINE OF THERAPY INCLUDING LENALIDOMIDE AND A PROTEASOME INHIBITOR
Status: Recruiting, Estimated PCD: 2024-12-27
Clinical trial
Phase I, Open-label Dose-escalation Study to Evaluate the Safety, Expansion, Persistence and Clinical Activity of UCARTCS1A (Allogenic Engineered T-cells Expressing Anti-CS1 Chimeric Antigen Receptor) Administered in Patients With Relapsed/Refractory Multiple Myeloma
Status: Terminated, Estimated PCD: 2023-06-18
Product
HG146
Clinical trial
A Phase 1 Study of Ruxolitinib, Steroids and Lenalidomide for Relapsed/Refractory Multiple Myeloma (RRMM) Patients
Status: Recruiting, Estimated PCD: 2024-09-01
Clinical trial
A Multicenter, Uncontrolled, Nonrandomized, Open-Label, Phase 1/2 Trial Investigating the Safety and Efficacy of OPC 415 in MMG49 Antigen-Positive Patients With Relapsed and/or Refractory Multiple Myeloma
Status: Recruiting, Estimated PCD: 2027-01-01
Clinical trial
A Phase 1, Open-label, Multicenter Study to Evaluate the Safety of bb2121 in Subjects With High Risk, Newly Diagnosed Multiple Myeloma (KarMMa-4)
Status: Completed, Estimated PCD: 2023-06-07
Product
OPC-415
Product
QLS32015
Product
Pemigatinib
Clinical trial
A Phase 1 Study of Oral LOXO-338, a Selective BCL-2 Inhibitor, in Patients With Advanced Hematologic Malignancies
Status: Active (not recruiting), Estimated PCD: 2023-05-01
Clinical trial
A Phase 1 Multi-Center, Open-Label, Dose-Escalation Study to Determine the Pharmacokinetics and Safety of Pomalidomide When Given in Combination With Low Dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma and Impaired Renal Function
Status: Completed, Estimated PCD: 2018-08-07
Product
2 mg Oral POM + 40 mg Oral DEX
Product
Teclistamab
Product
STRO-001
Product
CYT-0851
Product
FHND6091
Clinical trial
A Phase 1 Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies
Status: Active (not recruiting), Estimated PCD: 2023-01-01
Product
BCMA CAR-T
Product
Atezolizumab
Clinical trial
A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCB054828 in Subjects With Advanced Malignancies (FIGHT-101)
Status: Terminated, Estimated PCD: 2021-12-17
Product
Gemcitabine
Product
Docetaxel
Product
Cisplatin
Clinical trial
CRB-401 A Phase 1 Study of bb2121 in BCMA-Expressing Multiple Myeloma
Status: Completed, Estimated PCD: 2019-07-22
Product
INCB001158
Product
Retifanlimab
Product
Tiragolumab
Product
POM
Clinical trial
A Phase 2 Study of Pomalidomide as a Replacement for Lenalidomide for Multiple Myeloma Patients Relapsed or Refractory to a Lenalidomide-Containing Combination Regimen
Status: Terminated, Estimated PCD: 2020-10-23
Clinical trial
A Phase 1 Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ABBV-383 Monotherapy in Japanese Subjects With Relapsed or Refractory Multiple Myeloma (4L+ RRMM Monotherapy Study)
Status: Active (not recruiting), Estimated PCD: 2024-03-24
Clinical trial
A Multicenter, Open, Phase I Clinical Study of BEBT-908 for Injection in the Treatment of Relapsed Refractory Malignant Lymphoma, Multiple Myeloma and Chronic Lymphoblastic Leukemia
Status: Completed, Estimated PCD: 2019-03-08
Clinical trial
A Phase 1/2 Multicenter, Open-label Study to Assess the Safety, Pharmacokinetics and Efficacy of CC-92480 Monotherapy and in Combination With Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma
Status: Active (not recruiting), Estimated PCD: 2024-10-21
Clinical trial
An Open-Label, Rollover Protocol for Patients Previously Enrolled in Millennium-Sponsored Ixazomib Studies
Status: Active (not recruiting), Estimated PCD: 2023-12-31
Clinical trial
A Phase 1 Open-label, Multicenter, Dose Escalation Study of the Safety, Tolerability, and Pharmacokinetics of HPN217 in Patients With Relapsed/Refractory Multiple Myeloma
Status: Active (not recruiting), Estimated PCD: 2024-01-02
Product
BCMA targeted prime CAR-T cells
Clinical trial
A Randomized, Controlled, Open-Label Phase 3 Study of Melflufen in Combination With Daratumumab Compared With Daratumumab in Patients With Relapsed or Relapsed-Refractory Multiple Myeloma
Status: Terminated, Estimated PCD: 2022-02-07
Product
KTX-1001
Clinical trial
Phase 1, Open-Label, Dose Escalation Study of I-131-CLR1404 in Patients With Relapsed or Refractory Multiple Myeloma
Status: Completed, Estimated PCD: 2020-12-09
Product
ISB 1442
Clinical trial
A Phase 1/2, First-in-Human, Multicenter, Open-Label, Dose Escalation and Dose-Expansion Study of Single-Agent ISB 1442 in Participants With Relapsed/Refractory Multiple Myeloma
Status: Recruiting, Estimated PCD: 2027-05-01
Clinical trial
A Phase 3, Randomized, Double-Blind, Multicenter Study Comparing Oral Ixazomib (MLN9708) Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma
Status: Completed, Estimated PCD: 2014-10-01
Clinical trial
A Phase 3, Randomized, Double-Blind, Multicenter Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Newly Diagnosed Multiple Myeloma
Status: Completed, Estimated PCD: 2019-12-02
Clinical trial
A Phase 1/2a Open-label, Dose-Escalation Study to Investigate the Safety and Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of TAK-079 Administered Subcutaneously as a Single Agent in Patients With Relapsed/Refractory Multiple Myeloma
Status: Completed, Estimated PCD: 2022-01-28
Clinical trial
An Open-label, Multi-center Study to Evaluate the Pharmacokinetics, Safety, and Preliminary Efficacy of Isatuximab in Chinese Patients With Relapsed and/or Refractory Multiple Myeloma
Status: Completed, Estimated PCD: 2020-09-06
Clinical trial
A Phase 1/2 Multicenter, Open-label Study to Determine the Recommended Dose and Regimen of Durvalumab (MEDI4736) in Combination With Lenalidomide (LEN) With and Without Dexamethasone (DEX)in Subjects With Newly Diagnosed Multiple Myeloma (NDMM)
Status: Completed, Estimated PCD: 2017-12-15
Product
Chimeric Antigen Receptor NK Cell Injection Targeting BCMA
Clinical trial
A Randomized, Open-label, Phase 3 Study of Carfilzomib Plus Dexamethasone vs. Bortezomib Plus Dexamethasone in Patients With Relapsed Multiple Myeloma
Status: Completed, Estimated PCD: 2014-11-10
Product
Anti-CD20 Targeting agent
Clinical trial
A Non-interventional Post Authorisation Registry of Patients Treated With Pomalidomide for Relapsed and Refractory Multiple Myeloma Who Have Received at Least Two Prior Treatment Regimens, Including Both Lenalidomide and Bortezomib, and Have Demonstrated Disease Progression on the Last Therapy
Status: Completed, Estimated PCD: 2022-10-10
Product
C-4-29
Product
BCMA CAR-T cells
Product
Synthetic MVA-based SARS-CoV-2 Vaccine GEO-CM04S1
Clinical trial
A Randomized, Open-label, Phase 3 Study in Subjects With Relapsed and Refractory Multiple Myeloma Receiving Carfilzomib in Combination With Dexamethasone, Comparing Once-weekly Versus Twice-weekly Carfilzomib Dosing
Status: Completed, Estimated PCD: 2017-06-15
Product
MIT-001
Product
Normal Saline
Clinical trial
A Phase I Open-Label, Dose Escalation Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Clinical Activity of the Antibody Drug Conjugate GSK2857916 in Japanese Participants With Relapsed/Refractory Multiple Myeloma
Status: Active (not recruiting), Estimated PCD: 2023-04-06
Clinical trial
Oral ONC201 in Relapsed/Refractory Multiple Myeloma
Status: Active (not recruiting), Estimated PCD: 2022-12-31
Clinical trial
601-0018
Status:
Product
AO-176 + Dex + Bort
Clinical trial
A Phase 1, First-in-Human, Multicenter, Open-Label, Dose Escalation and Dose-Expansion Study of Single-Agent ISB 2001 in Subjects With Relapsed/Refractory Multiple Myeloma
Status: Not yet recruiting, Estimated PCD: 2027-07-01
Product
ISB 2001
Clinical trial
A Phase 1b/2 Study of Selinexor (KPT-330) in Combination With Backbone Treatments for Relapsed/Refractory Multiple Myeloma and Newly Diagnosed Multiple Myeloma
Status: Active (not recruiting), Estimated PCD: 2027-04-01
Product
Descartes-15
Product
CAR-BCMA T Cells
Product
DARA SC
Clinical trial
An Open-label, First-in-human, Single Agent, Dose-escalation and Expansion Study for the Evaluation of Safety, Pharmacokinetics, Pharmacodynamics and Anti-tumor Activity of SAR442085 in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)
Status: Terminated, Estimated PCD: 2022-08-29
Product
CIML NK Cells plus KP1237 and low dose IL-2
Product
Fully human BCMA chimeric antigen receptor autologous T cell injection
Clinical trial
A Phase 2, Open-Label Study of LCAR-B38M CAR-T Cells, a Chimeric Antigen Receptor T-cell (CAR-T) Therapy Directed Against BCMA in Chinese Subjects With Relapsed or Refractory Multiple Myeloma
Status: Recruiting, Estimated PCD: 2026-02-16
Clinical trial
PET Imaging of Subjects Using 124I-PU-AD: A Pilot Study
Status: Terminated, Estimated PCD: 2019-06-10
Product
agenT-797
Clinical trial
A Phase I Open-label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of the FHND6091 in Subjects With Relapsed/Refractory Multiple Myeloma
Status: Recruiting, Estimated PCD: 2023-12-31
Clinical trial
A Phase 1 Study of Autologous Memory-like Natural Killer (NK) Cell Immunotherapy With BHV-1100 (Formerly KP1237) and IVIG Followed by Low Dose IL-2 as Early Post-Autologous Transplant Consolidation in Minimal Residual Disease Positive, Multiple Myeloma (MM) Patients in First or Second Remission
Status: Recruiting, Estimated PCD: 2025-10-01
Product
CFZ
Product
CLA
Product
PRT1419
Product
SAR442085
Product
PU-AD
Product
LCAR-B38M CAR-T
Product
bb21217
Product
SENL103
Product
BEBT-908
Clinical trial
A Phase 2, Open Label, Randomized Trial Evaluating Ixazomib Compared to Ixazomib-Lenalidomide Combination Maintenance Therapy for Frontline Multiple Myeloma Patients
Status: Terminated, Estimated PCD: 2023-10-19
Product
POM + DEX
Product
Daratumumab/rHuPH20
Product
mRNA-2736
Clinical trial
A Phase Ia/Ib Open-Label, Multicenter Study Evaluating the Safety and Pharmacokinetics of Tiragolumab as a Single Agent and in Combination With Atezolizumab and/or Daratumumab in Patients With Relapsed or Refractory Multiple Myeloma, and as a Single Agent and in Combination With Rituximab in Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
Status: Terminated, Estimated PCD: 2023-03-28
Product
Steroids
Product
PLD
Product
BTZ
Product
CY
Clinical trial
A Phase Ib Clinical Study of Fully Human BCMA Chimeric Antigen Receptor Autologous T Cell Injection (CT103A) in the Treatment of Patients With Relapsed/Refractory Multiple Myeloma
Status: Not yet recruiting, Estimated PCD: 2024-05-20
Product
Human BCMA Targeted T Cells
Clinical trial
Post Marketing Surveillance on Safety Evaluation of POMALYST® (Pomalidomide) Treatment of Multiple Myeloma in Korea
Status: Recruiting, Estimated PCD: 2024-06-08
Clinical trial
A Phase 1/2 Study of Ixazomib as a Replacement for Bortezomib or Carfilzomib for Multiple Myeloma (MM) Patients Recently Relapsed or Refractory to Their Last Combination Regimen Containing Either Bortezomib or Carfilzomib
Status: Completed, Estimated PCD: 2018-01-19
Product
CYNK-001
Clinical trial
Pre-Approval Access Named Patient Program for Talquetamab (JNJ-64407564) for Treating Physician Use in Relapsed or Refractory Multiple Myeloma
Status:
Clinical trial
A Phase 1 Trial to Investigate the Safety, Pharmacokinetic Profiles and the Efficacy of Tinostamustine, a First-in-Class Alkylating Histone Deacetylase Inhibition (HDACi) Fusion Molecule, in Relapsed/Refractory Hematologic Malignancies
Status: Active (not recruiting), Estimated PCD: 2023-11-01
Clinical trial
A Disease Registry Encompassing the Care of Patients With Multiple Myeloma on Panobinostat (RECOMM)
Status: Completed, Estimated PCD: 2022-03-30
Clinical trial
A First-in-human, Phase I/II, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of EMB-06 in Patients With Relapsed or Refractory Multiple Myeloma
Status: Recruiting, Estimated PCD: 2023-12-01
Product
EMB-06
Clinical trial
Clinical Study of the Safety and Efficacy of Chimeric Antigen Receptor NK Cell Injection Targeting BCMA (BCMA CAR-NK) in Patients With Relapsed/Refractory Multiple Myeloma
Status: Recruiting, Estimated PCD: 2023-09-30
Product
Mezagitamab
Clinical trial
A Phase I, Multi Center, Open Label Study of CC-98633, BCMA Targeted NEX-T Chimeric Antigen Receptor (CAR) T Cells, in Subjects With Relapsed and/or Refractory Multiple Myeloma
Status: Active (not recruiting), Estimated PCD: 2025-06-23
Clinical trial
Phase I Clinical Study of CAR-T Cells (C-4-29) in the Treatment of Patients With Relapsed/Refractory Multiple Myeloma
Status: , Estimated PCD: 2023-12-31
Clinical trial
BCMA-Targeted CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma
Status: Recruiting, Estimated PCD: 2023-12-31
Product
HDP-101
Product
CC-98633
Product
JNJ-63723283
Clinical trial
A Phase 1/2a, First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of HDP-101 in Patients With Plasma Cell Disorders Including Multiple Myeloma
Status: Recruiting, Estimated PCD: 2024-08-01
Product
I-131-CLR1404
Clinical trial
Clinical Study of CAR-T Technique in the Treatment of Recurrent and Refractory Hematopoietic and Lymphatic Tumor
Status: Recruiting, Estimated PCD: 2023-01-26
Product
CAR-T Autologous T cell
Clinical trial
The Safety and Efficay Investigation of CAR-T Cell Therapy for Patients With Hematological Malignancies
Status: Recruiting, Estimated PCD: 2024-09-06
Clinical trial
A Phase I/II, Multiple Center, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of CM313 in Subjects With Relapsed or Refractory Multiple Myeloma
Status: Not yet recruiting, Estimated PCD: 2026-02-28
Clinical trial
Expanded Access Protocol (EAP) for Patients Receiving Idecabtagene Vicleucel That is Nonconforming for Commercial Release
Status:
Clinical trial
A Phase 2, Multicenter, Multi-cohort, Open-label Study of Pomalidomide in Combination With Low-dose Dexamethasone or Pomalidomide in Combination With Low-dose Dexamethasone and Daratumumab in Subjects With Relapsed or Refractory Multiple Myeloma Following Lenalidomide Based Therapy in the First or Second Line Setting.
Status: Active (not recruiting), Estimated PCD: 2025-05-24
Product
CM313
Clinical trial
A Phase IV, Post Marketing, Prospective, Observational Cohort Study to Investigate Safety and Effectiveness of Alvocade® in Iranian Patients With Multiple Myeloma
Status: Completed, Estimated PCD: 2022-12-01
Product
IGM-2644
Product
ONC201
Product
CAR-T
Clinical trial
A Phase 1, Open-label, Multicenter Study of Subcutaneous Delivery of JNJ-54767414 (Daratumumab) in Chinese Subjects With Multiple Myeloma
Status: Completed, Estimated PCD: 2021-04-27
Product
Immediate Release Formulation
Product
Gastro-Retentive (GR) Formulation
Clinical trial
(INTREPID-1) A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of Oprozomib in Combination With Pomalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
Status: Completed, Estimated PCD: 2022-10-06
Clinical trial
A Phase Ib/IIa, Open-Label, Dose-Escalation and Extension Study to Evaluate the Safety and Efficacy of An Anti-CD38 Antibody Drug Conjugate (STI-6129) in Patients With Relapsed or Refractory Multiple Myeloma
Status: Recruiting, Estimated PCD: 2025-03-07
Clinical trial
Protocol H125001: An Open-Label Phase 1/2 Study of JCARH125, BCMA-targeted Chimeric Antigen Receptor (CAR) T Cells, in Subjects With Relapsed or Refractory Multiple Myeloma
Status: Completed, Estimated PCD: 2023-03-30
Product
STI-6129
Clinical trial
A Phase I/II, Open-label, Dose Escalation and Expansion Study to Evaluate Safety, Tolerability, and Clinical Activity of the Antibody-Drug Conjugate GSK2857916 Administered in Combination With Lenalidomide Plus Dexamethasone (Arm A), or Bortezomib Plus Dexamethasone (Arm B) in Participants With Relapsed / Refractory Multiple Myeloma - DREAMM-6
Status: Active (not recruiting), Estimated PCD: 2023-02-28
Product
GIC-102
Product
oprozomib
Clinical trial
A Phase 3 Randomized, Open-label, Multicenter Study Comparing Isatuximab (SAR650984) in Combination With Pomalidomide and Low-Dose Dexamethasone Versus Pomalidomide and Low-Dose Dexamethasone in Patients With Refractory or Relapsed and Refractory Multiple Myeloma
Status: Completed, Estimated PCD: 2018-11-22
Clinical trial
A Phase 2, Multicenter, Open-label, Study to Determine the Safety and Efficacy for the Combination of Durvalumab (DURVA) and Daratumumab (DARA) (D2) in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)
Status: Terminated, Estimated PCD: 2022-01-03
Clinical trial
A Phase I, Open-Label, Multicenter Study of FT538 as Monotherapy in Relapsed/Refractory Acute Myelogenous Leukemia and in Combination With Monoclonal Antibodies in Relapsed/Refractory Multiple Myeloma
Status: Terminated, Estimated PCD: 2023-07-13
Product
ORIC-533
Clinical trial
An Open-label Phase 1b Study of ORIC-533 in Patients With Relapsed or Refractory Multiple Myeloma
Status: Recruiting, Estimated PCD: 2024-06-01
Product
KITE-585
Clinical trial
A Phase 1 Multicenter Study of KITE-585, an Autologous Anti-BCMA CAR T-Cell Therapy, in Subjects With Relapsed/Refractory Multiple Myeloma
Status: Terminated, Estimated PCD: 2018-12-17
Clinical trial
A Phase 1/2 Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 701 Monotherapy, or in Combination With Pomalidomide, With and Without Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma (ParadigMM-1B)
Status: Terminated, Estimated PCD: 2023-06-30
Clinical trial
A Phase 1a/1b Multicenter, Single-Arm, Open-Label, Dose-Escalation Study to Determine the Maximum Tolerated Dose, Safety, and Preliminary Activity of Oral ACY-241 Alone and in Combination With Pomalidomide and Low-Dose Dexamethasone in Patients With Relapsed or Relapsed-and-Refractory Multiple Myeloma
Status: Active (not recruiting), Estimated PCD: 2024-01-31
Clinical trial
A Randomized, Double-Blind, Multicenter Study of Denosumab Compared With Zoledronic Acid in the Treatment of Bone Disease in Subjects With Newly Diagnosed Multiple Myeloma
Status: Completed, Estimated PCD: 2016-07-19
Product
Denosumab
Clinical trial
A Phase III, Multicenter, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Pomalidomide and Dexamethasone (B-Pd) Versus Pomalidomide Plus Bortezomib and Dexamethasone (PVd) in Participants With Relapsed/Refractory Multiple Myeloma (DREAMM 8)
Status: Recruiting, Estimated PCD: 2024-09-16
Product
CTX120
Clinical trial
A Phase 1b/2a, Open-Label, Dose-Escalation Study of the Safety and Efficacy of an Anti-CD38 Antibody Drug Conjugate (STI-6129) in Patients With Relapsed or Refractory Multiple Myeloma
Status: Active (not recruiting), Estimated PCD: 2025-12-01
Product
BB2121
Clinical trial
An Exploratory Phase 1/2 Trial to Determine Recommended Phase 2 Dose (RP2D), Safety and Preliminary Efficacy of bb2121 (Ide-cel) Combinations in Subjects With Relapsed/Refractory Multiple Myeloma (KarMMa-7)
Status: Active (not recruiting), Estimated PCD: 2024-12-23
Product
Human BCMA targeted CAR-NK cells
Product
AMG 397
Clinical trial
A Phase 1b Study of SAR650984 (Anti-CD38 mAb) in Combination With Lenalidomide and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma
Status: Completed, Estimated PCD: 2023-06-20
Product
ALLO-605
Clinical trial
A Single-Arm, Open-Label, Phase 1/2 Study Evaluating the Safety, Efficacy, and Cellular Kinetics/Pharmacodynamics of ALLO-647 and ALLO-605, an Anti- BCMA Allogeneic CAR T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma
Status: Active (not recruiting), Estimated PCD: 2025-07-01
Clinical trial
Phase 2, Randomized, Open-Label Study Comparing Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) Versus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Subjects With Newly Diagnosed Multiple Myeloma Eligible for High-Dose Chemotherapy and Autologous Stem Cell Transplantation
Status: Completed, Estimated PCD: 2019-01-25
Clinical trial
A Phase 1/2a, Open-label, Dose-escalation, Dose-expansion Study to Evaluate the Safety and Clinical Activity of PBCAR269A, With or Without Nirogacestat, in Study Participants With Relapsed/Refractory Multiple Myeloma
Status: Terminated, Estimated PCD: 2022-10-19
Product
VP301
Clinical trial
A Phase I Trial Evaluating Escalating Doses of ²¹¹At-Labeled Anti-CD38 Monoclonal Antibody Followed by HLA-Matched or Haploidentical Donor Hematopoietic Cell Transplantation for High-Risk Multiple Myeloma
Status: Not yet recruiting, Estimated PCD: 2027-12-31
Product
Astatine At 211 Anti-CD38 Monoclonal Antibody OKT10-B10
Drug
cyclophosphamide
Drug
fludarabine
Clinical trial
Safety and Efficiency of VRd-based Regimen Followed by BCMA CAR-T for New-diagnosed Transplant-ineligible Multiple Myeloma Patients: a Prospective, Single-arm, Single-center, Phase II Study.
Status: Recruiting, Estimated PCD: 2025-03-10
Product
Anti-BCMA CAR-T
Drug
VRd
Clinical trial
A Phase II Study of Once Weekly Carfilzomib, Lenalidomide, Dexamethasone, and Isatuximab in Newly Diagnosed, Transplant-Eligible Multiple Myeloma
Status: Active (not recruiting), Estimated PCD: 2022-07-30
Drug
Carfilzomib
Clinical trial
Personalized NK Cell Therapy in CBT
Status: Recruiting, Estimated PCD: 2025-05-31
Product
Allogeneic Natural Killer Cell Line NK-92
Clinical trial
Study on the Efficacy and Safety of Low-dose Cyclophosphamide as Maintenance Therapy for Multiple Myeloma Unsuitable for Transplantation
Status: Recruiting, Estimated PCD: 2025-12-31
Clinical trial
Teclistamab or Talquetamab in Combination With Daratumumab SC for High-Risk Smoldering Myeloma: A Clinical and Correlative Phase 2 Sequential Cohort Immuno-Oncology Study to REVIVE Early Myeloma
Status: Recruiting, Estimated PCD: 2028-12-31
Drug
Teclistamab
Drug
Melphalan
Clinical trial
Phase II Study of Iberdomide (Cc220) Maintenance After Autologous Stem Cell Transplantation in Newly Diagnosed Multiple Myeloma Patients
Status: Active (not recruiting), Estimated PCD: 2023-07-27
Clinical trial
An Open Label, Phase 1 Study Evaluating the Activity of Modular CAR T for mYeloma
Status: Active (not recruiting), Estimated PCD: 2025-12-31
Product
BCMA CAR T cells
Product
BCMA/CD19 CAR T cells
Clinical trial
A Multicentre, Non-Blinded Study Exploring Self-Administration of Chemotherapy in the Home Environment
Status: Recruiting, Estimated PCD: 2024-05-01
Clinical trial
Propylene Glycol-Free Melphalan HCl (EVOMELA®) in Combination With Fludarabine and Total Body Irradiation Based Reduced Intensity Conditioning for Haploidentical Transplantation
Status: Recruiting, Estimated PCD: 2025-11-16
Clinical trial
A Phase 1/2, Dose and Schedule Evaluation Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin Administered in Combination With Daratumumab, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Transplant Ineligible (EAE 120)
Status: Recruiting, Estimated PCD: 2026-03-15
Clinical trial
A Randomised Phase II Trial of Selinexor, Cyclophosphamide and Prednisone vs Cyclophosphamide and Prednisone in Relapsed or Refractory Multiple Myeloma (RRMM) Patients
Status: Completed, Estimated PCD: 2022-10-25
Drug
Selinexor
Clinical trial
China Continuation: A Single-Arm, Open-Label Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation
Status: Completed, Estimated PCD: 2023-11-29
Clinical trial
An Open-Label, Multicenter, Phase 1 Study of IGM-2644 in Participants With Relapsed and/or Refractory Multiple Myeloma
Status: Recruiting, Estimated PCD: 2026-03-01
Clinical trial
An Open-Label Study to Determine the Maximum Tolerated Dose and Evaluate the Safety and Efficacy of CEP-18770 in Combination With Lenalidomide and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
Status: Completed, Estimated PCD: 2013-03-14
Clinical trial
NINLARO Capsules Drug Use-Results Survey (All-Case Surveillance) "Relapsed/Refractory Multiple Myeloma"
Status: Completed, Estimated PCD: 2022-03-08
Clinical trial
A Phase I/II, Multicenter, Open-label, First-in-human Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma
Status: Not yet recruiting, Estimated PCD: 2026-10-31
Product
PBCAR269A
Product
Eftozanermin alfa
Clinical trial
A Phase 1b, Open-Label Study of Eftozanermin Alfa (ABBV-621) in Combination With Bortezomib and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
Status: Active (not recruiting), Estimated PCD: 2024-10-31
Clinical trial
Open-label, Multi-center, Dose-escalation Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics/Pharmacodynamics of GIC-102 in Patients With Advanced Solid Tumors, R/R Non-Hodgkin Lymphoma, and Multiple Myeloma
Status: Recruiting, Estimated PCD: 2025-12-30
Clinical trial
A Phase 1 Dose Escalation and Expansion Study of CID-103, an Anti-CD38 Antibody, in Patients With Previously Treated Relapsed or Refractory Multiple Myeloma
Status: Active (not recruiting), Estimated PCD: 2023-09-01
Product
LCAR-B38M
Product
IDP-121
Clinical trial
A Phase I Study to Evaluate the Pharmacokinetics and Safety of Belantamab Mafodotin Monotherapy in Participants With Relapsed or Refractory Multiple Myeloma Who Have Normal and Varying Degrees of Impaired Hepatic Function (DREAMM 13)
Status: Recruiting, Estimated PCD: 2025-11-28
Clinical trial
Phase 1/2 FIH Study of REGN5459 (Anti-BCMA x Anti-CD3 Bispecific Antibody) in Patients With Relapsed or Refractory Multiple Myeloma
Status: Active (not recruiting), Estimated PCD: 2025-08-22
Product
CID-103
Product
CC-223
Clinical trial
Clinical Study of the Safety and Efficacy of Non-viral Site-directed Integrated PD1-BCMA-CART in Adult Treatment of Relapsed or Refractory Multiple Myeloma
Status: Not yet recruiting, Estimated PCD: 2025-01-01
Clinical trial
Phase 1b/2, Multicenter, Open-label Study of the Safety and Activity of Oprozomib in Patients With Hematologic Malignancies
Status: Terminated, Estimated PCD: 2016-08-08
Product
TNB-383B
Clinical trial
Multicenter Non-interventional Study to Investigate Drug Utilization of Pomalidomide in Clinical Practice for the Treatment of Relapsed/Refractory Multiple Myeloma (rrMM)
Status: Active (not recruiting), Estimated PCD: 2023-12-31
Clinical trial
A Phase I/II, Open-Label, Multiple Centre Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity and Preliminary Efficacy of LM-305 in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) and Other Plasma Cell Diseases
Status: Withdrawn, Estimated PCD: 2024-12-01
Clinical trial
A Phase 1 Study of SEA-BCMA in Patients With Relapsed or Refractory Multiple Myeloma
Status: Terminated, Estimated PCD: 2023-11-09
Product
FT538
Product
Zoledronic acid
Clinical trial
A Phase 2, Open-Label Study of Ixazomib+Daratumumab+Dexamethasone (IDd) in Relapsed and/or Refractory Multiple Myeloma (RRMM)
Status: Completed, Estimated PCD: 2022-01-01
Product
LAVA-051
Product
Interleukin 2
Clinical trial
Multiple Phase 1/2 Cohorts of Nivolumab Monotherapy or Nivolumab Combination Regimens Across Relapsed/Refractory Hematologic Malignancies
Status: Active (not recruiting), Estimated PCD: 2020-09-25
Product
Belantamab
Clinical trial
A Phase 1b, Open-Label Study of the Safety and Efficacy of Allogeneic Anti-CD38 A2 Dimeric Antigen Receptor (DAR)-T Cells in Patients With Relapsed or Refractory Multiple Myeloma
Status: Recruiting, Estimated PCD: 2025-12-01
Product
STI-1492
Clinical trial
A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of VP301 in Patients With Relapsed or Refractory Multiple Myeloma, Lymphoma, or Solid Tumors
Status: Terminated, Estimated PCD: 2023-06-19
Clinical trial
Phase I Safety Study of Descartes-11 in Patients With Relapsed/Refractory Multiple Myeloma
Status: Active (not recruiting), Estimated PCD: 2024-02-06
Clinical trial
A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Citrate (MLN9708) Maintenance Therapy in Patients With Multiple Myeloma Following Autologous Stem Cell Transplant
Status: Active (not recruiting), Estimated PCD: 2018-04-16
Clinical trial
Phase Ib / II Open-Label Stduy of APG-2575 Monotherapy or in Combination With Lenalidomide / Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
Status: Recruiting, Estimated PCD: 2024-01-01
Product
Rd
Product
ACY-241
Clinical trial
A Single-Arm, Open-Label, Phase 1 Study of the Safety, Efficacy, and Cellular Kinetics/Pharmacodynamics of ALLO-715 to Evaluate an Anti-BCMA Allogeneic CAR T Cell Therapy With or Without Nirogacestat in Subjects With Relapsed/Refractory Multiple Myeloma
Status: Active (not recruiting), Estimated PCD: 2027-09-01
Product
ALLO-647
Product
ALLO-715
Clinical trial
A Early Phase 1 Clinical Trial to Evaluate the Safety and Efficacy of Human BCMA Targeted CAR-NK Cells Injection for Subjects With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia
Status: Recruiting, Estimated PCD: 2025-09-30
Clinical trial
A Phase 1 Study of ENMD-2076 in Patients With Relapsed or Refractory Multiple Myeloma
Status: Completed, Estimated PCD: 2011-11-01
Clinical trial
A Phase 1 Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of AMG 397 in Subjects With Selected Relapsed or Refractory Hematological Malignancies
Status: Terminated, Estimated PCD: 2019-07-25
Clinical trial
Phase 1-2 UMBRELLA Trial Evaluating Isatuximab With or Without Dexamethasone in Combination With Novel Agents Compared to Isatuximab With Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma (RRMM) - Master Protocol
Status: Recruiting, Estimated PCD: 2027-12-02
Product
SAR439459
Product
Belumosudil
Product
Evorpacept
Product
AUTO CAR T cell therapy
Clinical trial
A Phase 1/2, Multicenter, Open-label, Study to Determine the Recommended Dose and Regimen, and Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Subjects With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)
Status: Active (not recruiting), Estimated PCD: 2026-11-30
Drug
Elotuzumab
Clinical trial
Phase I Study of Escalating-Doses of Bendamustine for Patients With Previously Treated Multiple Myeloma
Status: , Estimated PCD: 2020-01-01
Clinical trial
A Phase 2 Study to Evaluate Safety and Efficacy of Teclistamab in Combination With Daratumumab, Lenalidomide, and Dexamethasone With or Without Bortezomib as Induction Therapy and Teclistamab in Combination With Daratumumab and Lenalidomide as Maintenance Therapy in Participants With Newly Diagnosed Transplant Eligible Multiple Myeloma
Status: Recruiting, Estimated PCD: 2026-10-15
Clinical trial
Minimal Residual Disease-based Strategy With T-Cell Redirector After Treatment With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (D-VRd) in Newly Diagnosed Multiple Myeloma: A Phase 2 (IFM 2022-01)
Status: Not yet recruiting, Estimated PCD: 2026-04-20
Clinical trial
Phase II Study of Belantamab Mafodotin in Combination With Carfilzomib, Pomalidomide, and Dexamethasone (KPd) in Patients With Relapsed Multiple Myeloma
Status: Recruiting, Estimated PCD: 2028-07-01
Drug
Pomalidomide
Product
Clofarabine
Clinical trial
An Open Label, Single-arm Clinical Study Evaluating the Safety and Efficacy of ICI201 Infusion in Relapsed/Refractory Multiple Myeloma
Status: Withdrawn, Estimated PCD: 2023-10-18
Product
ICI201
Clinical trial
A Phase III Non-Inferiority Randomized Controlled Trial of Fixed Duration Versus Continuous Daratumumab Among Transplant Ineligible Older Adults With Newly Diagnosed Multiple Myeloma
Status: Recruiting, Estimated PCD: 2032-01-31
Clinical trial
A Phase I Study of Panobinostat in Combination With Daratumumab, Bortezomib, and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma
Status: Terminated, Estimated PCD: 2022-06-16
Clinical trial
A Phase Ib Study Of The Combination Of CD47 Blockade With SIRP-Alpha FC Fusion Proteins (TTI-622) And Daratumumab Hyaluronidase-fihj For Patients With Relapsed or Refractory Multiple Myeloma
Status: Active (not recruiting), Estimated PCD: 2025-10-01
Drug
TTI-622
Product
Daratumumab Hyaluronidase
Product
Daratumumab and Hyaluronidase
Clinical trial
MATCH Treatment Subprotocol Q: Ado-trastuzumab Emtansine in Patients With Tumors With HER2 Amplification (Except Breast and Gastric/Gastro-Esophageal Junction (GEJ) Adenocarcinomas)
Status: Active (not recruiting), Estimated PCD: 2019-03-09
Product
Trastuzumab Emtansine
Clinical trial
MATCH Treatment Subprotocol Z1A: Binimetinib in Patients With Tumors (Other Than Melanoma) With NRAS Mutations
Status: Active (not recruiting), Estimated PCD: 2019-05-03
Product
Binimetinib
Clinical trial
An Open-Label, Pilot Study of Romiplostim for Conditioning Regimen-Related Thrombocytopenia After High-Dose Therapy and Autologous Hematopoietic Cell Transplantation
Status: Completed, Estimated PCD: 2023-06-08
Product
Romiplostim
Clinical trial
Allogeneic Stem Cell Transplantation vs. Conventional Therapy as Salvage Therapy for Relapsed / Progressive Patients With Multiple Myeloma After First-line Therapy
Status: Recruiting, Estimated PCD: 2028-03-01
Product
Allogeneic Stem Cells
Product
Carfilzomib + Lenalidomide + Dexamethasone
Product
Elotuzumab + Lenalidomide + Dexamethasone
Product
Daratumumab + Bortezomib + Dexamethasone
Product
Daratumumab + Lenalidomide + Dexamethasone
Clinical trial
A Clinical Study of Legend Biotech BCMA-chimeric Antigen Receptor Technology in Treating Relapsed/Refractory (R/R) Multiple Myeloma Patients
Status: Active (not recruiting), Estimated PCD: 2023-12-31
Product
CEP-18770
Product
JCARH125
Product
JCARH125 + Anakinra
Clinical trial
A Phase 1/2 Multicenter, Open-label, Dose-escalation Study of IDP-121 in Patients With Relapsed/Refractory Hematologic Malignancies (CASSANDRA)
Status: Recruiting, Estimated PCD: 2024-12-22
Product
PD1-BCMA-CART
Clinical trial
A Phase 1/2, Multi-Center, Open-Label, Dose Finding Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the mTOR Kinase Inhibitor CC-223 Administered Orally to Subjects With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Multiple Myeloma
Status: Completed, Estimated PCD: 2016-11-15
Product
REGN5459
Clinical trial
Intermediate-Size Population Expanded Access Program (EAP) for Ciltacabtagene Autoleucel (Cilta-cel) Out-of-Specification (OOS) in Patients With Multiple Myeloma
Status:
Product
IBI3003
Clinical trial
A Protocol to Assess the Safety, Efficacy, and Pharmacokinetics of Continuous Subcutaneous Administration of Low-dose Lenalidomide (STAR-LLD) for the Treatment of Multiple Myeloma (MM)
Status: Recruiting, Estimated PCD: 2024-07-01
Product
REGN5458
Clinical trial
R5458-MM
Status:
Clinical trial
An Expanded Access Program for Elotuzumab in Combination With Lenalidomide Plus Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
Status:
Clinical trial
A Multicenter, Phase 1, Open-label, Dose-escalation and Expansion Study of TNB-383B, a Bispecific Antibody Targeting BCMA in Subjects With Relapsed or Refractory Multiple Myeloma
Status: Active (not recruiting), Estimated PCD: 2026-05-12
Product
LM-305
Product
SEA-BCMA
Clinical trial
A Randomized, Multi-center, Cross-over, Comparative Bioavailability Study of DOXIL/CAELYX Manufactured at a New Site in Patients With Advanced or Refractory Ovarian or Breast Cancer
Status: Not yet recruiting, Estimated PCD: 2024-04-01
Clinical trial
A Non-interventional Study of Selinexor (Nexpovio®) in Combination With Bortezomib and Dexamethasone (SVd) in Patients With Relapsed or Refractory Multiple Myeloma (R/RMM)
Status: Recruiting, Estimated PCD: 2025-09-15
Product
Ipilimumab
Product
Lirilumab
Product
DOXIL/CAELYX
Clinical trial
A Phase 1 Dose Escalation and Cohort Expansion Study of the Safety and Efficacy of Anti-BCMA Allogeneic CRISPR-Cas9-Engineered T Cells (CTX120) in Subjects With Relapsed or Refractory Multiple Myeloma
Status: Active (not recruiting), Estimated PCD: 2026-11-01
Clinical trial
Safety and Efficacy of BCMA-Targeted CAR-T Therapy for Relapsed/Refractory Multiple Myeloma
Status: Recruiting, Estimated PCD: 2023-12-31
Clinical trial
A Phase 1/2a Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Antitumor Activity of LAVA-051 in Patients With Relapsed or Refractory CLL, MM, or AML
Status: Active (not recruiting), Estimated PCD: 2024-09-24
Clinical trial
A Phase 2, Randomized, Parallel, Open-label Study to Investigate the Safety, Efficacy, and Pharmacokinetics of Various Dosing Regimens of Single-agent Belantamab Mafodotin (GSK2857916) in Participants With Relapsed or Refractory Multiple Myeloma (DREAMM-14)
Status: Recruiting, Estimated PCD: 2024-05-13
Product
Systemic Treatment
Clinical trial
An Exploratory Study of Fully Human Anti-GPRC5D Chimeric Antigen Receptor T Cells (CAR-GPRC5D) in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia
Status: Recruiting, Estimated PCD: 2024-03-01
Clinical trial
The Registry of Oncology Outcomes Associated With Testing and Treatment (ROOT)
Status: Recruiting, Estimated PCD: 2029-10-01
Clinical trial
A Phase I, Open-Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Ascending Doses of AZD0466 in Patients With Advanced Hematologic or Solid Tumors
Status: Terminated, Estimated PCD: 2021-06-18
Product
Descartes-11
Product
AZD0466
Product
Pegenzileukin
Clinical trial
Expanded Access Program for Belantamab Mafodotin in Patients With Relapsed/Refractory Multiple Myeloma Who Are Refractory to a Proteasome Inhibitor, and an Immunomodulatory Agent, and an Anti-CD38 Antibody
Status:
Product
ENMD-2076
Clinical trial
Long-term Follow-up of Patients Previously Treated With Autologous T Cells Genetically Modified With Viral Vectors
Status: , Estimated PCD: 2043-07-01
Clinical trial
ABE-DESCART Study: Characterization and Outcomes of Patients With Relapsed and Refractory Multiple Myeloma Eligible for Treatment or Treated With Abecma© (Idecabtagene Vicleucel) in Real World Setting in France. A Database Analysis Based on the DESCAR-T Registry
Status: Active (not recruiting), Estimated PCD: 2027-07-31
Clinical trial
Efficacy and Safety Study of Anti-FcRL5 CAR-T Cells in Subjects With Relapsed and Refractory Multiple Myeloma
Status: Recruiting, Estimated PCD: 2027-01-01
Product
Anti-FcRL5 CAR-T
Clinical trial
Evaluation of Immunologic Response After Pandemic Influenza A (H1N1) Vaccine in Oncologic and Hematologic Patients
Status: Completed, Estimated PCD: 2010-05-01
Product
NYMC X-179A
Clinical trial
EVALUATION OF CHOLECALCIFEROL (VitD3) MAINTENANCE SUPPLEMENTATION IN PATIENTS WITH MULTIPLE MYELOMA (MM) UNDERGOING TRANSPLANTATION AND IN COMBINATION WITH LENALIDOMIDE MAINTENANCE
Status: Not yet recruiting, Estimated PCD: 2028-05-01
Product
Vitamin D
Clinical trial
A PHASE II MULTI-CENTRE, RANDOMIZED, OPEN LABEL STUDY OF PROLONGED THERAPY WITH SC BORTEZOMIB TWICE MONTHLY ASSOCIATED WITH DEXAMETHASONE, IN RELAPSED AND REFRACTORY MULTIPLE MYELOMA PATIENTS AFTER SALVAGE WITH BORTEZOMIB-BASED THERAPY.
Status: Completed, Estimated PCD: 2021-04-01
Clinical trial
PET Imaging of Cancer Patients Using 124I-PUH71: A Pilot Study
Status: Active (not recruiting), Estimated PCD: 2024-12-01
Product
IPUH71
Clinical trial
Effects of Vagus Nerve Osteopathic Stimulations on Heart Rate Variability of Cancer Patients
Status: Terminated, Estimated PCD: 2021-09-19
Product
CRP assessment
Clinical trial
Phase 2, Multi-Center, Single-Arm, Open-Label Study to Evaluate the Efficacy and Safety of the Combination Regimen Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma
Status: Recruiting, Estimated PCD: 2025-09-15
Clinical trial
Pilot Study T Cell Depletion in the Setting of Autologous Stem Cell Transplantation for Patients With Multiple Myeloma
Status: Active (not recruiting), Estimated PCD: 2025-09-12
Drug
Filgrastim
Drug
Plerixafor
Product
Basiliximab
Product
Anti-Thymocyte Globulin
Product
Busulfan
Drug
Varlilumab
Clinical trial
Phase 1/2 Trial of Ixazomib in Combination With Cyclophosphamide and Dexamethasone in Patients With Previously Untreated Symptomatic Multiple Myeloma or Light Chain Amyloidosis
Status: Active (not recruiting), Estimated PCD: 2021-04-30
Clinical trial
Phase I Study of Adoptive Transfer of Autologous T Lymphocytes Engrafted With a Chimeric Antigen Receptor Targeting the Kappa Light Chain of Immunoglobulin Expressed in Patients With CLL, B-Cell Lymphoma or Multiple Myeloma
Status: Recruiting, Estimated PCD: 2025-01-01
Product
Kappa CD28 T cells
Clinical trial
Frontline Management of High-Risk Multiple Myeloma or Plasmacytoma With BCMA and GPRC5D Combination CAR-T Cell Therapy
Status: Recruiting, Estimated PCD: 2027-07-11
Product
CAR-T cells
Clinical trial
Lenalidomide Plus Melphalan as a Preparative Regimen for Autologous Stem Cell Transplantation in Relapsed Multiple Myeloma: A Phase 1 / 2 Study
Status: Active (not recruiting), Estimated PCD: 2024-12-01
Drug
lenalidomide
Product
melphalan
Clinical trial
Phase 2 Study of Cevostamab Consolidation Following BCMA CAR T Cell Therapy for Relapsed/Refractory Multiple Myeloma
Status: Recruiting, Estimated PCD: 2027-05-01
Clinical trial
A Trial of the Safety and Immunogenicity of the COVID-19 Vaccine (mRNA-1273) in Participants With Hematologic Malignancies and Various Regimens of Immunosuppression, and in Participants With Solid Tumors on PD1/PDL1 Inhibitor Therapy, Including Booster Doses of Vaccine
Status: Completed, Estimated PCD: 2023-05-25
Product
mRNA-1273
Clinical trial
Telehealth-based Symptom Management for Veterans Treated With Selinexor
Status: Not yet recruiting, Estimated PCD: 2026-07-01
Clinical trial
Belantamab Mafodotin, Cyclophosphamide and Dexamethasone in Relapsed/Refractory Multiple Myeloma
Status: Active (not recruiting), Estimated PCD: 2023-06-30
Product
Belantamab Mafodotin, Cyclophosphamide and Dexamethasone
Clinical trial
A Phase Ib, Multi-center, Study of Talquetamab in Combination With Iberdomide and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma
Status: Not yet recruiting, Estimated PCD: 2026-06-30
Clinical trial
MATCH Treatment Subprotocol S2: Phase II Study of Trametinib in Patients With Tumors With GNAQ or GNA11 Mutations
Status: Active (not recruiting), Estimated PCD: 2020-09-01
Clinical trial
A Phase I/II Trial of Isatuximab, Bendamustine, and Prednisone in Refractory Multiple Myeloma
Status: Terminated, Estimated PCD: 2023-03-13
Drug
R-CHOP
Product
Ixazomib + Lenalidomide + Dexamethasone
Product
Pomalidomide + Bortezomib + Dexamethasone
Product
Carfilzomib + Daratumumab + Dexamethasone
Product
Autologous Stem Cells
Product
Daratumumab + Pomalidomide + Dexamethasone
Product
Isatuximab + Carfilzomib + Dexamethasone
Product
Selinexor + Bortezomib + Dexamethasone
Clinical trial
Phase 1b Study to Assess Safety and Efficacy of Elotuzumab, CC-92480, and Dexamethasone in Relapsed/Refractory Myeloma After CD38- and BCMA-Targeted Therapies
Status: Recruiting, Estimated PCD: 2024-12-31
Clinical trial
Phase 2 Study of Isatuximab Plus Lenalidomide and Dexamethasone in Highly Toxicity-vulnerable Subjects With Newly Diagnosed Multiple Myeloma
Status: Recruiting, Estimated PCD: 2026-03-01
Clinical trial
A Phase I/II Trial of Bendamustine in Combination With Bortezomib and Pegylated Liposomal Doxorubicin in Patients With Relapsed or Refractory Multiple Myeloma: Hoosier Cancer Research Network MM08-141
Status: Terminated, Estimated PCD: 2017-12-01
Product
Doxorubicin
Clinical trial
Phase I/II Trial of Mezigdomide Plus Ixazomib and Dexamethasone for Relapsed and Refractory Multiple Myeloma
Status: Recruiting, Estimated PCD: 2026-10-01
Clinical trial
Phase Ib Trial of Low-Dose Selinexor (KPT-330) in Combination With Choline Salicylate (CS) for the Treatment of Patients With Non-Hodgkin Lymphoma (NHL), Hodgkin Lymphoma, Histiocytic/Dendritic Cell Neoplasms, or Multiple Myeloma
Status: Recruiting, Estimated PCD: 2024-12-15
Product
Choline Salicylate
Clinical trial
Randomized Phase 2 Trial of Isatuximab During Autologous Stem Cell Collection and Transplantation Period in Patients With Multiple Myeloma, Relapsed Hodgkin's and Non-Hodgkin's Lymphoma
Status: Recruiting, Estimated PCD: 2025-03-01
Clinical trial
A Phase II Randomized Adaptive Platform Trial Evaluating Novel Therapies in Relapsed or Refractory Multiple Myeloma
Status: Not yet recruiting, Estimated PCD: 2029-07-31
Product
Investigational Agent
Clinical trial
Talquetamab Consolidation After BCMA CART Cell Therapy for Relapsed or Refractory Multiple Myeloma
Status: Recruiting, Estimated PCD: 2026-10-01
Clinical trial
Phase 1/2 Trial of Selinexor in Combination With Pomalidomide and Dexamethasone ± Carfilzomib for Patients With Proteasome-Inhibitor and Immunomodulatory Drug Refractory Multiple Myeloma (SCOPE)
Status: Recruiting, Estimated PCD: 2025-03-04
Clinical trial
A Phase 1 Study Evaluating the Safety of Venetoclax and Tocilizumab in African American and Non-African American Subjects With Relapsed or Refractory t(11;14) Multiple Myeloma
Status: Recruiting, Estimated PCD: 2026-02-12
Drug
Tocilizumab
Clinical trial
Autologous Stem Cell Transplantation With Nivolumab in Patients With Multiple Myeloma
Status: Active (not recruiting), Estimated PCD: 2024-12-30
Drug
T-VEC
Clinical trial
Phase 2 Study of Iberdomide Maintenance Therapy Following Autologous Stem Cell Transplant in Patients With Multiple Myeloma
Status: Recruiting, Estimated PCD: 2025-03-01
Clinical trial
A Multi-arm Phase 1b Study of Teclistamab With Other Anticancer Therapies in Participants With Multiple Myeloma
Status: Active (not recruiting), Estimated PCD: 2024-10-31
Drug
Nirogacestat
Clinical trial
Phase II Study of Daratumumab Based Response Adapted Therapy for Older Adults With Newly Diagnosed Multiple Myeloma
Status: Active (not recruiting), Estimated PCD: 2023-11-08
Clinical trial
Phase I/II Trial of MLN9708 Plus Pomalidomide and Dexamethasone for Relapsed or Relapsed Refractory Multiple Myeloma
Status: Completed, Estimated PCD: 2016-05-18
Drug
dexamethasone
Clinical trial
A Clinical Study to Evaluate the Safety and Effectiveness of CD19-BCMA CAR-T Cells Immunotherapy in Patients With Relapsed or Refractory Multiple Myeloma
Status: Recruiting, Estimated PCD: 2024-09-30
Clinical trial
Phase I/II Trial of AT-101 in Combination With Lenalidomide and Dexamethasone in Patients With Relapsed Symptomatic Multiple Myeloma
Status: Completed, Estimated PCD: 2018-10-26
Product
R-(-)-Gossypol
Clinical trial
MUK Nine b: OPTIMUM. A Phase II Study Evaluating Optimised Combination of Biological Therapy in Newly Diagnosed High Risk Multiple Myeloma and Plasma Cell Leukaemia.
Status: Active (not recruiting), Estimated PCD: 2025-10-01
Clinical trial
MATCH Treatment Subprotocol Z1M: Phase 2 Study of Nivolumab and BMS-986016 (Relatlimab) in Patients With LAG-3+ Tumors With Mismatch Repair Deficiency (MMR-d) After Progression on Anti-PD-1/PD-L1 Therapy
Status: Withdrawn, Estimated PCD: 2023-01-17
Product
Relatlimab
Clinical trial
A Phase 2 Study of Teclistamab in Combination With Daratumumab or Lenalidomide in Elderly Patients With Newly Diagnosed Multiple Myeloma
Status: Not yet recruiting, Estimated PCD: 2025-05-01
Clinical trial
A Randomized Phase III Study Of Thalidomide And Prednisone As Maintenance Therapy Following Autologous Stem Cell Transplant in Patients With Multiple Myeloma
Status: Completed, Estimated PCD: 2011-10-19
Drug
prednisone
Drug
thalidomide
Clinical trial
A Phase II Trial Evaluating 18F-Fluciclovine PET/CT in Multiple Myeloma
Status: Recruiting, Estimated PCD: 2026-12-06
Product
18F-fluciclovine
Clinical trial
Phase I Study of BCMA-TGF-BETA Insensitive Armored CAR T Cells in Patients With Relapsed and/or Refractory Multiple Myeloma
Status: Not yet recruiting, Estimated PCD: 2027-05-01
Product
BCMA-TGFβ CAR-T cells
Product
Maximum tolerated dose
Clinical trial
Denosumab for High Risk SMM and SLiM CRAB Positive, Early Myeloma Patients- a Randomized, Placebo Controlled Phase II Trial "DEFENCE" (DEnosumab For the rEductioN of the Smoldering Myeloma transformatioN inCidence ratE)
Status: Active (not recruiting), Estimated PCD: 2023-09-14
Clinical trial
Immuno-consolidation for Newly Diagnosed Multiple Myeloma Using Lack of MRD Negativity After Initial cOmbination Therapy to Pursue Deeper Responses With Linvoseltamab ANd Delay Transplant
Status: Not yet recruiting, Estimated PCD: 2027-06-30
Clinical trial
A Phase I Study of Adoptive Immunotherapy for Advanced B-Cell Maturation Antigen (BCMA)+ Multiple Myeloma With Autologous CD4+ and CD8+ T Cells Engineered to Express a BCMA-Specific Chimeric Antigen Receptor
Status: Completed, Estimated PCD: 2021-05-03
Product
Autologous Anti-BCMA-CAR-expressing CD4+/CD8+ T-lymphocytes FCARH143
Clinical trial
A Randomized, Phase III Study Comparing Conventional Dose Treatment Using a Combination of Lenalidomide, Bortezomib, and Dexamethasone (RVD) to High-Dose Treatment With Peripheral Stem Cell Transplant in the Initial Management of Myeloma in Patients Up to 65 Years of Age
Status: Active (not recruiting), Estimated PCD: 2021-12-01
Clinical trial
Phase 1/2 Study of Daratumumab, Bortezomib, Dexamethasone With or Without Venetoclax in Relapsed/Refractory Multiple Myeloma With Assessment for t(11;14) Status
Status: Withdrawn, Estimated PCD: 2020-05-28
Clinical trial
Randomized Phase 1 / 2 Trial of Belantamab Mafodotin, Lenalidomide, and Daratumumab in Relapsed or Newly Diagnosed Multiple Myeloma Patients
Status: Completed, Estimated PCD: 2024-03-18
Clinical trial
Isatuximab and Autologous Hematopoietic Stem Cell Transplantation for Relapsed Multiple Myeloma Patients (Isabel Study)
Status: Active (not recruiting), Estimated PCD: 2023-11-28
Product
Isatuximab-dexamethasone
Clinical trial
A Phase I Clinical Trial With TriPRIL CAR T Cells for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma
Status: Recruiting, Estimated PCD: 2026-01-01
Product
TriPRIL CAR T Cells
Clinical trial
Study of Isatuximab Plus Pomalidomide and Dexamethasone in Highly Toxicity-vulnerable Subjects With Relapsed or Refractory Multiple Myeloma
Status: Recruiting, Estimated PCD: 2028-12-28
Clinical trial
A Prospective Clinical, Mixed-method Study Exploring Patient and Health Care Perspectives
Status: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
Use of Natural Signals and Ambient Dendritic Cells to Culture-Expand Cancer Targeting T-Cells Directly From Unfractionated Peripheral Blood: A Phase 1 T-Cell Dose Escalation Trial Targeting Relapsed and Refractory MUC1-Expressing Multiple Myeloma
Status: Recruiting, Estimated PCD: 2024-10-01
Product
Autologous MUC1-activated T-cells
Clinical trial
A Phase 2 Study of Subcutaneous Daratumumab in Combination With Dose-Attenuated Bortezomib, Lenalidomide, and Dexamethasone in Elderly Newly Diagnosed Multiple Myeloma Patients
Status: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
Clinical Study to Evaluate the Safety and Efficacy of Daratumumab and Carfilzomib-based Induction/Consolidation/Maintenance Therapy in Transplant-eligible, Ultra High-risk, Newly Diagnosed Multiple Myeloma
Status: Recruiting, Estimated PCD: 2026-10-20
Drug
Cisplatin
Clinical trial
Phase I Dose-Escalation Study of BCMA/CS1 Bispecific Chimeric Antigen Receptor (CAR)-T Cells for Relapsed/Refractory Multiple Myeloma
Status: Withdrawn, Estimated PCD: 2027-03-28
Drug
epirubicin
Product
Etoposide
Drug
bortezomib
Clinical trial
A PHASE 1B, OPEN-LABEL STUDY OF ELRANATAMAB IN COMBINATION WITH CARFILZOMIB PLUS DEXAMETHASONE AND ELRANATAMAB IN COMBINATION WITH PF-07901801 IN PARTICIPANTS WITH RELAPSED REFRACTORY MULTIPLE MYELOMA
Status: Recruiting, Estimated PCD: 2026-02-08
Drug
Elranatamab
Clinical trial
Multiple Myeloma Outcomes Based on Maintenance Therapy Post Autologous Stem Cell Transplant
Status: Recruiting, Estimated PCD: 2025-02-01
Product
Immunomodulatory Agent
Clinical trial
Phase 2, Single-Arm Study of Iberdomide, Daratumumab, Carfilzomib, and Dexamethasone (Iber-KDd) in Patients With Relapsed/Refractory Multiple Myeloma
Status: Recruiting, Estimated PCD: 2029-03-01
Clinical trial
MATCH Treatment Subprotocol Z1I: Phase II Study of AZD1775 in Patients With Tumors Containing BRCA1 and BRCA2 Mutations
Status: Active (not recruiting), Estimated PCD: 2025-06-30
Drug
Adavosertib
Clinical trial
A Phase II Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate Uproleselan (GMI-1271) for GI Toxicity Prophylaxis During Melphalan-Conditioned Autologous Hematopoietic Cell Transplantation (Auto-HCT) for Multiple Myeloma (MM)
Status: Completed, Estimated PCD: 2022-11-11
Product
Uproleselan
Product
Proteasome Inhibitor
Clinical trial
Blockade of PD-1 in Conjunction With the Dendritic Cell/Myeloma Vaccines Following Stem Cell Transplantation
Status: Active (not recruiting), Estimated PCD: 2024-09-01
Product
CT-011
Product
Dendritic Cell Fusion Vaccine
Clinical trial
Phase II Clinical Study of Daratumumab Combined With Bortezomib, Lenalidomide and Dexamethasone (DVRd) in the Treatment of Patients With Newly Diagnosed Double-hit Multiple Myeloma
Status: Recruiting, Estimated PCD: 2026-12-01
Product
DVRd
Clinical trial
Maintenance Therapy With Carfilzomib, Pomalidomide and Dexamethasone (CPd) in High-Risk Myeloma Patients: A Phase 2 Study With a Safety Run-In
Status: Active (not recruiting), Estimated PCD: 2025-03-31
Clinical trial
Phase II Study of Umbilical Cord Blood-Derived Natural Killer Cells in Conjunction With Elotuzumab, Lenalidomide and High Dose Melphalan Followed by Autologous Stem Cell Transplant for Patients With Multiple Myeloma
Status: Active (not recruiting), Estimated PCD: 2025-06-30
Product
Natural Killer Cell Therapy
Product
Umbilical Cord Blood-Derived Lymphocyte Therapy
Clinical trial
Phase 2 Trial of Pembrolizumab, Ixazomib, and Dexamethasone for Relapsed Multiple Myeloma
Status: Completed, Estimated PCD: 2019-11-14
Clinical trial
A Phase II Trial of Haploidentical Allogeneic Stem Cell Transplantation Utilizing Mobilized Peripheral Blood Stem Cells
Status: Active (not recruiting), Estimated PCD: 2023-08-28
Clinical trial
A Phase I-II Open-label Study of Reduced Intensity-allogeneic Transplant of ECT-001 (UM171/ Fed-batch Culture System) Expanded Cord Blood in Patients With High-risk Multiple Myeloma
Status: Active (not recruiting), Estimated PCD: 2023-10-28
Product
ECT-001
Clinical trial
MATCH Treatment Subprotocol S1: Phase II Study of Trametinib in Patients With Tumors With NF1 Mutations
Status: Active (not recruiting), Estimated PCD: 2020-06-30
Clinical trial
Targeted Agent and Profiling Utilization Registry (TAPUR) Study
Status: Recruiting, Estimated PCD: 2024-12-31
Product
Palbociclib
Product
Sunitinib
Product
Temsirolimus
Product
Trastuzumab + Pertuzumab
Product
Vemurafenib + Cobimetinib
Clinical trial
Open Label, Phase 2, Single-Arm Study of Selinexor, Daratumumab, Carfilzomib and Dexamethasone for High-Risk, Relapsed and Relapsed/Refractory Multiple Myeloma Patients Who Have Received 1 - 3 Prior Lines of Therapy
Status: Recruiting, Estimated PCD: 2024-09-30
Clinical trial
Phase 2 Study of Belantamab Mafodotin as Pre- and Post-autologous Stem Cell Transplant Consolidation and Maintenance for Multiple Myeloma
Status: Recruiting, Estimated PCD: 2026-07-11
Clinical trial
Reduce Intensity Conditioning (RIC) Allogenic Hematopoietic Stem Cell Transplantation (Allo HSCT) for Patients With Relapsed Multiple Myeloma: A Pilot Study
Status: Terminated, Estimated PCD: 2021-05-08
Clinical trial
A Phase III Study Comparing Lenalidomide and Subcutaneous Daratumumab (R-Dara SC) vs Lenalidomide and Dexamethasone (Rd) in Frail Subjects With Previously Untreated Multiple Myeloma Who Are Ineligible for High Dose Therapy
Status: Active (not recruiting), Estimated PCD: 2026-10-01
Product
Daratumumab SC in combination with Lenalidomide
Clinical trial
A Phase II Study Incorporating Bone Marrow Microenvironment (ME) - Co-Targeting Bortezomib Into Tandem Melphalan-Based Autotransplants With DTPACE for Induction/Consolidation and Thalidomide + Dexamethasone for Maintenance
Status: Active (not recruiting), Estimated PCD: 2025-08-01
Product
Adriamycin
Clinical trial
Phase Ib/II Trial Of Iberdomide-Combinations In Patients With Positive Minimal Residual Disease (>10-5) After Autologous Hematopoietic Cell Transplantation In The Upfront Management Of Patients With Multiple Myeloma
Status: Recruiting, Estimated PCD: 2025-12-01
Clinical trial
Phase I Trial of Systemic Administration of Vesicular Stomatitis Virus Genetically Engineered to Express NIS and Human Interferon, in Patients With Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia, Lymphomas, or Histiocytic/Dendritic Cell Neoplasms
Status: Recruiting, Estimated PCD: 2028-12-31
Product
Recombinant Vesicular Stomatitis Virus-expressing Human Interferon Beta and Sodium-Iodide Symporter
Drug
Larotrectinib
Product
Tucatinib plus Trastuzumab Subcutaneous
Product
Futibatinib
Clinical trial
A Phase II Study of ISABELA: Isatuximab, Belantamab Mafodotin, Pomalidomide, and Dexamethasone in Relapsed and Refractory Multiple Myeloma
Status: Not yet recruiting, Estimated PCD: 2025-12-01
Clinical trial
Safety and the Anti- Tumor Effects of Escalating Doses of Adoptively Infused Ex Vivo Expanded Autologous Natural Killer (NK) Cells Against Metastatic Cancers or Hematological Malignancies Sensitized to NK-TRAIL Cytotoxicity With Bortezomib
Status: Completed, Estimated PCD: 2021-04-06
Product
NK cells
Clinical trial
Post-Transplant Maintenance Therapy With Isatuximab Plus Lenalidomide for High-Risk Multiple Myeloma Patients
Status: Recruiting, Estimated PCD: 2025-12-31
Clinical trial
Value of Chemokine Receptor CXCR4-targeting Molecular Imaging for Diagnosis and Prognostic Evaluation in Lymphoproliferative Diseases
Status: Recruiting, Estimated PCD: 2024-12-01
Product
68Ga-Pentixafor
Clinical trial
A Randomized Phase II, 2-armed Study in Transplant Ineligible (TI) Patients With Newly Diagnosed Multiple Myeloma (NDMM) Comparing Carfilzomib + Thalidomide + Dexamethasone (KTd) Versus Carfilzomib + Lenalidomide + Dexamethasone (KRd) Induction Therapy With Respect to Response Rates and Investigating a Carfilzomib (K) Monotherapy Maintenance Strategy
Status: Completed, Estimated PCD: 2024-03-28
Clinical trial
A Phase 2, Randomized, Open-Label Study to Assess the Safety and Efficacy of GPC 100 and Propranolol With and Without G-CSF for the Mobilization of Stem Cells in Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplant
Status: Recruiting, Estimated PCD: 2025-03-29
Product
GPC-100
Product
Propranolol
Clinical trial
A Phase 1/1b Study Evaluating the Safety, Pharmacokinetics, and Preliminary Efficacy of LP-118 in Subjects With Relapsed or Refractory Hematological Malignancies
Status: Recruiting, Estimated PCD: 2025-10-01
Product
LP-118
Clinical trial
A Retrospective Study to Compare Clinical Outcomes Between Advanced Immunotherapy and Classical Immunochemotherapy in Patients With Relapsed/Refractory Multiple Myeloma
Status: Active (not recruiting), Estimated PCD: 2025-12-31
Product
Immunotherapy
Clinical trial
REsponse Adapted Combination Therapy Approaches for High-Risk Multiple Myeloma (REACH)
Status: Recruiting, Estimated PCD: 2027-11-20
Clinical trial
A Phase Ib Study of Isatuximab, Velcade, and Dexamethasone in Patients With Multiple Myeloma and Severe KIDNEY Disease
Status: Terminated, Estimated PCD: 2022-12-06
Clinical trial
Carfilzomib - Lenalidmide - Dexamethasone (KRd) Versus Lenalidomi - Dexamethasone (Rd) in Newly Diagnosed Myeloma Patients Not Eligible for Autologous Stem Cell Transplantation: a Randomized Phas III Trial
Status: Active (not recruiting), Estimated PCD: 2024-07-01
Clinical trial
Exploratory Study Evaluating the Relevance of [68Ga]Ga -PentixaFor for Initial Staging and Therapeutic Evaluation of Symptomatic Multiple Myeloma Patients in First Line Treatment
Status: Recruiting, Estimated PCD: 2029-12-21
Product
[68Ga]Ga-PentixaFor
Clinical trial
Phase II Trial for Newly Diagnosed Low-risk Multiple Myeloma Patients Comparing 6 Cycles of Isatuximab With Lenalidomide/Bortezomib/Dexamethasone (I-VRD) Compared to 3 Cycles of I-VRD Followed by One Cycle of High-dose Therapy and Both Arms Followed by Maintenance Therapy With I-R.
Status: Recruiting, Estimated PCD: 2027-08-01
Clinical trial
Stage I Multiple Myeloma Treatment
Status: Completed, Estimated PCD: 2009-11-01
Product
zometa
Clinical trial
A Phase II Pilot Study to Evaluate the Role of Siltuximab in Treatment of Cytokine Release Syndrome (CRS) and Immune Effector Cell Associated Neurotoxicity (ICANS) Related to Chimeric Antigen Receptor T-Cell Therapy (CAR-T) in Hematological Malignancies
Status: Recruiting, Estimated PCD: 2024-12-31
Product
Siltuximab
Clinical trial
A Phase 2 Study of Daratumumab, Bortezomib, and Dexamethasone (DVd), Followed by Daratumumab, Ixazomib, and Dexamethasone (DId) for Relapsed and/or Refractory Myeloma
Status: Active (not recruiting), Estimated PCD: 2024-12-31
Clinical trial
Selinexor, Venetoclax, and Dexamethasone (XVenD) in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma (SELVEDge Study)
Status: Recruiting, Estimated PCD: 2026-03-26
Clinical trial
A Phase I/II Dose-Escalation Trial of Leflunomide in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma
Status: Completed, Estimated PCD: 2018-09-18
Product
Leflunomide
Clinical trial
Administration of Tumor-Associated Antigen (TAA)-Specific Cytotoxic T-Lymphocytes to Patients With Active Myeloma (TACTAM)
Status: Recruiting, Estimated PCD: 2024-12-22
Product
TAA-specific CTLs
Clinical trial
A Phase 3 Randomized Study Comparing Teclistamab in Combination With Daratumumab SC and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab SC and Lenalidomide (Tal-DR) Versus Daratumumab SC, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma Who Are Either Ineligible or Not Intended for Autologous Stem Cell Transplant as Initial Therapy
Status: Recruiting, Estimated PCD: 2031-04-30
Clinical trial
A Phase I Study of Duvelisib in Combination With BMS-986345 in Lymphoid Malignancy
Status: Active (not recruiting), Estimated PCD: 2024-03-01
Product
BMS-986345
Product
Duvelisib
Clinical trial
Phase 1/1b Study of the Efficacy and Safety of the Combination of Panobinostat + Carfilzomib in Patients With Relapsed/Refractory Myeloma
Status: Completed, Estimated PCD: 2019-11-07
Clinical trial
MInimal Residual Disease Adapted Strategy: Frontline Therapy for Patients Eligible for Autologous Stem Cell Transplantation Less Than 66 Years; a Prospective Study
Status: Active (not recruiting), Estimated PCD: 2024-12-01
Clinical trial
Efficacy of Daratumumab in Patients With Relapsed/Refractory Myeloma With Renal Impairment
Status: Completed, Estimated PCD: 2021-03-22
Clinical trial
A Multicenter, Randomized, Controlled, Non-inferiority Study of Narlumosbart Compared With Denosumab in the Treatment of Bone Disease in Patients With Multiple Myeloma
Status: Not yet recruiting, Estimated PCD: 2024-12-31
Product
Narlumosbart
Clinical trial
Phase 2 Study With Minimal Residual Disease (MRD) Driven Adaptive Strategy in Treatment for Newly Diagnosed Multiple Myeloma (MM) With Upfront Daratumumab-based Therapy
Status: Active (not recruiting), Estimated PCD: 2024-08-01
Clinical trial
A MULTIARM, OPEN LABEL, RANDOMIZED PHASE II STUDY OF MLN9708 PLUS ORAL DEXAMETHASONE or PLUS ORAL CYCLOPHOSPHAMIDE AND DEXAMETHASONE or PLUS ORAL THALIDOMIDE AND DEXAMETHASONE FOLLOWED BY MAINTENANCE WITH MLN9708 IN NEWLY DIAGNOSED ELDERLY MULTIPLE MYELOMA PATIENTS
Status: Completed, Estimated PCD: 2023-10-01
Drug
ixazomib
Clinical trial
A Clinical Study on the Whole-course Management (BCD-KPD-AutoHSCT) Scheme for Patients With Multiple Myeloma and Kidney Injury
Status: Recruiting, Estimated PCD: 2025-11-30
Clinical trial
A Phase 1 Study of JNJ-64407564, a Humanized GPRC5D * CD3 Bispecific Antibody in Japanese Subjects With Relapsed or Refractory Multiple Myeloma
Status: Active (not recruiting), Estimated PCD: 2022-10-14
Clinical trial
Isatuximab in Combination With Lenalidomide-Dexamethasone Compared to Lenalidomide-Dexamethasone in Elderly Patients (Aged ≥70 Years) With Newly Diagnosed Myeloma: a Randomized Phase II Study (SGZ-2019-12650)
Status: Recruiting, Estimated PCD: 2027-12-01
Product
Isatuximab-Irfc
Clinical trial
A Phase I Study of the Combination of a Selective Inhibitor of Nuclear Export (SINE), Selinexor With Carfilzomib and Dexamethasone in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma
Status: Recruiting, Estimated PCD: 2024-07-01
Product
selinexor
Drug
Regorafenib
Product
Olaparib
Product
Nivolumab and Ipilimumab
Product
Abemaciclib
Product
Talazoparib
Product
Atezolizumab and Talazoparib
Drug
Entrectinib
Clinical trial
Anakinra: Efficacy of Anakinra for the Management of Fever During Neutropenia and Mucositis in Patients With Multiple Myeloma Receiving an Autologous Hematopoietic Stem Cell Transplantation After High-dose Melphalan - An RCT
Status: Active (not recruiting), Estimated PCD: 2023-03-14
Product
Anakinra
Product
Placebos
Clinical trial
A Prospective Phase 2 Study to Assess the Minimal Residual Disease After Ixazomib Plus Lenalidomide Plus Dexamethasone (IRd) Treatment for Newly Diagnosed Transplant Eligible Myeloma Patients
Status: Active (not recruiting), Estimated PCD: 2027-12-31
Clinical trial
Phase II Study of Pembrolizumab in Multiple Myeloma Patients Relapsing After or Refractory to Anti-BCMA CAR-T Therapies
Status: Terminated, Estimated PCD: 2023-12-31
Clinical trial
Short Course Daratumumab in Minimal Residual Disease (MRD) Positive Myeloma Patients After Induction Therapy With/Without Consolidative High Dose Chemotherapy/Autologous Stem Cell Support
Status: Completed, Estimated PCD: 2023-03-23
Clinical trial
LGX818 in Combination With MEK162 in Refractory or Relapsed Multiple Myeloma Patients With BRAFV600E or BRAFV600K Mutation
Status: Completed, Estimated PCD: 2023-03-29
Product
Encorafenib
Clinical trial
Real-World Analysis of Belantamab Mafodotin Care Patterns in Patients With Relapsed and/or Refractory Multiple Myeloma
Status: Completed, Estimated PCD: 2023-11-07
Product
Blenrep
Clinical trial
Daratumumab Provided at Home Experience: An Open, Single-center, Mixed-method Project Initiated on Behalf of Odense University Hospital
Status: Completed, Estimated PCD: 2023-12-15
Clinical trial
Phase I, Open Label, Non-randomised, Non-comparative, Multi-center Study, Evaluating S65487, a Bcl-2 Inhibitor Intravenously Administered, in Patients With Relapsed or Refractory Acute Myeloid Leukemia, Non Hodgkin Lymphoma, Multiple Myeloma or Chronic Lymphocytic Leukemia
Status: Completed, Estimated PCD: 2023-11-06
Product
S65487
Product
Mycophenolate Mofetil
Product
Tacrolimus
Clinical trial
A Phase 1/2, Dose and Schedule Evaluation Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin Administrated in Combination With Lenalidomide, Dexamethasone and Nirogacestat in Patients With Transplant Ineligible Newly Diagnosed Multiple Myeloma
Status: Recruiting, Estimated PCD: 2026-10-31
Clinical trial
Rivaroxaban for Improvement of Thromboembolism Outcomes in Patients With Multiple Myeloma on Lenalidomide-based Therapy: RithMM Trial
Status: Active (not recruiting), Estimated PCD: 2023-12-01
Drug
Rivaroxaban
Drug
ASA
Clinical trial
A Phase Ib Study to Evaluate Safety and Persistence of ex Vivo Expanded Universal Donor NK Cells in Combination With IL-2 and TGFbeta Receptor I Inhibitor Vactosertib in Patients With Locally Advanced/Metastatic Colorectal Cancer and Relapsed/Refractory Hematologic Malignancies
Status: Recruiting, Estimated PCD: 2025-12-31
Product
Vactosertib
Clinical trial
MATCH Treatment Subprotocol E: Osimertinib (AZD9291) in Patients With Tumors Having EGFR T790M Mutations or Rare Activating Mutations of EGFR
Status: Active (not recruiting), Estimated PCD: 2024-05-26
Drug
Osimertinib
Clinical trial
Pilot Study of Pembrolizumab and Single-Fraction, Low-Dose, Radiation Therapy in Patients With Relapsed or Refractory Multiple Myeloma
Status: Completed, Estimated PCD: 2022-09-02
Clinical trial
A Pilot Study of Dendritic Cell DKK1 Vaccine for Patients With Monoclonal Gammopathy and Stable or Smoldering Myeloma
Status: Withdrawn, Estimated PCD: 2024-08-01
Product
DKK1
Clinical trial
Phase 1 Study of Tasquinimod Alone and in Combination With Standard Therapy for Relapsed or Refractory Myeloma
Status: Recruiting, Estimated PCD: 2024-07-01
Product
Tasquinimod
Product
IRd
Clinical trial
A Phase I Trial of B-cell Maturation Antigen (BCMA) Targeted EGFRt/BCMA-41BBz Chimeric Antigen Receptor (CAR) Modified T Cells With or Without Lenalidomide for the Treatment of Multiple Myeloma (MM)
Status: Active (not recruiting), Estimated PCD: 2025-02-01
Product
EGFRt/BCMA-41BBz CAR T
Product
Lenalidomide.
Clinical trial
A Phase I/II Study of Carfilzomib, Lenalidomide, Vorinostat, and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma
Status: Active (not recruiting), Estimated PCD: 2024-11-01
Product
Vorinostat
Clinical trial
Phase II Study of the Combination of MLN 9708 With Lenalidomide as Maintenance Therapy Post Autologous Stem Cell Transplant in Patients With Multiple Myeloma
Status: Completed, Estimated PCD: 2023-04-12
Clinical trial
Minimal Residual Disease Guided Maintenance Therapy With Belantamab Mafodotin and Lenalidomide After Autologous Hematopoietic Cell Transplantation in Patients With Newly Diagnosed Multiple Myeloma
Status: Recruiting, Estimated PCD: 2025-03-31
Clinical trial
A Phase I Study to Assess the Tolerability of 225Ac-DOTATATE in Patients With Refractory and Relapsing Multiple Myeloma Expressing Somatostatin Receptors
Status: Not yet recruiting, Estimated PCD: 2026-10-01
Product
225Ac-DOTATATE
Clinical trial
A Phase 1/Phase 2 Study to Investigate Safety, Tolerability and Efficacy With TG01/QS-21 Vaccine Administration in Patients With Confirmed KRAS or NRAS Codon 12/13 Mutation and High-risk Smoldering Multiple Myeloma or Multiple Myeloma and Evidence of Measurable Disease ≥ 1 Line of Treatment
Status: Recruiting, Estimated PCD: 2027-05-19
Product
TG01
Clinical trial
Exploratory Study Evaluating the Relevance of [68Ga]Ga-PentixaFor for Initial Staging and Detection of Minimal Residual Disease in Multiple Myeloma Patients Eligible for Autologous Stem Cell Transplantation Less Than 66 Years Included in the Prospective IFM 2020-02.
Status: Withdrawn, Estimated PCD: 2023-05-04
Clinical trial
IIT2022-04-Sasine-CAR-T: A Phase 1 Single-arm, Open-label Study to Evaluate the Feasibility and Safety of Collecting and Combining Autologous Hematopoietic Stem Cells With Chimeric Antigen Receptor (CAR) T-Cell Therapy in Subjects With Relapsed/Refractory Hematological Malignancies
Status: Recruiting, Estimated PCD: 2025-12-15
Product
Autologous Hematopoietic Stem Cells
Clinical trial
Engineered Dendritic Cell Vaccines for Remission Maintenance in Multiple Myeloma Patients
Status: Recruiting, Estimated PCD: 2027-07-11
Product
DC vaccines
Clinical trial
Phase 2 Trial of Pomalidomide, Ixazomib and Dexamethasone in Patients With Multiple Myeloma With Extramedullary Disease or Plasma Cell Leukemia
Status: Completed, Estimated PCD: 2020-10-30
Product
Ixazomib Citrate
Clinical trial
A Phase 1 Study of CPI-0610, a Small Molecule Inhibitor of BET (Bromodomain and Extra-terminal) Proteins, in Patients With Previously Treated Multiple Myeloma
Status: Completed, Estimated PCD: 2016-11-08
Product
CPI-0610
Clinical trial
Daratumumab-Based Maintenance in Patients With Relapsed Multiple Myeloma After Salvage Autologous Stem Cell Transplantation
Status: Active (not recruiting), Estimated PCD: 2025-04-23
Clinical trial
Zn-DDC to Target Hypoxia-NFkappaB-CSCs Pathway and Improve the Treatment Outcomes of Haematological Malignancies - A Translation Bench Study
Status: Recruiting, Estimated PCD: 2025-12-31
Product
Zn-DDC
Product
Lanalidomide
Clinical trial
An Open-Label, Multicenter, Phase I Study Evaluating the Safety and Pharmacokinetics of Escalating Doses of Forimtamig (RO7425781) in Participants With Relapsed or Refractory Multiple Myeloma
Status: Recruiting, Estimated PCD: 2026-08-15
Clinical trial
MLN9708 (Ixazomib) and MLN4924 (Pevonedistat) in Relapsed/Refractory Multiple Myeloma Patients: A Phase 1b Trial
Status: Completed, Estimated PCD: 2022-09-12
Product
Pevonedistat
Clinical trial
Pilot Trial Evaluating Viral Protein Production From the Combination of Reolysin and Carfilzomib in Multiple Myeloma
Status: Completed, Estimated PCD: 2021-05-05
Product
Pelareorep
Clinical trial
A Phase II, Open-label Study of Bortezomib Following Nonmyeloablative Allogeneic Stem Cell Transplant in Patients With High-risk Multiple Myeloma
Status: Completed, Estimated PCD: 2018-09-27
Clinical trial
Phase II Study of the Combination of Elotuzumab With Lenalidomide as Maintenance Therapy Post Autologous Stem Cell Transplant in Patients With Multiple Myeloma
Status: Active (not recruiting), Estimated PCD: 2025-04-30
Clinical trial
Post-Op Pain Control for Prophylactic Intramedullary Nailing.
Status: Recruiting, Estimated PCD: 2024-08-01
Product
Ketorolac
Product
Normal saline
Clinical trial
FeAsiBility of a Treatment Free Interval in Newly Diagnosed mUltiple myeLOma Patients Treated With DaratumUmab-Lenalidomide-DexamethaSone- the FABULOUS Study. A Nationwide Open-label Randomized Phase III Clinical Trial Comparing Daratumumab-lenalidomide-dexamethasone Continuously Versus Including a Treatment Free Interval
Status: Not yet recruiting, Estimated PCD: 2031-01-01
Clinical trial
Phase II Trial of Daratumumab for Transplant-Eligible Multiple Myeloma Patients
Status: Active (not recruiting), Estimated PCD: 2025-12-01
Clinical trial
Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for the Treatment of Hematological Diseases
Status: Recruiting, Estimated PCD: 2024-10-01
Product
Cyclosporine A
Product
Mycophenylate mofetil
Product
Umbilical cord blood
Clinical trial
Open-label, Randomized Comparative Study to Assess Biosimilar Pegfilgrastim Versus Biosimilar Filgrastim in Patients With Multiple Myeloma and Lymphoma Post Autologous Hematopoietic Stem Cell Transplantation
Status: Not yet recruiting, Estimated PCD: 2024-11-01
Product
Grastofil®
Clinical trial
Novel Combination of Belantamab Mafodotin and Elotuzumab to Enhance Therapeutic Efficacy in Multiple Myeloma
Status: Recruiting, Estimated PCD: 2025-01-01
Clinical trial
LCI-HEM-MYE-CRD-002: A Phase II Study of Carfilzomib- Revlimid-Dexamethasone-Elotuzumab in Relapsed/Refractory Multiple Myeloma
Status: Active (not recruiting), Estimated PCD: 2021-06-04
Product
Lapelga
Clinical trial
Optimizing Prolonged Treatment In Myeloma Using MRD Assessment (OPTIMUM)
Status: Active (not recruiting), Estimated PCD: 2023-08-06
Clinical trial
A Single-arm Prospective Study of the Treatment in High-risk Newly Diagnosed Multiple Myeloma With Minimal Residual Disease Detection
Status: Not yet recruiting, Estimated PCD: 2027-09-01
Clinical trial
A Phase 2B Study of Selinexor (KPT-330), in Combination With Carfilzomib, Daratumumab or Pomalidomide in Patients With Multiple Myeloma Relapsing on Current Therapy
Status: Recruiting, Estimated PCD: 2025-01-01
Clinical trial
A Phase 1b/2 Study of Standard Doses of Bortezomib and Pembrolizumab ± Reovirus (Pelareorep) Combination Therapy in Patients With Relapsed Multiple Myeloma (AMBUSH Study)
Status: Recruiting, Estimated PCD: 2025-10-07
Clinical trial
A Single Arm, Response-adapted, Open Label Study of Iberdomide, Weekly Bortezomib and Dexamethasone (IberBd) With Isatuximab Added on Demand for Transplant-ineligible, Newly Diagnosed Multiple Myeloma Patients: the BOREALIS Trial
Status: Not yet recruiting, Estimated PCD: 2028-03-01
Clinical trial
A Phase 1/2 Study of Belantamab Mafodotin in Combination With Lenalidomide and Dexamethasone in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma
Status: Active (not recruiting), Estimated PCD: 2028-09-08
Clinical trial
An Open-Label Phase I/II Study of the Safety and Efficacy of Bortezomib, Lenalidomide and Dexamethasone Combination Therapy for Patients With Newly Diagnosed Multiple Myeloma
Status: Active (not recruiting), Estimated PCD: 2009-07-01
Drug
Ketamine
Clinical trial
Data, Tissue, Blood, and Urine Repository for Amyloid Diseases
Status: Recruiting, Estimated PCD: 2040-12-01
Product
Clonality Analysis
Product
Polymerase Chain Reaction
Product
Protein Analysis
Clinical trial
A Pilot Study of Romosozumab Efficacy and Safety for the Management of Myelomarelated OsteoLytic Disease in Postmenopausal Women With Multiple Myeloma and Osteoporosis (REMOLD-MM)
Status: Recruiting, Estimated PCD: 2025-03-01
Product
Romosozumab
Clinical trial
A Pilot Trial Examining Myeloid-Derived Suppressor Cells and Checkpoint Immune Regulators' Expression in Allogeneic Stem Cell Transplant Recipients Using Myeloablative Busulfan and Fludarabine
Status: Completed, Estimated PCD: 2019-06-07
Product
Methotrexate
Clinical trial
Randomized Phase III Trial of Bortezomib, Lenalidomide, and Dexamethasone (VRd) Versus Carfilzomib, Lenalidomide, and Dexamethasone (CRd) Followed by Limited or Indefinite Duration Lenalidomide Maintenance in Patients With Newly Diagnosed Symptomatic Multiple Myeloma (ENDURANCE)
Status: Active (not recruiting), Estimated PCD: 2025-11-30
Clinical trial
A Phase I Clinical Trial of T Cells Expressing a Novel Fully-human Anti-BCMA CAR for Treating Multiple Myeloma
Status: Active (not recruiting), Estimated PCD: 2023-01-01
Clinical trial
A Phase I Trial to Evaluate Safety and Immunogenicity of a Cytomegalovirus Peptide Vaccine Co-Injected With PF-03512676 Adjuvant in Recipients of Allogeneic Hematopoietic Stem Cell Transplant
Status: Completed, Estimated PCD: 2024-02-02
Product
Tetanus-CMV Fusion Peptide Vaccine
Clinical trial
A Pilot Study to Assess Impact of Low Dose Melphalan on Disease Burden Measured by Next Generation Sequencing Before Autologous Hematopoietic Cell Transplant (AHCT) for Multiple Myeloma Patients
Status: Withdrawn, Estimated PCD: 2023-12-01
Clinical trial
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) Trial: PRIME
Status: Terminated, Estimated PCD: 2020-12-10
Product
Abiraterone
Clinical trial
A Phase I/II Study of the c-Met Inhibitor Cabozantinib as a Targeted Strategy to Reverse Resistance to the Proteasome Inhibitor Carfilzomib in Refractory Multiple Myeloma
Status: Terminated, Estimated PCD: 2021-04-12
Product
Cabozantinib
Clinical trial
Phase 1a/1b Study of Itacitinib (INCB039110) for Cytokine Release Syndrome Prevention and Minimization of Immunosuppression Following Nonmyeloablative Related Partially HLA-mismatched Peripheral Blood Stem Cell Transplant (PBSCT) With High-dose Posttransplantation Cyclophosphamide in Older Patients (Age 60 Years)
Status: Recruiting, Estimated PCD: 2028-03-01
Product
Itacitinib
Product
Afatinib
Clinical trial
Phase 1 Trial of 111Indium/225Actinium-DOTA-Daratumumab in Patients With Relapsed/Refractory Multiple Myeloma
Status: Recruiting, Estimated PCD: 2025-03-22
Product
Actinium Ac 225-DOTA-Daratumumab
Product
Indium In 111-DOTA-Daratumumab
Clinical trial
A Multisite, Phase II Study of Bortezomib, Isatuximab, Cyclophosphamide and Dexamethasone (VICD) Induction in Transplant-Eligible Multiple Myeloma Patients
Status: Recruiting, Estimated PCD: 2025-12-01
Clinical trial
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) for Transplantation in Pediatric and Adult Patients With Hematologic Malignancies and Other Indications
Status: Recruiting, Estimated PCD: 2041-10-01
Product
Cryopreserved Cord Blood Units
Product
Dabrafenib
Product
Cabazitaxel
Clinical trial
A Phase II Study of Xisomab 3G3, a Monoclonal Antibody Preventing the Activation of FXI by FXIIa, for the Prophylaxis of Catheter-Associated Thrombosis
Status: Terminated, Estimated PCD: 2021-10-05
Product
Xisomab 3G3
Clinical trial
Carfilzomib/Cyclophosphamide/Dexamethasone With Maintenance Carfilzomib in Untreated Transplant-eligible Patients With Symptomatic MM to Evaluate the Benefit of Upfront ASCT
Status: Active (not recruiting), Estimated PCD: 2019-11-01
Product
CarCyDex
Clinical trial
MATCH Treatment Subprotocol L: Phase II Study of MLN0128 (TAK-228) in Patients With Tumors Wtih mTOR Mutations
Status: Active (not recruiting), Estimated PCD: 2024-12-31
Product
Sapanisertib
Clinical trial
Phase 1, Multicenter, Open-label, Dose-escalation Study of Sotatercept (ACE-011) in Combination With Lenalidomide or Pomalidomide and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma
Status: Active (not recruiting), Estimated PCD: 2024-12-01
Product
ACE-011
Clinical trial
A Clinical Study to Evaluate the Safety and Efficacy of BCMA-GPRC5D CAR-T in Patients With R/R MM Who Received Three or More Lines of Therapy
Status: Recruiting, Estimated PCD: 2025-07-27
Clinical trial
Minimal Residual Disease Response-adapted Deferral of Transplant in Dysproteinemia - MILESTONE Trial
Status: Recruiting, Estimated PCD: 2025-01-01
Product
DaraVRD
Clinical trial
Allogeneic Peripheral Blood Stem Cell Transplantation With Minimally Myelosuppressive Regimen of Pentostatin and Low-dose Total-body Irradiation
Status: Completed, Estimated PCD: 2008-12-30
Product
Pentostatin
Clinical trial
Phase II Study of Interleukin 6 Blockade With Siltuximab to Decrease Symptom Burden in Patients Age 60-75 Undergoing Autologous Stem Cell Transplantation for Multiple Myeloma and AL Amyloidosis
Status: Active (not recruiting), Estimated PCD: 2024-10-01
Clinical trial
Phase 1/2 Trial of Iberdomide in Combination With Daratumumab, BortEzomib and DexamethAsone in Patients With Newly Diagnosed Multiple MyeLoma (IDEAL)
Status: Recruiting, Estimated PCD: 2027-05-01
Clinical trial
A Phase I Trial of Vaccination With CT7, MAGE-A3, and WT1 mRNA-electroporated Autologous Langerhans-type Dendritic Cells as Consolidation for Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation
Status: Completed, Estimated PCD: 2022-06-20
Product
CT7, MAGE-A3, and WT1 mRNA-electroporated Langerhans cells
Clinical trial
Medical Professor,CHONGQING UNIVERSITY CANCER HOSPITAL
Status: Recruiting, Estimated PCD: 2023-12-31
Product
Pegylated Recombinant Human Granulocyte-Colony Stimulating Factor
Clinical trial
Phase II Multicenter Trial of Single Autologous Hematopoietic Cell Transplant Followed by Lenalidomide Maintenance for Multiple Myeloma With or Without Vaccination With Dendritic Cell/Myeloma Fusions (BMT CTN 1401)
Status: Completed, Estimated PCD: 2020-06-30
Product
Myeloma vaccine
Drug
GM-CSF
Clinical trial
A Multi-ARM Phase Ib Study of SAR650984 (Isatuximab, an Anti-CD38 mAb) in Combination With Standard Carfilzomib, and High-dose Weekly Carfilzomib and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma
Status: Active (not recruiting), Estimated PCD: 2024-12-31
Product
Oxycodone Acetaminophen
Product
Morphine
Product
Hydrocodone/Acetaminophen
Product
Oxycodone
Clinical trial
Phase Ib of Cyclophosphamide, Pomalidomide, Dexamethasone and Daratumumab (CPD-DARA) in Patients With Relapsed/Refractory Multiple Myeloma. (The CPD-DARA Study)
Status: Active (not recruiting), Estimated PCD: 2022-04-29
Clinical trial
Monoclonal Antibody-Based Sequential Therapy for Deep Remission in Multiple Myeloma - MASTER Trial
Status: Completed, Estimated PCD: 2023-05-01
Product
KRdD
Clinical trial
MRD-Guided Sequential Therapy For Deep Response in Newly Diagnosed Multiple Myeloma - MASTER-2 Trial
Status: Recruiting, Estimated PCD: 2026-12-01
Product
Dara-VRd
Product
AHCT intensification
Clinical trial
A Phase 3 Randomized Study Comparing JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against BCMA, Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Subjects With Relapsed and Lenalidomide-Refractory Multiple Myeloma
Status: Active (not recruiting), Estimated PCD: 2026-04-10
Clinical trial
A Phase III Randomized, Double-Blind Study of Maintenance Therapy With CC-5013 (NSC # 703813) or Placebo Following Autologous Stem Cell Transplantation for Multiple Myeloma
Status: Active (not recruiting), Estimated PCD: 2012-12-31
Clinical trial
PD1 Blockade and Oncolytic Virus in Relapsed Multiple Myeloma
Status: Completed, Estimated PCD: 2022-10-10
Clinical trial
Lymphodepleting Chemotherapy With Fludarabine and Cyclophosphamide Prior to Infusion of CAR T Cell Therapy in Patients With Moderate-Severe Renal Dysfunction
Status: Not yet recruiting, Estimated PCD: 2025-08-31
Clinical trial
MATCH Treatment Subprotocol Z1H: Phase II Study of Copanlisib in Patients With Tumors With Deleterious PTEN Sequencing Result and PTEN Expression by IHC
Status: Active (not recruiting), Estimated PCD: 2024-11-15
Product
Copanlisib
Clinical trial
MATCH Treatment Subprotocol R: Phase II Study of Trametinib in Patients With BRAF Fusions, or With NonV600E, Non-V600K BRAF Mutations
Status: Active (not recruiting), Estimated PCD: 2019-03-18
Clinical trial
Phase I Study of Carfilzomib-based Chemotherapy Mobilization for Autologous Stem Cell Transplantation in Multiple Myeloma
Status: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
Multi-institutional Prospective Pilot Study of Radiology Evaluation of Acute Leukemia Infiltration analyZed by Experimental Imaging
Status: Recruiting, Estimated PCD: 2025-03-01
Product
FLT
Clinical trial
Feasibility Trial of Autologous Anti-B Cell Maturation Antigen Chimeric Antigen Receptor T Cell Therapy Using Ide-Cel for Multiple Myeloma Patients Status Post Hematopoietic Cell Transplantation
Status: Recruiting, Estimated PCD: 2025-05-01
Product
Ide-cel
Clinical trial
A Clinical Trial to Explore the Safety and Efficacy of CT071 Injection in Patients With Relapsed/Refractory Multiple Myeloma or Primary Plasma Cell Leukemia
Status: Recruiting, Estimated PCD: 2024-11-30
Clinical trial
A Phase 3, Two-stage, Randomized, Multicenter, Open-label Study Comparing Mezigdomide (CC-92480/BMS-986348), Carfilzomib, and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM): SUCCESSOR-2
Status: Recruiting, Estimated PCD: 2026-02-04
Clinical trial
Tacrolimus, Mini-dose Methotrexate and Mycophenolate Mofetil Versus Tacrolimus and Methotrexate for the Prevention of Acute Graft-versus-Host-Disease
Status: Completed, Estimated PCD: 2020-10-09
Clinical trial
A Two Step Approach to Non-Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Hematologic Malignancies
Status: Active (not recruiting), Estimated PCD: 2024-02-13
Clinical trial
A Phase II Trial of Allogeneic Peripheral Blood Stem Cell Transplantation From Matched Unrelated Donors in Patients With Advanced Hematologic Malignancies and Hematological Disorders
Status: Active (not recruiting), Estimated PCD: 2007-03-13
Product
Fludarabine phosphate
Drug
methotrexate
Drug
mycophenolate mofetil
Drug
sirolimus
Clinical trial
A Phase III Randomized Trial for Newly Diagnosed Multiple Myeloma (NDMM) Patients Considered Frail or in a Subset of "Intermediate Fit" Comparing Upfront Three-Drug Induction Regimens Followed by Double or Single-Agent Maintenance
Status: Recruiting, Estimated PCD: 2030-03-31
Clinical trial
A MULTICENTER, OPEN LABEL PHASE II STUDY OF CARFILZOMIB, CYCLOPHOSPHAMIDE AND DEXAMETHASONE IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS
Status: Completed, Estimated PCD: 2012-10-01
Clinical trial
A Phase 2 Trial of Leflunomide, Pomalidomide, and Dexamethasone for Relapsed/Refractory Multiple Myeloma
Status: Recruiting, Estimated PCD: 2024-06-30
Clinical trial
A Phase II Study of the Efficacy and Safety of Lenalidomide, Subcutaneous Bortezomib and Dexamethasone Combination Therapy for Patients With Newly Diagnosed Multiple Myeloma
Status: Active (not recruiting), Estimated PCD: 2021-12-01
Clinical trial
A Phase I Trial of VS-6766 (RO5126766) (a Dual RAF/MEK Inhibitor) Exploring Intermittent, Oral Dosing Regimens in Patients With Solid Tumours or Multiple Myeloma, With an Expansion to Explore Intermittent Dosing in Combination With Everolimus
Status: Recruiting, Estimated PCD: 2024-05-01
Drug
Avutometinib
Product
Everolimus
Clinical trial
Phase I Dose-Escalation and Dose-Expansion Trial of a Novel Glutaminase Inhibitor (CB-839 HCl) in Combination With Carfilzomib and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma
Status: Active (not recruiting), Estimated PCD: 2025-01-30
Product
Telaglenastat
Clinical trial
A Prospective Study of Bortezomib in Combination With Melphalan and Prednisone for Patients With Previously Untreated Multiple Myeloma
Status: Completed, Estimated PCD: 2008-02-01
Clinical trial
MATCH Treatment Subprotocol Y: AZD5363 in Patients With Tumors With AKT Mutations
Status: Active (not recruiting), Estimated PCD: 2019-11-08
Product
Capivasertib
Clinical trial
An Open, Randomised, Controlled, Phase II Trial of CellProtect in Combination With Isatuximab Antibody Versus Isatuximab Antibody Alone as Maintenance Treatment in Patients With Multiple Myeloma Undergoing High Dose Treatment
Status: Recruiting, Estimated PCD: 2027-12-31
Product
CellProtect
Clinical trial
A Phase 3 Randomized Study Comparing Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible
Status: Recruiting, Estimated PCD: 2033-06-01
Clinical trial
Phase 2 Trial of Intensive Chemo-immunotherapy With Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab for Relapsed/Refractory Myeloma in the Context of Salvage Autologous Hematopoietic Cell Transplantation
Status: Active (not recruiting), Estimated PCD: 2025-07-01
Clinical trial
Pharmacokinetic (PK)-Directed Dosing of Captisol Enabled Melphalan for Patients With Multiple Myeloma or Light Chain (AL) Amyloidosis Undergoing High Dose Therapy and Autologous Hematopoietic Progenitor Cell Transplant
Status: Active (not recruiting), Estimated PCD: 2024-09-01
Product
Pegfilgrastim
Clinical trial
Ixazomib (MLN9708) and Dexamethasone in High Risk Smoldering Multiple Myeloma: A Clinical and Correlative Pilot Study
Status: Completed, Estimated PCD: 2024-05-08
Clinical trial
A Phase 1 Dose-Escalation and Exploratory Dose Expansion Study of KRT-232 (AMG 232) in Combination With Carfilzomib, Lenalidomide, and Dexamethasone in Relapsed and/or Refractory Myeloma
Status: Recruiting, Estimated PCD: 2024-12-31
Drug
Navtemadlin
Clinical trial
LCI-HEM-MYE-CRD-004 (MMRC-073 CARJAK): Phase I/II Study of Carfilzomib, Ruxolitinib, and Low Dose Dexamethasone for Carfilzomib-Refractory Multiple Myeloma
Status: Completed, Estimated PCD: 2022-11-07
Clinical trial
Universal CAR-T Cells for the Treatment of Multiple Myeloma
Status: Recruiting, Estimated PCD: 2026-09-30
Product
MM-specific universal CAR T cells
Clinical trial
Phase I Study of Autologous CAR T-Cells Targeting the CD138 Antigen for Relapsed or Refractory Multiple Myeloma
Status: Recruiting, Estimated PCD: 2024-07-01
Product
CAR138
Clinical trial
Myeloablative Allogeneic Hematopoietic Cell Transplantation Using a Related or Unrelated Donor for the Treatment of Hematological Diseases
Status: Recruiting, Estimated PCD: 2025-01-10
Product
HSCT with TBI Regimen
Product
HSCT
Clinical trial
A Randomized Phase 2 Study of Daratumumab-Selinexor-Velcade-Dexamethasone (Dara-SVD) for High-Risk Newly Diagnosed Multiple Myeloma
Status: Recruiting, Estimated PCD: 2026-09-30
Clinical trial
A Phase 2 Study of Selinexor, Pomalidomide, and Dexamethasone For Multiple Myeloma With Central Nervous System Involvement
Status: Recruiting, Estimated PCD: 2024-07-10
Product
Selinexor Oral Tablet
Clinical trial
A Pilot Study Evaluating Lenalidomide and CC-486 in Combination With Radiotherapy For Patients With Plasmacytoma (LENAZART Study)
Status: Active (not recruiting), Estimated PCD: 2024-11-19
Product
CC-486
Clinical trial
Pilot Study of the Infusion of Differentiated Autologous T-cells From Peripheral Blood, Expanded and Transduced With a Lentivirus to Express a Chimeric Antigen Receptor With Anti-BCMA (TNFRSF17) Specificity Humanized Conjugated With the Co-stimulatory Region 4-1BB and Signal-transduction CD3z (ARI0002h) in Patients With Relapsed/Refractory Multiple Myeloma With Previous Treatment With Proteasome Inhibitor, Immunomodulatory Drug and Anti-CD38 Monoclonal Antibody
Status: Active (not recruiting), Estimated PCD: 2025-04-01
Product
Adult differentiated autologous T-cells
Clinical trial
DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial): An Umbrella-Basket Platform Trial to Evaluate the Efficacy of Targeted Therapies in Rare Adult, Paediatric and Teenage/Young Adult (TYA) Cancers With Actionable Genomic Alterations, Including Common Cancers With Rare Actionable Alterations Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers.
Status: Recruiting, Estimated PCD: 2029-10-01
Product
Vemurafenib
Clinical trial
A Phase II Study of AT9283 in Patients With Relapsed or Refractory Multiple Myeloma
Status: Completed, Estimated PCD: 2014-10-29
Product
Fludarabine + Cyclophosphamide + BCMA-GPRC5D CAR-T Cells
Clinical trial
Anti-Viral Central Memory CD8 Veto Cells in Haploidentical Hematopoietic Stem Cell Transplantation
Status: Recruiting, Estimated PCD: 2025-12-01
Product
Dasatinib
Clinical trial
Clinical Research of Pomalidomide Maintenance Therapy for Primary Multiple Myeloma
Status: Recruiting, Estimated PCD: 2025-05-30
Product
Darolutamide
Drug
etoposide
Clinical trial
KRd Consolidation in Myeloma Patients With a Positive PET-CT After Standard First Line Treatment. A Phase II Study
Status: Active (not recruiting), Estimated PCD: 2021-11-01
Clinical trial
A Phase II Study of Steroid Sparing Treatment With Daratumumab and Lenalidomide in Newly Diagnosed Transplant Ineligible Patients With Multiple Myeloma
Status: Recruiting, Estimated PCD: 2024-07-31
Clinical trial
Pre-transplant Purging and Post-transplant MRD-guided Maintenance Therapy With Elranatamab in Patients With High-risk Multiple Myeloma
Status: Not yet recruiting, Estimated PCD: 2029-12-31
Product
VRD
Clinical trial
A Pilot Study to Determine the Safety and Efficacy of Repeated Hyperbaric Oxygen Therapy in Multiple Myeloma Patients Undergoing High-Dose Therapy and Autologous Stem/Progenitor Transplantation
Status: Recruiting, Estimated PCD: 2024-05-15
Product
Hyperbaric oxygen
Clinical trial
A Phase I/II Clinical Study of Chimeric Antigen Receptor T-cell Therapy Targeting CD19 and BCMA (GC012F) in Patients With Relapsed/Refractory Multiple Myeloma
Status: Recruiting, Estimated PCD: 2026-03-01
Drug
GC012F
Clinical trial
An Open-Label, Single Arm, Phase 2a Study of Bortezomib, Lenalidomide, Dexamethasone and Elotuzumab in Newly Diagnosed Multiple Myeloma
Status: Active (not recruiting), Estimated PCD: 2021-12-15
Clinical trial
Outpatient-based Teclistamab Step-up Dosing in Patients With Relapsed/Refractory Multiple Myeloma: Process Development in Academic and Community Centres, and Evaluating Impact on Caregiver Burden
Status: Not yet recruiting, Estimated PCD: 2025-04-15
Clinical trial
Determining Safety and Maximum Tolerated Dose (MTD) of Anti-BCMA CAR-NK Therapy in Relapsed or Refractory Multiple Myeloma
Status: Not yet recruiting, Estimated PCD: 2026-04-30
Product
Anti-BCMA CAR-NK
Clinical trial
Phase I Clinical Trial of Venetoclax (ABT-199) in Combination With Ixazomib and Dexamethasone for Patients With Relapsed Multiple Myeloma
Status: Completed, Estimated PCD: 2021-12-20
Clinical trial
A Randomized Phase II Study to Compare the Net Clinical Benefit of Cyclosporine and Sirolimus Combined With MMF or Post-Transplant Cyclophosphamide as GVHD Prophylaxis After HLA-Matched or HLA-Mismatched Unrelated G-CSF Mobilized Blood Cell Transplantation Using Nonmyeloablative or Reduced Intensity Conditioning for Patients With Hematologic Malignancies
Status: Recruiting, Estimated PCD: 2026-10-11
Product
Cyclosporine
Clinical trial
A Phase II Study of Selinexor In Addition to Lenalidomide for Consolidation and Maintenance Treatment After Autologous Hematopoietic Cell Transplant in Multiple Myeloma
Status: Recruiting, Estimated PCD: 2027-01-31
Clinical trial
Phase II Trial for Evaluation of Alternate Doses and Dosing Schedules of Belantamab Mafodotin in Triple-Class Refractory Multiple Myeloma
Status: Recruiting, Estimated PCD: 2026-05-29
Product
Granulocyte Colony-Stimulating Factor
Clinical trial
Evaluating Mechanisms of Immunomodulator Sensitivity and Resistance in Multiple Myeloma
Status: Active (not recruiting), Estimated PCD: 2024-11-01
Clinical trial
Detection of Poor Mobilizer (PM) in Multiple Myeloma (MM) Patients: Prospective Product Registry
Status: Completed, Estimated PCD: 2021-01-19
Clinical trial
Phase I Study of A CXCR4 Modified BCMA CAR-T in Patients With Refractory and/or Relapsed Multiple Myeloma
Status: Recruiting, Estimated PCD: 2025-12-31
Product
CXCR4 modified anti-BCMA CAR T cells
Clinical trial
Pomalidomide, Ixazomib, and Dexamethasone (PId) With or Without Intensification by Cyclophosphamide (PICd): A Phase II Study in Relapsed or Refractory Multiple Myeloma
Status: Active (not recruiting), Estimated PCD: 2023-12-01
Clinical trial
A Multicenter Phase 1-DEC (Dose Expansion Cohort) Open-label Study of Iberdomide (CC-220) in Combination With Elotuzumab and Dexamethasone for Relapsed/Refractory Multiple Myeloma
Status: , Estimated PCD: 2024-08-01
Clinical trial
An Open-Label Phase 1 Study of Metformin and Nelfinavir in Combination With Bortezomib in Patients With Relapsed and/or Refractory Multiple Myeloma
Status: Active (not recruiting), Estimated PCD: 2022-09-21
Drug
Metformin
Clinical trial
A Phase 1/2 Open Label Study of SL-401 in Combination With Pomalidomide and Dexamethasone in Relapsed or Relapsed and Refractory Multiple Myeloma
Status: Terminated, Estimated PCD: 2019-12-01
Product
SL-401
Clinical trial
Open Label Single Arm Study to Assess the Implementation of Home Based Daratumumab Administration in Patients Being Treated for Multiple Myeloma
Status: Active (not recruiting), Estimated PCD: 2025-01-08
Product
Daratumumab and Hyaluronidase-fihj
Clinical trial
Bone Healing During Ninlaro Exposure. An Open Label Phase 2 Single Centre Clinical Trial
Status: Completed, Estimated PCD: 2024-04-01
Product
Rabbit ATG
Clinical trial
A Phase 2, Open-Label, Single-Arm Study of Selinexor in Combination With Clarithromycin, Pomalidomide and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma
Status: Terminated, Estimated PCD: 2022-11-30
Clinical trial
Improving Host Factors in Patients With Monoclonal Gammopathies
Status: Recruiting, Estimated PCD: 2025-06-28
Product
Beta-Adrenergic Antagonist
Clinical trial
Prospective, Single-arm, Multicenter Exploratory Clinical Study of the Combination of Etoposide, Cytarabine and PEG-rhG-CSF (EAP Regimen) as First Line Mobilization Regimen of Hematopoietic Stem Cells in Patients With Hematological Malignancies
Status: Recruiting, Estimated PCD: 2024-06-01
Product
Cytarabine
Drug
PEG-rhG-CSF
Clinical trial
A Phase 2 Study of CC220 (Iberdomide) Combined With Low-dose Cyclophosphamide and Dexamethasone in Relapsed/Refractory Multiple Myeloma (IberCd): ICON Study
Status: Active (not recruiting), Estimated PCD: 2024-12-01
Clinical trial
MATCH Treatment Subprotocol B: Phase II Study of Afatinib in Patients With Tumors With HER2 Activating Mutations
Status: Active (not recruiting), Estimated PCD: 2021-01-22
Clinical trial
A Phase Ib/IIa Study of Romidepsin in Combination With Lenalidomide in Adults With Relapsed or Refractory Lymphomas and Myeloma
Status: Completed, Estimated PCD: 2023-10-01
Product
Romidepsin
Product
Prochlorperazine
Clinical trial
Phase 2 Trial of Ixazomib Combinations in Patients With Relapsed Multiple Myeloma
Status: Active (not recruiting), Estimated PCD: 2026-02-01
Drug
Atezolizumab
Product
Anti-B Cell Maturation Antigen chimeric antigen receptors T cells
Product
Bicalutamide
Clinical trial
A Multicenter Phase II Study of Maintenance Belantamab Mafodotin (Blenrep®) After BCMA-Directed Chimeric Antigen Receptor T-cell Therapy in Patients With Relapsed and/or Refractory Multiple Myeloma
Status: Recruiting, Estimated PCD: 2027-01-01
Product
Mycophenolate mofetil
Drug
tacrolimus
Clinical trial
Opioid-Sparing Pain Treatment In Myeloma And Lymphoma Patients Undergoing High-Dose Chemotherapy (OPTIMAL-HiChemo): Randomized Controlled Trial
Status: Active (not recruiting), Estimated PCD: 2025-06-01
Product
opioid
Clinical trial
Belantamab Mafodotin in Combination With Nirogacestat and Pomalidomide in Patients With Relapsed or Refractory Multiple Myeloma
Status: Recruiting, Estimated PCD: 2026-10-01
Product
Dacomitinib
Clinical trial
Phase II Trial of Sequential Treatment of Multiple Myeloma With Antibody Therapy
Status: Active (not recruiting), Estimated PCD: 2024-10-31
Drug
UTD1
Clinical trial
Phase 2 Study Assessing Feasibility and Tolerance of the Combination of Elotuzumab, Lenalidomide and Dexamethasone in Induction, Consolidation and Maintenance Treatment of Transplant-Eligible Patients Newly Diagnosed With Multiple Myeloma
Status: Completed, Estimated PCD: 2021-07-27
Product
elotuzumab
Clinical trial
A Single Arm Phase II Study of High-Dose Weekly Carfilzomib Plus Cyclophosphamide and Dexamethasone in the Treatment of Relapsed Multiple Myeloma After 1-3 Prior Therapies
Status: Completed, Estimated PCD: 2019-06-19
Product
Cytokine-treated Veto Cells
Drug
AN0025
Drug
Celecoxib
Product
T Cell-Depleted Donor Lymphocyte Infusion
Product
Nelfinavir
Clinical trial
A Single-Arm Phase II Study of Isatuximab With Carfilzomib and Pomalidomide in Relapsed or Refractory Multiple Myeloma
Status: Active (not recruiting), Estimated PCD: 2026-04-15
Clinical trial
An Intergroup Phase III Randomized Controlled Trial Comparing Melphalan, Prednisone and Thalidomide (MPT) Versus Melphalan, Prednisone and Lenalidomide (Revlimid(TM))(MPR) in Newly Diagnosed Multiple Myeloma Patients Who Are Not Candidates for High-Dose Therapy
Status: Active (not recruiting), Estimated PCD: 2014-01-18
Clinical trial
MATCH Treatment Subprotocol I: GDC-0032 (Taselisib) in Patients With Tumors (Other Than Breast Cancer) With PIK3CA Mutation But Without KRAS Mutation or PTEN Loss
Status: Active (not recruiting), Estimated PCD: 2020-11-10
Product
Taselisib
Clinical trial
AMN006 - Phase 2 Study of Daratumumab in Combination With Bortezomib and Dexamethasone in Newly Diagnosed Transplant Ineligible Multiple Myeloma Patients
Status: Active (not recruiting), Estimated PCD: 2021-09-30
Clinical trial
An Exploratory Clinical Study of the Safety and Efficacy of NKG2D Chimeric Antigen Receptor NK Cell Injections for the Treatment of Efractory Recurrent Multiple Myeloma
Status: Not yet recruiting, Estimated PCD: 2025-12-31
Product
NKG2D Chimeric Antigen Receptor NK Cell
Clinical trial
Molecular Analysis for Therapy Choice (MATCH)
Status: Active (not recruiting), Estimated PCD: 2025-12-31
Clinical trial
An Open-label, Pilot Study of Dabrafenib and/or Trametinib in Patients With Relapsed and/or Refractory Multiple Myeloma
Status: Recruiting, Estimated PCD: 2024-09-15
Clinical trial
A Randomized Phase II Dose Finding Study of Revlimid™ and Melphalan in Patients With Previously Untreated Multiple Myeloma
Status: Completed, Estimated PCD: 2008-06-30
Clinical trial
Phase III Study of Isatuximab-Carfilzomib-Lenalidomide-Dexamethasone (Isa-KRd) Versus Carfilzomib-Lenalidomide-Dexamethasone (KRd) in Newly Diagnosed Multiple Myeloma Patients Eligible for Autologous Stem Cell Transplantation (IsKia TRIAL
Status: Active (not recruiting), Estimated PCD: 2025-07-31
Product
Carfilzomib Lenalidomide Dexamethasone
Product
Isatuximab Carfilzomib Lenalidomide Dexamethasone
Clinical trial
Alternating the Administration of Ixazomib and Lenalidomide as Maintenance Therapy After Autologous Transplant for Treating Multiple Myeloma
Status: Active (not recruiting), Estimated PCD: 2022-06-01
Clinical trial
Phase 2 Study Applying Innovative Minimal Residual Disease (MRD) Techniques for Participants With Previously Untreated Multiple Myeloma Treated With D-VRd Prior To and After High-dose Therapy Followed by Autologous Stem Cell Transplantation (ASCT) - TAURUS
Status: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
A Phase II Study Using the Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in Patients With Metastatic Cancer
Status: Recruiting, Estimated PCD: 2027-03-23
Drug
Erlotinib
Clinical trial
Phase I Study of Bortezomib With or Without Total Marrow Irradiation (TMI) Using Intensity Modulated Radiation Therapy (IMRT) in Combination With Fludarabine (FLU) and Melphalan (MEL) as a Preparative Regimen for Allogeneic Hematopoietic Stem Cell (HSC) Transplantation in Patients With High Risk Multiple Myeloma
Status: Active (not recruiting), Estimated PCD: 2019-07-20
Clinical trial
A Phase I Study of Ibrutinib (PCI-32765) in Combination With Revlimid/Dexamethasone (Rd) in Relapsed/Refractory Multiple Myeloma
Status: Active (not recruiting), Estimated PCD: 2025-03-01
Clinical trial
Phase II Multicenter Trial of Anti-BCMA CAR T-Cell Therapy for MM Patients With Sub-Optimal Response After Auto HCT and Maintenance Len. BMTCTN1902
Status: Active (not recruiting), Estimated PCD: 2025-01-01
Clinical trial
A Phase I Study of B-Cell Maturation Antigen (BCMA)-Specific Chimeric Antigen Receptor T Cells in Combination With JSMD194, a Small Molecule Inhibitor of Gamma Secretase, in Patients With Relapsed or Persistent Multiple Myeloma
Status: Terminated, Estimated PCD: 2022-04-20
Product
BCMA-specific CAR-expressing T Lymphocytes
Product
LY3039478
Clinical trial
An Open Label, Single Arm, Multi-Center Exploratory Study to Evaluate the Efficacy and Safety of SVRd for the Treatment of Newly Diagnosed Multiple Myeloma Patients Presenting With Extramedullary Disease.
Status: Recruiting, Estimated PCD: 2024-08-30
Clinical trial
A Multi-centre Phase II Trial of GVHD Prophylaxis Following Unrelated Donor Stem Cell Transplantation Comparing Thymoglobulin vs. Calcineurin Inhibitor or Sirolimus-based Post-transplant Cyclophosphamide
Status: Recruiting, Estimated PCD: 2026-01-01
Clinical trial
UARK 2013-13, Total Therapy 4B - Formerly 2008-01 - A Phase III Trial for Low Risk Myeloma Ages 65 and Under: A Trial Enrolling Subjects to Standard Total Therapy 3 (S-TT3)
Status: Active (not recruiting), Estimated PCD: 2024-09-01
Product
M-VTD-PACE
Clinical trial
A Phase 1b Trial of Vactosertib in Combination With Pomalidomide (POM) in Relapsed or Relapsed and Refractory Multiple Myeloma (RRMM)
Status: Completed, Estimated PCD: 2022-02-27
Product
TT3-LITE Regimen
Clinical trial
A Phase 3, Multicentre, Randomized, Controlled Study to Determine the Efficacy and Safety of Cyclophosphamide, Lenalidomide and Dexamethasone (CRD) Versus Melphalan (200 mg/m2) Followed By Stem Cell Transplant In Newly Diagnosed Multiple Myeloma Subjects
Status: Active (not recruiting), Estimated PCD: 2021-09-01
Clinical trial
Combination Post-transplant Consolidation Therapy With Isatuximab, Lenalidomide, Dexamethasone (IsaRD) in Multiple Myeloma Patients With Persistent Marrow Minimal Residual Disease (Elimination of MRD After Transplant; E-MAT)
Status: Recruiting, Estimated PCD: 2026-09-15
Clinical trial
A 2 Step Approach to Haploidentical Transplant Using Radiation-Based Reduced Intensity Conditioning
Status: Recruiting, Estimated PCD: 2024-10-01
Clinical trial
Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced Intensity Conditioning (RIC) for the Treatment of Hematological Diseases [MT2015-32]
Status: Completed, Estimated PCD: 2023-04-17
Product
Peripheral Blood Stem Cells
Product
Bone Marrow Cells
Clinical trial
Post-Autologous Transplant Maintenance With Isatuximab and Lenalidomide in Minimal Residual Disease Positive Multiple Myeloma
Status: Recruiting, Estimated PCD: 2030-12-01
Clinical trial
Phase I Trial of G Protein-coupled Receptor Class C Group 5 Member D (GPRC5D) Targeted MCARH109 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of Multiple Myeloma
Status: Active (not recruiting), Estimated PCD: 2024-08-01
Clinical trial
IBEX: Phase 2 Trial of Iberdomide + SQ Daratumumab as Post-Autologous Stem Cell Transplant Maintenance Therapy in Multiple Myeloma
Status: Recruiting, Estimated PCD: 2025-12-31
Clinical trial
A Phase I Study of Amifostine Followed by High-Dose Escalation of Melphalan With Stem Cell Reconstitution for Patients With Primary Systemic Amyloidosis
Status: Terminated, Estimated PCD: 2007-09-01
Product
Amifostine
Clinical trial
A Diagnostic Study of CD38-Targeted ImmunoPET of Myeloma: Phase 2 Trial of Clinical Applications
Status: Recruiting, Estimated PCD: 2026-01-31
Product
89Zr-daratumumab
Clinical trial
Combination Treatment of Belantamab Mafodotin and Venetoclax in Treatment of Relapsed and Refractory t(11;14) Multiple Myeloma (Phase I/IIa) The BELI(E)VE-Trial
Status: Recruiting, Estimated PCD: 2026-11-01
Clinical trial
A Phase 3, Two-Stage, Randomized, Multicenter, Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Subjects With Relapsed or Refractory Multiple Myeloma (RRMM)
Status: Recruiting, Estimated PCD: 2026-03-18
Clinical trial
A Phase І Study of BCMA-targeted Chimeric Antigen Receptor T Cell (SYS6020) Injection in Relapsed or Refractory Multiple Myeloma
Status: Not yet recruiting, Estimated PCD: 2027-05-01
Product
BCMA Targeted CAR T-cells
Clinical trial
A PHASE III, MULTI-CENTER, RANDOMIZED OPEN LABEL STUDY OF VELCADE, MELPHALAN, PREDNISONE AND THALIDOMIDE (V-MPT) Versus VELCADE, MELPHALAN, PREDNISONE (V-MP) IN ELDERLY UNTREATED MULTIPLE MYELOMA PATIENTS
Status: Completed, Estimated PCD: 2014-07-01
Clinical trial
S1803, Phase III Study of Daratumumab/rHuPH20 (NSC-810307) + Lenalidomide or Lenalidomide as Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients With Multiple Myeloma (MM) Using Minimal Residual Disease to Direct Therapy Duration (DRAMMATIC Study)
Status: Recruiting, Estimated PCD: 2029-07-01
Clinical trial
A Phase II Trial Of Autologous Stem Cell Transplant Followed By Mini-Allogeneic Stem Cell Transplant In Lieu Of Standard Allogeneic Bone Marrow Transplantation For Treatment Of Multiple Myeloma
Status: Completed, Estimated PCD: 2007-02-01
Product
cyclosporine
Clinical trial
Phase 2 Trial of Induction With Ixazomib, Pomalidomide, Dexamethasone Prior to Salvage Autologous Stem Cell Transplant Followed by Consolidation With Ixazomib, Pomalidomide, and Dexamethasone and Ixazomib Maintenance in Multiple Myeloma
Status: Completed, Estimated PCD: 2021-04-13
Product
AT9283
Clinical trial
Prospective Comparison Between Prophylactic and On-demand Use of Tocilizumab in CAR-T Recipients - a Randomized, Two Arm, Open-label, Single-center Trial
Status: Not yet recruiting, Estimated PCD: 2026-12-01
Clinical trial
A Phase 1b/2 Dose-Escalation and Cohort-Expansion Study to Determine the Safety and Efficacy of BGB-11417as Monotherapy, in Combination With Dexamethasone and Carfilzomib/Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma and t(11;14)
Status: Recruiting, Estimated PCD: 2026-11-01
Drug
Sonrotoclax
Clinical trial
Mitoxantrone Hydrochloride Liposome Combination Regimen in the Treatment of High-risk/Extramedullary Multiple Myeloma:A Single-arm, Single-center, Prospective Clinical Trial
Status: Recruiting, Estimated PCD: 2025-11-30
Product
Lipo-MIT
Clinical trial
Phase Ib/II Trial to Evaluate Safety and Efficacy of Oral Ixazomib in the Prophylaxis of Chronic Graft-versus-host Disease.
Status: Active (not recruiting), Estimated PCD: 2024-01-11
Product
Any prophylaxis for GVHD
Drug
busulfan
Clinical trial
Selinexor in Combination With Chemotherapy to Treat Relapsed/Refractory Multiple Myeloma Patients
Status: Recruiting, Estimated PCD: 2024-12-30
Product
Pegylated liposomal doxorubicin
Clinical trial
MATCH Treatment Subprotocol Z1L: BVD-523FB (Ulixertinib) in Patients With Tumors With BRAF Fusions, or With Non-V600E, Non-V600K BRAF Mutations
Status: Active (not recruiting), Estimated PCD: 2025-03-24
Product
Ulixertinib
Clinical trial
MATCH Treatment Subprotocol F: Crizotinib in Patients With Tumors (Other Than Adenocarcinoma of Lung or ALCL) With ALK Rearrangements
Status: Active (not recruiting), Estimated PCD: 2020-03-20
Product
Crizotinib
Clinical trial
A Phase 2A Multi Centre, Open Label, Pilot Study Of Pembrolizumab Added to The Standard First-Line Therapy Of Cyclophosphamide, Bortezomib And Dexamethasone (CyBorD) In Newly Diagnosed Multiple Myeloma Patients Not Eligible For Autologous Stem Cell Transplantation
Status: Withdrawn, Estimated PCD: 2022-10-31
Drug
mFOLFOX6
Clinical trial
Phase II Trial Studying the Efficacy of a Triplet Combination of MLN9708, Lenalidomide and Dexamethasone as Induction Prior to, and as Consolidation After High-dose Therapy With Peripheral Stem Cell Transplantation Followed by MLN9708 Maintenance in the Initial Management of Multiple Myeloma in Patients Younger Than 66 Years
Status: Completed, Estimated PCD: 2019-03-01
Clinical trial
Efficacy of Curcumin and Piperine in Patients on Active Surveillance for Either Monoclonal Gammopathy of Unknown Significance (MGUS), Low-risk Smoldering Multiple Myeloma (SMM) or Early Stage Prostate Cancer: A Pilot Study
Status: Recruiting, Estimated PCD: 2024-05-31
Product
Curcumin + Piperine
Clinical trial
A Study of Elranatamab Management With Outpatient and Intermittent Dosing in Relapsed/Refractory Multiple Myeloma
Status: Not yet recruiting, Estimated PCD: 2025-12-01
Clinical trial
A Phase II Study of Daratumumab With Weekly Carfilzomib, Pomalidomide, and Dexamethasone in Relapsed and Refractory Multiple Myeloma
Status: Recruiting, Estimated PCD: 2025-05-01
Clinical trial
A Phase 1 Randomized, Open Label Pharmacokinetic Comparability Study Comparing Pre- and Post-change Teclistamab in Participants With Relapsed/Refractory Multiple Myeloma
Status: Not yet recruiting, Estimated PCD: 2025-07-04
Clinical trial
A Multicenter, Open-Label, Safety and Efficacy Study of High Dose Melphalan Hydrochloride for Injection for Myeloablative Conditioning in Multiple Myeloma Patients Undergoing Autologous Hematopoietic Stem Cell Transplantation
Status: Completed, Estimated PCD: 2021-07-08
Product
Melphalan Hydrochloride
Clinical trial
Phase I/II Study of Ixazomib in Combination With Pomalidomide, Clarithromycin and Dexamethasone (PiC-D) in Patients With Double Refractory Multiple Myeloma
Status: Active (not recruiting), Estimated PCD: 2024-08-01
Clinical trial
A Phase I Trial Evaluating Escalating Doses of 211At-Labeled Anti-CD38 Monoclonal Antibody (211At-OKT10-B10) Combined With Melphalan as Conditioning Prior to Autologous Hematopoietic Cell Transplantation for Patients With Multiple Myeloma
Status: Withdrawn, Estimated PCD: 2025-10-01
Clinical trial
A Phase II Study of Lenalidomide, Ixazomib, Dexamethasone, and Daratumumab in Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma
Status: Active (not recruiting), Estimated PCD: 2025-10-01
Clinical trial
Bortezomib-bendamustine-melphalan vs High-dose Melphalan in Autologous Hematopoietic Stem Cell Transplantation for Relapsed Multiple Myeloma - a Single Center Retrospective Cohort Study
Status: Not yet recruiting, Estimated PCD: 2025-03-31
Product
Bortezomib-bendamustine-melphalan
Clinical trial
A Multisite, Phase II Study of Isatuximab, Pomalidomide, Elotuzumab and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma
Status: Recruiting, Estimated PCD: 2025-01-01
Clinical trial
Phase I Trial of Concurrent Administration of GPRC5D-Targeted CAR T Cell MCARH109 and BCMA-Targeted CAR T Cell MCARH125 in Patients With Relapsed or Refractory Multiple Myeloma
Status: Recruiting, Estimated PCD: 2024-06-20
Product
MCARH125
Product
MCARH109
Clinical trial
A Phase 1b Study of REOLYSIN® (Reovirus Serotype 3 - Dearing Strain) Combined With Standard Doses of Bortezomib and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma
Status: Completed, Estimated PCD: 2022-04-19
Clinical trial
Phase 1/2 Study of IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers
Status: Recruiting, Estimated PCD: 2025-12-30
Product
IDP-023
Clinical trial
Phase I/II Study of Anti-CD3 x Anti-SLAMF7 (Anti-CS-1) Bispecific Antibody Armed Fresh Peripheral Blood Mononuclear Cells (SLAMF7 FPBMC) in Relapsed/Refractory Multiple Myeloma
Status: Withdrawn, Estimated PCD: 2023-11-01
Product
SLAMF7 FPBMC
Clinical trial
A Phase 1b/2 Dose Escalation and Expansion Study of the Combination of the Bispecific T Cell Redirection Antibodies Talquetamab and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
Status: Recruiting, Estimated PCD: 2025-06-27
Product
Wild-type Reovirus
Clinical trial
Bioequivalence Studies of Dasatinib 100 mg Tablets in Healthy Colombian Subjects in Postprandial Condition
Status: Not yet recruiting, Estimated PCD: 2023-12-20
Clinical trial
An Open Label, Dose Escalation, Multicenter Phase 1/2 Study of KW-2478 in Combination With Bortezomib in Subjects With Relapsed and/or Refractory Multiple Myeloma
Status: Completed, Estimated PCD: 2013-11-01
Product
KW-2478
Drug
IL-2
Clinical trial
Matched Unrelated Donor Allogeneic Hematopoietic Stem Cell Transplantation With a Conditioning Regimen of Targeted Busulfan, Cyclophosphamide, and Thymoglobulin
Status: Completed, Estimated PCD: 2008-02-01
Product
Polymorphism Analysis
Clinical trial
MATCH Treatment Subprotocol T: GDC-0449 (Vismodegib) in Patients With Tumors (Except Basal Cell Skin Carcinoma) With Smoothened (SMO) or Patched 1 (PTCH1) Mutations
Status: Active (not recruiting), Estimated PCD: 2024-11-04
Product
Vismodegib
Clinical trial
Phase I Clinical Trial of Bcl2 Inhibitor Venetoclax in Combination With Lenalidomide and Dexamethasone (Ven-Rd), Daratumumab and Dexamethasone (Ven-Dd), or Daratumumab-Lenalidomide-Dexamethasone (Ven-DRd) in t(11;14) Multiple Myeloma
Status: Recruiting, Estimated PCD: 2028-12-01
Product
Thymoglobulin
Clinical trial
The Prophylactic Use of Loratadine for Granulocyte-Colony Stimulating Factor (G-CSF) Induced Bone Pain in Multiple Myeloma Patients Undergoing Stem Cell Mobilization
Status: Recruiting, Estimated PCD: 2024-02-28
Product
Loratadine
Clinical trial
CAR-T Injection in Transplant In-Eligible Newly Diagnosed Multiple Myeloma Patients
Status: Recruiting, Estimated PCD: 2025-09-30
Product
GC012F
Clinical trial
MATCH Treatment Subprotocol M: Phase II Study of MLN0128 (Tak-228) in Patients With Tumors With TSC1 or TSC2 Mutations
Status: Active (not recruiting), Estimated PCD: 2025-01-06
Clinical trial
An Exploratory Clinical Study on the Safety and Efficacy of YTS104 Cell Injection in the Treatment of Relapsed or Refractory Multiple Myeloma
Status: Not yet recruiting, Estimated PCD: 2025-12-30
Product
YTS104
Clinical trial
Pilot Study Of Redirected Autologous T Cells Engineered To Contain an Anti-BCMA scFv Coupled To TCRζ And 4-1BB Signaling Domains in Patients With Relapsed and/or Refractory Multiple Myeloma
Status: Completed, Estimated PCD: 2019-08-21
Clinical trial
A Randomized Phase II, Open Label, Study of Daratumumab, Weekly Low-Dose Oral Dexamethasone and Cyclophosphamide With or Without Pomalidomide in Patients With Relapsed and Refractory Multiple Myeloma
Status: Completed, Estimated PCD: 2022-06-24
Product
DCdP
Product
DCd+P
Clinical trial
A Phase I Trial to Establish the Safety and Maximum Tolerated Dose of High-affinity Autologous BCMA-targeting CAR T-cells in Patients With Relapsed and Refractory B-cell Malignancies
Status: Recruiting, Estimated PCD: 2025-06-01
Product
MDC-CAR-BCMA001
Product
ATG
Clinical trial
Randomized Phase 2 Study of Iberdomide Maintenance Therapy Following Idecaptagene Vicleucel CAR-T in Multiple Myeloma Patients
Status: Recruiting, Estimated PCD: 2027-10-31
Clinical trial
Post-Transplant Use of Irradiated Haplo-Allogeneic Cells
Status: Terminated, Estimated PCD: 2022-06-30
Product
Irradiated Allogeneic Cells
Clinical trial
A Randomized Phase III Study to Compare Bortezomib, Melphalan, Prednisone (VMP) With High Dose Melphalan Followed by Bortezomib, Lenalidomide, Dexamethasone (VRD) Consolidation and Lenalidomide Maintenance in Patients With Newly Diagnosed Multiple Myeloma
Status: Active (not recruiting), Estimated PCD: 2020-12-01
Product
Bortezomib, Melphalan, Prednisone
Product
HDM
Product
Bortezomib, Lenalidomide, Dexamethasone
Clinical trial
Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone in Newly-Diagnosed Multiple Myeloma: A Clinical and Correlative Phase II Study
Status: Active (not recruiting), Estimated PCD: 2024-09-01
Drug
daratumumab
Clinical trial
A Phase 2, Multicohort Open-Label Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against BCMA in Subjects With Multiple Myeloma
Status: Active (not recruiting), Estimated PCD: 2025-05-30
Clinical trial
A Phase 1, Multicenter, Open-Label Study of CB-011, a CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma (CaMMouflage Trial)
Status: Recruiting, Estimated PCD: 2025-02-01
Product
CB-011
Clinical trial
A Phase Ib, Open-label, Multicenter Dose-escalation Study to Evaluate the Safety, Pharmacokinetics, and Activity of XmAb24306 in Combination With Cevostamab in Patients With Relapsed/Refractory Multiple Myeloma
Status: Recruiting, Estimated PCD: 2026-08-21
Clinical trial
Isa-RVD Study: Phase II, Multi-centre, Single-Arm, Open-Label Study to Evaluate the Efficacy and Safety of the Combination Regimen Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma
Status: Recruiting, Estimated PCD: 2025-06-15
Clinical trial
A Phase II Trial of Vaccination With Dendritic Cell (DC)/Myeloma Fusions in Combination With Nivolumab in Patients With Relapsed Multiple Myeloma
Status: Terminated, Estimated PCD: 2021-01-31
Product
DC/myeloma fusions/GM-CSF
Clinical trial
Selinexor With Alternating Bortezomib or Lenalidomide Plus Dexamethasone in Transplant Ineligible Newly Diagnosed Multiple Myeloma Patients (SABLe): An Investigator Sponsored Trial
Status: Active (not recruiting), Estimated PCD: 2024-06-01
Clinical trial
MATCH Treatment Subprotocol C1: Crizotinib in Patients With Tumors With MET Amplification
Status: Active (not recruiting), Estimated PCD: 2024-11-15
Clinical trial
MATCH Treatment Subprotocol C2: Crizotinib in Patients With Tumors With MET Exon 14 Deletion
Status: Active (not recruiting), Estimated PCD: 2024-11-15
Clinical trial
Study of Safety and ASCT-related Symptom Burden Optimization of Tocilizumab in ASCT Following High-dose Melphalan Conditioning in Patients With Multiple Myeloma
Status: Recruiting, Estimated PCD: 2024-08-31
Clinical trial
UARK 2008-03 Phase II Trial for Patients Not Qualifying for TT4 and TT5 Protocols Because of Prior Therapy (No Prior Transplant)
Status: Active (not recruiting), Estimated PCD: 2024-12-01
Clinical trial
Autologous Stem Cell Transplant With Pomalidomide (CC-4047®) Maintenance Versus Continuous Clarithromycin/ Pomalidomide / Dexamethasone Salvage Therapy in Relapsed or Refractory Multiple Myeloma: A Phase 2 Open-Label Randomized Study by Tristate Consortium
Status: Active (not recruiting), Estimated PCD: 2024-12-01
Clinical trial
A Phase 2 Study of Colesevelam for Lenalidomide-Associated Diarrhea
Status: Active (not recruiting), Estimated PCD: 2024-06-01
Product
Colesevelam
Clinical trial
Lenalidomide, Bortezomib, and Dexamethasone Combination Therapy as Induction Followed by Bortezomib and Lenalidomide Maintenance in Patients With Newly Diagnosed High Risk Multiple Myeloma
Status: Recruiting, Estimated PCD: 2025-12-30
Clinical trial
A Phase II Trial of High-dose Bendamustine, Etoposide, Cytarabine, and Melphalan (BeEAM) in the Up-front Treatment of Multiple Myeloma
Status: Completed, Estimated PCD: 2020-03-26
Product
BeEAM
Clinical trial
A Randomized Phase I/II Study of Optimal Induction Therapy of Bortezomib, Dexamethasone and Lenalidomide With or Without Elotuzumab (NSC-764479) for Newly Diagnosed High Risk Multiple Myeloma (HRMM)
Status: Active (not recruiting), Estimated PCD: 2020-02-01
Clinical trial
A Phase 3, Two-Stage, Randomized, Multicenter, Open-Label Study Comparing Mezigdomide (CC-92480), Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Subjects With Relapsed or Refractory Multiple Myeloma (RRMM): SUCCESSOR-1
Status: Recruiting, Estimated PCD: 2025-11-03
Drug
mezigdomide
Clinical trial
MATCH Treatment Subprotocol Z1F: Phase II Study of Copanlisib in Patients With Tumors With PIK3CA Mutations (PTEN Loss Allowed)
Status: Active (not recruiting), Estimated PCD: 2021-01-06
Clinical trial
VRd-based Regimen Combined With CART-ASCT-CART2 as First-line Therapy for Newly Diagnosed Multiple Myeloma Patients With P53 Abnormalities：a Prospective, One-arm, Single-center Phase II Study
Status: Recruiting, Estimated PCD: 2025-04-01
Product
anti-BCMA CAR-T
Product
VRD-based Regimen
Clinical trial
An Open Label, International, Multicenter, Dose Escalating Phase I/II Trial Investigating the Safety of Daratumumab in Combination With Lenalidomide and Dexamethasone in Patients With Relapsed or Relapsed and Refractory Multiple Myeloma
Status: Active (not recruiting), Estimated PCD: 2015-10-02
Clinical trial
UARK 2008-02, A Phase II Trial for High-risk Myeloma Evaluation Accelerating and Sustaining Complete Remission (AS-CR) by Applying Non-host-exhausting and Timely Dose-reduced MEL-80-VRD-PACE Tandem Transplants
Status: Active (not recruiting), Estimated PCD: 2024-10-01
Clinical trial
MATCH Treatment Subprotocol V: Phase II Study of Sunitinib in Patients With Tumors With cKIT Mutations (Excluding GIST, Renal Cell Carcinoma or Pancreatic Neuorendocrine Tumor)
Status: Active (not recruiting), Estimated PCD: 2025-03-24
Clinical trial
A Phase 3, Randomized, Open-Label Study to Compare the Efficacy and Safety of Anitocabtagene Autoleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Multiple Myeloma
Status: Not yet recruiting, Estimated PCD: 2028-07-01
Product
Anitocabtagene Autoleucel
Product
Enasidenib
Clinical trial
A Phase I/II Assessment of Combination Immuno-Oncology Drugs Elotuzumab, Anti-LAG-3 (BMS-986016) and Anti-TIGIT (BMS-986207)
Status: Active (not recruiting), Estimated PCD: 2023-12-30
Product
Anti-LAG-3
Product
Anti-LAG-3 + Pomalidimide + Dexamethasone
Drug
Tiragolumab
Product
Anti-TIGIT + Pomalidimide + Dexamethasone
Product
Enzalutamide
Clinical trial
A Phase I, Open-Label, Dose-escalation, Multicentre Study of KW-2478 Administered as a Single Agent Intravenously in a Consecutive Dosing Schedule in Patients With Relapsed/Refractory Multiple Myeloma, Chronic Lymphocytic Leukaemia or B-cell Non-Hodgkin's Lymphoma
Status: Completed, Estimated PCD: 2010-08-01
Drug
doxorubicin
Product
Ibrutinib
Clinical trial
Prospective Phase I/II Trial to Jointly Optimize the Administration Schedule(s) and Dose(s) of Melphalan for Injection (Evomela) as a Preparative Regimen for Autologous Hematopoietic Stem Cell Transplantation in Patients With Newly Diagnosed Multiple Myeloma
Status: Active (not recruiting), Estimated PCD: 2024-12-31
Clinical trial
A Phase I Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of BCMA-targeted LCAR-BCDR Cells Product in Patients With Relapsed/Refractory Multiple Myeloma
Status: Recruiting, Estimated PCD: 2024-06-01
Product
LCAR-BCDR
Clinical trial
A Multicenter Phase II Study of Subcutaneous Velcade Plus Oral Melphalan and Prdnisone or Plus Cycloposphamide and Prednisone or Plus Prednisone in Newly Diagnosed Elderly Multiple Myeloma Patients
Status: Completed, Estimated PCD: 2012-05-01
Product
Velcade Cyclophosphamide Prednisone
Product
Velcade + Prednisone
Clinical trial
A Pilot Study of Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies
Status: Not yet recruiting, Estimated PCD: 2026-06-01
Product
Darzalex Faspro
Clinical trial
Tandem Autologous Hematopoietic Stem Cell Transplant With Melphalan Followed by Melphalan and Bortezomib in Patients With Multiple Myeloma
Status: Completed, Estimated PCD: 2023-07-15
Clinical trial
Open-Label, Multi-Center, Dose Escalation Phase 1/2 Study of Anti-GM2 Ganglioside Monoclonal Antibody BIW-8962 as Monotherapy in Subjects With Previously Treated Multiple Myeloma
Status: Terminated, Estimated PCD: 2011-05-01
Product
BIW-8962
Clinical trial
MATCH Treatment Subprotocol U: VS-6063 (Defactinib) in Patients With Tumors With NF2 Loss
Status: Active (not recruiting), Estimated PCD: 2025-05-31
Product
Defactinib
Clinical trial
A Randomized Phase 2 Trial Investigating the Impact of Budesonide Prophylaxis on Incidence of ≥ Grade 2 Diarrhea in Multiple Myeloma (MM) Patients Undergoing Autologous Stem Cell Transplant
Status: Recruiting, Estimated PCD: 2025-02-01
Product
Budesonide
Clinical trial
Observational Study in Patient With Multiple Myeloma Relapse/Refractory Treated With Belantamab Mafotidine on Monotherapy Previously Exposed to at Least One Proteasome Inhibitor, Immunomodulatory Agent, and Anti-CD38 Antibody.
Status: Recruiting, Estimated PCD: 2024-06-01
Clinical trial
A Multicenter, Open Label, Randomized Phase II Study Comparing Daratumumab Combined With Bortezomib-Cyclophosphamide-dexamethasone (Dara-VCd) Versus the Association of Bortezomib-Thalidomide-dexamethasone (VTd) as Pre Transplant Induction and Post Transplant Consolidation, Both Followed by a Maintenance Phase With Ixazomib Alone or in Combination With Daratumumab, in Newly Diagnosed Multiple Myeloma (MM) Young Patients Eligible for Autologous Stem Cell Transplantation
Status: Active (not recruiting), Estimated PCD: 2024-05-01
Product
Velcade Thalidomide Dexamethasone
Drug
Allopurinol
Clinical trial
Desensitization of Immunomodulating Agent-Related Hypersensitivity Reactions as a Means to Provide Therapeutic Options in the Management of Plasma Cell Disorders (DeHyperPCD)
Status: Completed, Estimated PCD: 2022-06-30
Clinical trial
Phase 2 Study of JNJ-42756493 (Erdafitinib) in Patients With Tumors With FGFR Amplifications
Status: Active (not recruiting), Estimated PCD: 2024-06-30
Product
Erdafitinib
Clinical trial
Phenotypic Personalized Medicine: Systematically Optimized Combination Therapy in Multiple Myeloma Using CURATE.AI
Status: Recruiting, Estimated PCD: 2025-09-10
Clinical trial
A MULTICENTER, OPEN LABEL PHASE I/II STUDY OF CARFILZOMIB, POMALIDOMIDE AND DEXAMETHASONE IN RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA (MM) PATIENTS
Status: Completed, Estimated PCD: 2015-07-01
Clinical trial
Clinical Phase II, Multicenter, Open-label Study Evaluating iNduction, Consolidation and Maintenance With Isatuximab (SAR650984), Carfilzomib, LEnalidomide and Dexamethasone (I-KRd) in Primary Diagnosed High-risk Multiple Myeloma paTients
Status: Active (not recruiting), Estimated PCD: 2026-05-01
Product
Individual Patient TCR-Transduced PBL
Clinical trial
A Phase 1 Study of Mezigdomide (CC-92480) and Dexamethasone Post Idecabtagene Vicleucel in Relapsed Multiple Myeloma
Status: Recruiting, Estimated PCD: 2026-03-21
Product
XmAb24306
Clinical trial
A Collaborative Community Effort Using Belantamab Mafodotin in Relapsed/Refractory Myeloma
Status: Not yet recruiting, Estimated PCD: 2025-09-01
Clinical trial
Phase 1 / 2 Trial of Idasanutlin in Combination With Ixazomib and Dexamethasone in Patients With 17p Deleted, Relapsed Multiple Myeloma
Status: Active (not recruiting), Estimated PCD: 2021-01-31
Product
Idasanutlin
Clinical trial
Exploratory Clinical Trial of the Safety and Efficacy of CT071 Injection in Patients With High Risk Newly Diagnosed Multiple Myeloma
Status: Not yet recruiting, Estimated PCD: 2027-06-03
Product
Chimeric antigen receptor modified T cells
Clinical trial
MATCH Treatment Subprotocol H: Phase II Study of Dabrafenib and Trametinib in Patients With Tumors With BRAF V600E or V600K Mutations (Excluding Melanoma, Thyroid Cancer, Colorectal Adenocarcinoma, and Non-Small Cell Lung Cancer)
Status: Active (not recruiting), Estimated PCD: 2025-04-02
Clinical trial
A Phase 3, Intergroup Multicentre, Randomized, Controlled 3 Arm Parallel Group Study to Determine the Efficacy and Safety of Lenalidomide in Combination With Dexamethasone (RD) Versus Melphalan, Prednisone and Lenalidomide (MPR) Versus Cyclophosphamide, Prednisone and Lenalidomide (CPR) in Newly Diagnosed Elderly Multiple Myeloma Subjects
Status: Active (not recruiting), Estimated PCD: 2012-11-01
Clinical trial
A Multicenter, Open Label Phase I/II Study of Carfilzomib, Cyclophosphamide and Dexamethasone in Newly Diagnosed Multiple Myeloma (MM) Patients
Status: Completed, Estimated PCD: 2015-06-01
Clinical trial
Phase 2 Study Of Autologous T Cells Engineered To Express an Anti-CD19 Chimeric Antigen Receptor (CART-19) Following First-line Autologous Stem Cell Transplantation for High-risk Multiple Myeloma
Status: Terminated, Estimated PCD: 2019-02-01
Product
CART-19
Clinical trial
Phase 1 Study of Lintivirally Transduced T Cells Engineered to Contain Anti-CD38 Linked to TCRζ and 4-1BB Signaling Domains in Subjects With Acute Myeloid Leukemia and Multiple Myeloma
Status: Recruiting, Estimated PCD: 2041-05-01
Clinical trial
Maintenance Therapy With Belantamab, Pomalidomide and Dexamethasone (BPd) in High-Risk Myeloma Patients: A Phase 2 Study With a Safety Run-In
Status: Recruiting, Estimated PCD: 2024-10-21
Clinical trial
A Phase II Study of Carfilzomib, Oral Cyclophosphamide, and Dexamethasone for Relapsed and/or Refractory Multiple Myeloma
Status: Not yet recruiting, Estimated PCD: 2027-06-30
Clinical trial
Lenalidomide Maintenance in Plasma Cell Myeloma
Status: Active (not recruiting), Estimated PCD: 2024-08-01
Clinical trial
A Phase 1/2 Proof-of-Concept Study of the Combination of ACP-196 and ACP-319 in Subjects With B-cell Malignancies
Status: Active (not recruiting), Estimated PCD: 2020-06-01
Product
ACP-319
Clinical trial
Safety And Efficacy Of Lenalidomide As Maintenance Therapy In Patients With Newly Diagnosed Multiple Myeloma Following A Tandem Autologous-Allogeneic Transplant
Status: Completed, Estimated PCD: 2012-12-01
Clinical trial
A Randomized Phase III Trial Assessing the Benefit of the Addition of Isatuximab to Lenalidomide / Bortezomib / Dexamethasone (RVd) Induction and Lenalidomide Maintenance in Patients With Newly Diagnosed Multiple Myeloma
Status: Active (not recruiting), Estimated PCD: 2025-05-01
Clinical trial
Phase 2 Trial of Ixazomib, Lenalidomide, Dexamethasone, and Daratumumab in Patients With Newly Diagnosed Multiple Myeloma
Status: Active (not recruiting), Estimated PCD: 2024-05-01
Clinical trial
Clinical Study to Evaluate the Safety, Tolerability and Initial Efficacy of Anti-GPRC5D-CD19-CAR-T in Patients With Relapsed/Refractory Multiple Myeloma
Status: Not yet recruiting, Estimated PCD: 2026-05-31
Product
GPRC5D-CD19 CAR T
Clinical trial
A Phase 1b, Dose Escalation/Dose Expansion, Multicenter, Open-Label Study to Assess the Safety and Tolerability of OPN-6602 Monotherapy and in Combination With Dexamethasone in Subjects With Relapsed and/or Refractory Multiple Myeloma
Status: Not yet recruiting, Estimated PCD: 2026-07-01
Product
OPN-6602
Clinical trial
Phase II Study of Salvage Radiation Treatment After B-cell Maturation Antigen Chimeric Antigen Receptor T-cell Therapy for Relapsed Refractory Multiple Myeloma
Status: Recruiting, Estimated PCD: 2024-12-07
Product
Radiation Therapy
Clinical trial
A Randomized, Open-label Phase 3 Study of Carfilzomib, Lenalidomide, and Dexamethasone Versus Bortezomib, Lenalidomide and Dexamethasone (KRd vs. VRd) in Patients With Newly Diagnosed Multiple Myeloma (COBRA)
Status: Recruiting, Estimated PCD: 2024-12-24
Clinical trial
A Phase II Study Evaluating the Safety and Efficacy of BL-8040 for the Mobilization of Donor Hematopoietic Stem Cells and Allogeneic Transplantation in Patients With Advanced Hematological Malignancies
Status: Completed, Estimated PCD: 2018-04-12
Drug
Motixafortide
Product
Colchicine
Clinical trial
A Single-center Clinical Trial to Evaluate the Efficacy and Safety of Colchicine Combined With Conventional Therapy in Multiple Myeloma Patients
Status: Recruiting, Estimated PCD: 2024-12-31
Clinical trial
A Phase II Study of Enhancing Anti-Tetanus Vaccine Response After Autologous Stem Cell Transplantation
Status: Terminated, Estimated PCD: 2022-12-21
Product
T Cell-Depleted Hematopoietic Stem Cell Transplantation
Product
Tetanus Toxoid Vaccine
Clinical trial
A Single-arm, Prospective Study of Cyclosporine in Combination With Carfilzomib and Dexamethasone in Patients With Relapsed Multiple Myeloma Refractory to Carfilzomib With High Expression of the Peptidylprolyl Isomerase A (PPIA) Gene in Myeloma Cells
Status: Recruiting, Estimated PCD: 2024-04-01
Clinical trial
Daratumumab Versus Lenalidomide Maintenance Therapy for Multiple Myeloma: A Randomized Pilot Study Comparing Patient-Reported Health Related Quality of Life Measures With a Plant Based Nutrition Intervention Sub Study (NUTRIVENTION-4)
Status: Recruiting, Estimated PCD: 2025-08-01
Clinical trial
Anti-BCMA Chimeric Antigen Receptor (CARTemis-1) T-lymphocyte Therapy in the Treatment of Patients With Multiple Myeloma in Relapse After Allogeneic Transplant: Endothelial Growth Factor Receptor Expression as a Control Mechanism of Treatment-derived Complications
Status: Not yet recruiting, Estimated PCD: 2029-12-31
Product
CARTemis-1
Clinical trial
Pilot PET Imaging Study of [89Zr]DFO-YS5 for Detecting CD46 Positive Malignancy in Multiple Myeloma
Status: Recruiting, Estimated PCD: 2026-08-01
Product
Zirconium Zr 89-DFO-YS5
Clinical trial
Umbilical Cord Blood Transplantation From Unrelated Donors
Status: Recruiting, Estimated PCD: 2025-06-01
Product
Mesna
Clinical trial
Phase II Study of Daratumumab in Combination With Azacitidine and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients Previously Treated With Daratumumab
Status: Terminated, Estimated PCD: 2023-04-30
Clinical trial
Vaccination With Dendritic Cell/Tumor Fusions in Conjunction With Autologous Stem Cell Transplant in Patients With Multiple Myeloma
Status: Completed, Estimated PCD: 2012-04-01
Product
Dendritic Cell Tumor Fusion
Clinical trial
A Randomized Parallel Phase 2 Study of Elotuzumab Plus Lenalidomide (Elo/Rev) for the Treatment of Serologic Relapse/Progression While on Lenalidomide Maintenance for Multiple Myeloma
Status: Terminated, Estimated PCD: 2021-02-18
Clinical trial
Phase I/II Trial of Ibrutinib, Dexamethasone, and Lenalidomide as Initial Therapy for Transplant Ineligible Multiple Myeloma Patients
Status: Terminated, Estimated PCD: 2022-10-18
Clinical trial
Selinexor(ATG-010) Plus Bortezomib, Lenalidomide and Dexamethasone (XVRd) in High Risk Newly Diagnosed Multiple Myeloma
Status: Recruiting, Estimated PCD: 2025-06-30
Clinical trial
A Phase II Study of Sequential Carfilzomib, Clarithromycin (Biaxin®), Lenalidomide (Revlimid®), and Dexamethasone (Decadron®) [Car-BiRD] Therapy for Subjects With Newly Diagnosed Multiple Myeloma
Status: Active (not recruiting), Estimated PCD: 2016-06-07
Clinical trial
Transplantation of Umbilical Cord Blood From Unrelated Donors in Patients With Hematological Diseases Using a Non-Myeloablative Preparative Regimen
Status: Active (not recruiting), Estimated PCD: 2023-02-22
Clinical trial
Clinical-grade Molecular Profiling of Patients With Multiple Myeloma and Related Plasma Cell Malignancies
Status: Active (not recruiting), Estimated PCD: 2023-06-01
Product
Genetic Sequencing
Clinical trial
Safety and Efficacy Study of Novel CAR-T Cell Therapy in the Treatment of Hematopoietic and Lymphoid Malignancies
Status: Withdrawn, Estimated PCD: 2025-12-31
Product
Autologous CAR-T cells
Clinical trial
Long-term Follow-up Study for Participants Previously Treated With Ciltacabtagene Autoleucel
Status: Recruiting, Estimated PCD: 2037-07-29
Clinical trial
A Phase 3 Study Comparing Daratumumab, Lenalidomide, and Dexamethasone (DRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects With Previously Untreated Multiple Myeloma Who Are Ineligible for High Dose Therapy
Status: Active (not recruiting), Estimated PCD: 2018-09-24
Clinical trial
A PHASE III, MULTICENTRE, RANDOMIZED, CONTROLLED STUDY TO DETERMINE THE EFFICACY AND SAFETY OF STANDARD SCHEDULE VERSUS A NEW ALGORITHM OF DOSE REDUCTIONS IN ELDERLY AND UNFIT NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS RECEIVING LENALIDOMIDE PLUS STEROIDS
Status: Active (not recruiting), Estimated PCD: 2022-07-01
Clinical trial
Magnolia Study Prolonged Protection From Bone Disease in Multiple Myeloma. An Open Label Phase 3 Multicenter International Randomised Trial
Status: Completed, Estimated PCD: 2023-02-16
Clinical trial
Efficacy of Generic Pegfilgrastim vs Brand Name Pegfilgrastim for Neutrophil Recovery After Autologous Stem Cell Transplant
Status: Completed, Estimated PCD: 2023-02-25
Drug
pegfilgrastim
Clinical trial
Carfilzomib, Lenalidomide, and Dexamethasone in Newly-Diagnosed Multiple Myeloma: A Clinical and Correlative Phase I/II Dose Escalation Study
Status: Active (not recruiting), Estimated PCD: 2024-10-01
Clinical trial
2015-12: A Phase II Study Exploring the Use of Early and Late Consolidation/Maintenance With Anti-CD38 (Protein) Monoclonal Antibody to Improve Progression Free Survival in Patients With Newly Diagnosed Multiple Myeloma
Status: Active (not recruiting), Estimated PCD: 2024-10-01
Clinical trial
Corneal Findings in Patients Treated With Belantamab Mafodotin - a Prospective Study Focusing on Corneal Nerves
Status: Not yet recruiting, Estimated PCD: 2026-06-01
Clinical trial
A Phase 2 Adaptive Study of Subcutaneous Daratumumab, Once Weekly Carfilzomib, and Dexamethasone (DKd) in Patients With High-Risk Smoldering Multiple Myeloma
Status: Recruiting, Estimated PCD: 2026-10-31
Clinical trial
Reduced Intensity Conditioning and Transplantation of Partially HLA-Mismatched Peripheral Blood Stem Cells for Patients With Hematologic Malignancies
Status: Completed, Estimated PCD: 2019-11-05
Clinical trial
A Phase I/II Study of the Safety, Tolerability and Efficacy of Belantamab Mafodotin (GSK2857916) in Combination With Iberdomide (CC-220)/Dexamethasone Versus Belantamab Mafodotin (GSK2857916)/Dexamethasone in Relapsed Refractory Multiple Myeloma
Status: Not yet recruiting, Estimated PCD: 2028-05-01
Clinical trial
A Multi-arm Phase 1b Study of Talquetamab With Other Anticancer Therapies in Participants With Multiple Myeloma
Status: Recruiting, Estimated PCD: 2025-07-02
Clinical trial
A Phase 3 Randomized Study Comparing Talquetamab SC in Combination With Daratumumab SC and Pomalidomide (Tal-DP) or Talquetamab SC in Combination With Daratumumab SC (Tal-D) Versus Daratumumab SC, Pomalidomide and Dexamethasone (DPd), in Participants With Relapsed or Refractory Multiple Myeloma Who Have Received at Least 1 Prior Line of Therapy
Status: Recruiting, Estimated PCD: 2026-02-06
Clinical trial
Belantamab Mafadotin Maintenance Therapy After Salvage Autologous Hematopoietic Cell Transplantation in Patients With Relapse Refractory Multiple Myeloma
Status: Recruiting, Estimated PCD: 2025-05-01
Clinical trial
A Phase I Dose Escalation Trial of WT1-specific Donor-derived T Cells Following T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Relapsed/Refractory Multiple Myeloma
Status: Active (not recruiting), Estimated PCD: 2024-12-01
Product
Anti-thymocyte globulin
Clinical trial
A Phase 1, Randomized, Dose and Schedule Evaluation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Belantamab Mafodotin Administered in Combination With Standard of Care in Participants With Newly Diagnosed Multiple Myeloma
Status: Recruiting, Estimated PCD: 2024-11-15
Product
3x10(6) CART-38 cellls
Product
7x10(5) CART-38 cells
Product
CART-38 cells
Product
3x10(7) CART-38 cells
Clinical trial
Multicenter Phase II Study to Demonstrate Clinical Benefit of Lenalidomide and Dexamethasone in Elderly Unfit Patients With Newly Diagnosed Multiple Myeloma
Status: Active (not recruiting), Estimated PCD: 2024-12-31
Clinical trial
A Phase 3, Multicenter, Randomized, Controlled, Open-label Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination With VMP (D-VMP), in Subjects With Previously Untreated Multiple Myeloma Who Are Ineligible for High-Dose Therapy (Asia Pacific Region)
Status: Completed, Estimated PCD: 2020-07-02
Clinical trial
Phase 2 Study of the Initial and Post-Transplant Treatment With Carfilzomib, Lenalidomide and Low Dose Dexamethasone (CRd) in Transplant Candidates With Newly Diagnosed, Multiple Myeloma Requiring Systemic Chemotherapy
Status: Active (not recruiting), Estimated PCD: 2018-04-01
Clinical trial
Adoptive Immunotherapy Utilizing Activated Marrow Infiltrating Lymphocytes in the Autologous Transplant Setting in Multiple Myeloma
Status: Completed, Estimated PCD: 2014-06-01
Product
MILs
Product
PCV13
Clinical trial
A MULTICENTER, OPEN LABEL STUDY OF WEEKLY CARFILZOMIB, CYCLOPHOSPHAMIDE AND DEXAMETHASONE (wCCyd) IN NEWLY DIAGNOSED MULTIPLE MYELOMA (MM) PATIENTS
Status: Active (not recruiting), Estimated PCD: 2013-11-01
Clinical trial
A Phase 1 and Phase 2 Study of Daratumumab in Combination With All-trans Retinoic Acid in Relapsed/Refractory Multiple Myeloma
Status: Completed, Estimated PCD: 2022-10-18
Product
All-trans retinoic acid
Clinical trial
MATCH Treatment Subprotocol Z1K: Ipatasertib in Patients With Tumors With AKT Mutations
Status: Active (not recruiting), Estimated PCD: 2025-03-03
Product
Ipatasertib
Clinical trial
Phase II Study of Pembrolizumab as Salvage Therapy Among Multiple Myeloma Patients Progressing on CAR-T Cell Therapy
Status: Recruiting, Estimated PCD: 2024-10-21
Clinical trial
Pilot Study Of Redirected Autologous T Cells Engineered To Contain Anti-CD19 Attached To TCRζ And 4-1BB Signaling Domains Coupled With Salvage Autologous Stem-Cell Transplantation (ASCT) In Multiple Myeloma Patients With Early Relapse/Progression After Initial ASCT
Status: Completed, Estimated PCD: 2015-09-01
Clinical trial
A Phase I/II Study of Carfilzomib, Lenalidomide, Dexamethasone and the Anti-B-Cell Maturation Antigen (BCMA) Antibody Drug Conjugate Belantamab Mafodotin in Multiple Myeloma
Status: Active (not recruiting), Estimated PCD: 2024-10-01
Clinical trial
A Phase 2 Evaluation of Daratumumab-Based Treatment in Newly Diagnosed Multiple Myeloma Patients With Renal Insufficiency
Status: Recruiting, Estimated PCD: 2024-04-30
Clinical trial
A Phase II Study of Elotuzumab in Combination With Pomalidomide, Bortezomib, and Dexamethasone in Relapsed and Refractory Multiple Myeloma
Status: Active (not recruiting), Estimated PCD: 2024-12-01
Clinical trial
Phase II Study of Palifermin With Leuprolide Acetate or Degarelix For the Promotion of Immune Recovery Following Total Body Irradiation Based T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation
Status: Active (not recruiting), Estimated PCD: 2024-12-01
Product
Palifermin
Drug
LHRH agonist
Product
Thiotepa
Product
Degarelix
Clinical trial
A PHASE III STUDY OF PSC-833 IN COMBINATION WITH VINCRISTINE, DOXORUBICIN AND DEXAMETHASONE (PSC-833/VAD) VERSUS VAD ALONE IN PATIENTS WITH RELAPSING OR REFRACTORY MULTIPLE MYELOMA
Status: , Estimated PCD: 2003-04-01
Product
valspodar
Drug
Vincristine
Clinical trial
The SABRE Trial: A Single-arm Prospective Study Measuring Safety, Tolerability and Pharmacokinetics of Two SARS-CoV-2 Neutralising Antibodies (C135-LS and C144-LS) Amongst High-risk Special Populations of Vaccine Non-responders.
Status: Withdrawn, Estimated PCD: 2022-03-04
Product
BMS-986414
Product
BMS-986413
Clinical trial
MATCH Treatment Subprotocol G: Phase II Study of Crizotinib in Patients With ROS1 Translocations (Other Than Patients With Non-Small Cell Lung Cancer)
Status: Active (not recruiting), Estimated PCD: 2020-03-20
Clinical trial
MATCH Treatment Subprotocol A: Phase II Trial of Afatinib in Patients With Solid Tumors (Other Than Small Cell and Non-Small Cell Lung Cancer) or Lymphomas, That Have Activating Mutations of EGFR and Have Progressed After Standard Treatment
Status: Active (not recruiting), Estimated PCD: 2024-12-06
Clinical trial
A Randomized Phase III Non-inferiority Trial Assessing Lenalidomide, Bortezomib and Dexamethasone Induction Therapy With Either Intravenous or Subcutaneous Isatuximab in Transplant-eligible Patients With Newly Diagnosed Multiple Myeloma.
Status: Recruiting, Estimated PCD: 2025-07-24
Clinical trial
Carfilzomib, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma: a Clinical and Correlative Pilot Study
Status: Active (not recruiting), Estimated PCD: 2022-03-03
Clinical trial
Effective Quadruplet Utilization After Treatment Evaluation (EQUATE): A Randomized Phase 3 Trial for Newly Diagnosed Multiple Myeloma Not Intended for Early Autologous Transplantation
Status: Recruiting, Estimated PCD: 2027-12-31
Clinical trial
A Phase II Study of IRD (Ixazomib, Lenalidomide, & Dexamethasone) for Consolidation Therapy Post Autologous Stem Cell Transplantation Followed by Maintenance Ixazomib or Lenalidomide for Multiple Myeloma
Status: Active (not recruiting), Estimated PCD: 2020-02-05
Clinical trial
Phase II Study of Timed Sequential Busulfan in Combination With Fludarabine in Allogeneic Stem Cell Transplantation
Status: Completed, Estimated PCD: 2022-08-11
Drug
Docetaxel
Clinical trial
Isatuximab in Combination With Bortezomib and Lenalidomide With Minimal Dexamethasone in Transplant-ineligible Multiple Myeloma
Status: Active (not recruiting), Estimated PCD: 2024-06-01
Clinical trial
Phase 1 Study of CART-BCMA With or Without huCART19 as Consolidation of Standard First or Second-Line Therapy for High-Risk Multiple Myeloma
Status: Active (not recruiting), Estimated PCD: 2036-03-01
Product
BCMA CART
Product
CART BCMA
Product
BCMA CART + huCART19
Clinical trial
Daratumumab-containing Induction Effects on Stem Cells Mobilization, colLection and Engraftment in Newly Diagnosed Multiple MyelomA Patients (DILEMMA).
Status: Recruiting, Estimated PCD: 2023-12-31
Drug
rapamycin
Product
Umbilical cord blood cell infusion
Clinical trial
Clinical Study on the Safety and Effectiveness of Autologous Hematopoietic Stem Cell Transplantation Combined With CAR-T Cells in the Treatment of Refractory and Relapsed Multiple Myeloma
Status: Recruiting, Estimated PCD: 2025-03-01
Clinical trial
A Randomized Phase II Trial Comparing Stem Cell Mobilization With Chemotherapy and Cytokine (G-CSF) Versus Cytokine (G-CSF) Alone in Myeloma Patients (MOCCCA-trial).
Status: Active (not recruiting), Estimated PCD: 2023-02-03
Drug
Gemcitabine
Clinical trial
Nivolumab for Relapsed or Refractory Disease Post Chimeric Antigen Receptor T-Cell Treatment in Patients With Hematologic Malignancies
Status: Active (not recruiting), Estimated PCD: 2025-04-05
Clinical trial
Pomalidomide, Bortezomib and Dexamethasone (PVd) Versus Bortezomib and Dexamethasone (Vd) in NDMM Patients With Renal Injury (RI)：A Multicenter, Randomized Controlled, Open-label Trial.
Status: Recruiting, Estimated PCD: 2023-12-31
Clinical trial
Novel BCMA-targeted CAR-T Cell Therapy for Multiple Myeloma
Status: Recruiting, Estimated PCD: 2023-10-01
Product
Cyclophosphamid
Clinical trial
Exploratory Study of Ixazomib in Combination With Reduced Dose Lenalidomide Versus Ixazomib Alone for Maintenance Treatment of High Risk Multiple Myeloma
Status: Recruiting, Estimated PCD: 2024-06-30
Product
Ixazomib + Lenalidomide
Clinical trial
A Phase I Study Evaluating the Efficacy and Safety of Sodium Selenite in Combination With Palliative Radiation Therapy in Patients With Metastatic Cancer
Status: Completed, Estimated PCD: 2018-05-01
Product
Sodium Selenite
Clinical trial
A Phase 2 Study of Elranatamab as Consolidation After Idecabtagene Vicleucel in Relapsed Refractory Multiple Myeloma
Status: Recruiting, Estimated PCD: 2025-12-01
Clinical trial
Phase I/II Study of Twice Weekly Ixazomib Plus Pomalidomide and Dexamethasone in Relapsed/or Refractory Multiple Myeloma
Status: Recruiting, Estimated PCD: 2024-12-20
Clinical trial
A Randomized Phase III Trial Assessing Iberdomide Versus Iberdomide Plus Isatuximab Maintenance Therapy Post Autologous Hematopoietic Stem-Cell Transplantation in Patients With Newly Diagnosed Multiple Myeloma
Status: Recruiting, Estimated PCD: 2028-12-01
Clinical trial
Phase I Trial of Universal Donor NK Cell Therapy in Combination With ALT-803
Status: Completed, Estimated PCD: 2021-06-01
Product
Natural Killer Cells
Product
ALT803
Clinical trial
Phase I Clinical Trial Using an Engineered Peripheral Blood Graft for Haploidentical Transplantation
Status: Completed, Estimated PCD: 2023-02-13
Clinical trial
Lenalidomide and Dexamethasone (Rd) Versus Clarithromycin [Biaxin®] / Lenalidomide [Revlimid®] / Dexamethasone (BiRd) as Initial Therapy in Multiple Myeloma
Status: Terminated, Estimated PCD: 2022-06-22
Clinical trial
A Prospective, Open-label, Single-arm Clinical Study of Mitoxantrone Hydrochloride Liposome Injection Combined With Daratumumab and Dexamethasone in the Treatment of Relapsed/Refractory Multiple Myeloma
Status: Recruiting, Estimated PCD: 2025-01-31
Product
Mitoxantrone liposome/Dexamethasone/Daratumumab
Clinical trial
A Phase I/II, Multi-center, Open Label Study of Pomalidomide, Cyclophosphamide and Prednisone (PCP) in Patients With Multiple Myeloma Relapsed and/or Refractory to Lenalidomide
Status: Completed, Estimated PCD: 2011-06-01
Clinical trial
(PRO#11307) Phase III Randomized Study of Autologous Stem Cell Transplantation With High-dose Melphalan Versus High-dose Melphalan and Bortezomib in Patients With Multiple Myeloma 65 Year or Older
Status: Terminated, Estimated PCD: 2022-05-01
Clinical trial
An Open, Single-arm Clinical Study Evaluating the Safety and Efficacy of IBI346 Infusion in Relapsed/Refractory Multiple Myelom
Status: Completed, Estimated PCD: 2022-12-21
Product
IBI346
Clinical trial
A Phase I/II Study of Carfilzomib, Iberdomide (CC-220) and Dexamethasone (KID) in Patients With Newly Diagnosed Transplant Eligible Multiple Myeloma
Status: , Estimated PCD: 2025-11-01
Clinical trial
Immuno-PRISM (PRecision Intervention Smoldering Myeloma): A Randomized Phase II Platform Study of Select Immunotherapies for High-Risk Smoldering Myeloma
Status: Recruiting, Estimated PCD: 2030-07-31
Clinical trial
Phase II Trial of Ixazomib and Dexamethasone Versus Ixazomib, Dexamethasone and Lenalidomide, Randomized With NFKB2 Rearrangement. (Proteasome Inhibitor NFKB2 Rearrangement Driven Trial, PINR)
Status: Active (not recruiting), Estimated PCD: 2023-12-01
Clinical trial
A Phase Ib/2 Trial of Fludarabine/Melphalan/Total Body Irradiation With Post Transplant Cyclophosphamide as Graft Versus Host Disease Prophylaxis in Matched-Related and Matched-Unrelated Allogeneic Hematopoietic Cell Transplantation
Status: Active (not recruiting), Estimated PCD: 2023-08-21
Clinical trial
A Phase II Trial of the Anti -PD-1 Monoclonal Antibody Pembrolizumab (MK-3475) + Lenalidomide + Dexamethasone as Post Autologous Transplant Consolidation in Patients With High-risk Multiple Myeloma
Status: Terminated, Estimated PCD: 2022-05-01
Clinical trial
CAR- PRISM (PRecision Intervention Smoldering Myeloma): A Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against BCMA in High-Risk Smoldering Myeloma
Status: Recruiting, Estimated PCD: 2026-01-15
Product
Ciltacabtagene Autoleucel
Clinical trial
Multicenter, Open-label, Single-arm, Phase 1b/2 Study of the Safety and Efficacy of Combination Treatment With Pomalidomide, Dexamethasone, and Carfilzomib (PdC) in Subjects With Relapsed and Relapsed/Refractory Multiple Myeloma
Status: Recruiting, Estimated PCD: 2024-11-01
Clinical trial
Phase 1 Trial of Autologous T Cells Engineered to Express NY-ESO-1 TCR and CRISPR Gene Edited to Eliminate Endogenous TCR and PD-1 (NYCE T Cells)
Status: Terminated, Estimated PCD: 2020-02-29
Product
NY-ESO-1 redirected autologous T cells with CRISPR edited endogenous TCR and PD-1
Clinical trial
A Single-arm, Multisite, Prospective Study of Ixazomib-pomalidomide-dexamethasone as Second or Third-line Combination Treatment for Patients With Relapsed and Refractory Multiple Myeloma (RRMM) Previously Treated With Daratumumab, Lenalidomide and Bortezomib (IPoD-790 Study)
Status: Recruiting, Estimated PCD: 2024-09-01
Product
ixazomib-pomalidomide-dexamethasone
Clinical trial
Clinical Study of Safety and Tolerability of Melphalan Hydrochloride for Injection in the Treatment of Relapsed or Relapsed and Refractory Multiple Myeloma
Status: Recruiting, Estimated PCD: 2023-12-31
Clinical trial
Assessment of Bortezomib (Alvocade ®) Efficacy and Safety in Newly Diagnosed Multiple Myeloma Patients
Status: Withdrawn, Estimated PCD: 2021-07-30
Clinical trial
Phase II Randomized Trial of Continuation of Post-Transplant Maintenance With Single-Agent Lenalidomide vs. Consolidation/Maintenance With Ixazomib-Lenalidomide-Dexamethasone in Patients With Residual Myeloma
Status: Active (not recruiting), Estimated PCD: 2024-03-01
Clinical trial
A Randomized Phase II Trial Comparing Treosulfan and Melphalan With Melphalan Alone as Conditioning Regimen for Autologous Stem Cell Transplantation (ASCT) in Myeloma Patients (TreoMel Trial)
Status: Recruiting, Estimated PCD: 2028-01-01
Product
Treosulfan
Clinical trial
Open-label, Single-arm, Phase 2 Study of Initial Treatment With Elotuzumab, Carfilzomib (Kyprolis), Lenalidomide (Revlimid) and Low Dose Dexamethasone (E-KRd) in Newly Diagnosed, Multiple Myeloma Requiring Systemic Chemotherapy
Status: Active (not recruiting), Estimated PCD: 2025-03-01
Clinical trial
A Randomized Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Patients With Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant
Status: Active (not recruiting), Estimated PCD: 2024-06-10
Clinical trial
Pilot Clinical Study of GCSF in Combination With Desipramine for Autologous Stem Cell Mobilization in Multiple Myeloma
Status: Terminated, Estimated PCD: 2015-03-01
Product
Desipramine
Clinical trial
Phase II Study of Salvage Cellular Immunotherapy for Patients With Persistent or Recurrent Multiple Myeloma After Allogeneic Bone Marrow Transplantation From an HLA-Matched Sibling Donor
Status: Completed, Estimated PCD: 2007-02-01
Product
Therapeutic Allogeneic Lymphocytes
Clinical trial
A Phase Ib Study of TGFbi NK Cells and Isatuximab for Myeloma Relapsed/Refractory to BCMA Targeting Therapy
Status: Recruiting, Estimated PCD: 2024-12-31
Product
Universal Donor Expanded TGF-beta-imprinted NK Cells
Clinical trial
A Phase II Study of Daratumumab, Clarithromycin, Pomalidomide And Dexamethasone (D-ClaPd) In Multiple Myeloma Patients Previously Exposed to Daratumumab
Status: Recruiting, Estimated PCD: 2024-09-01
Clinical trial
A Phase I Study of Disulfiram and Copper Gluconate in Patients With Treatment-Refractory Multiple Myeloma
Status: Terminated, Estimated PCD: 2021-12-09
Product
Disulfiram
Product
Copper Gluconate
Clinical trial
The Combination of Lenalidomide and Dexamethasone With or Without Intensification by High-dose Melphalan in the Treatment of Multiple Myeloma
Status: Completed, Estimated PCD: 2020-01-31
Product
Lenalidomide + Dexamethasone + PBSCT
Clinical trial
Exploratory Study to Assess the Safety and Efficacy of CT0594CP CAR-T Cells in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia
Status: Recruiting, Estimated PCD: 2026-04-29
Product
CT0594CP
Clinical trial
A Phase II Study of High-Dose Melphalan With Hematopoietic Stem Cell Reconstitution for Patients With Primary Systemic Amyloidosis
Status: , Estimated PCD: 2002-12-01
Clinical trial
Selinexor in Combination With Immunomodulator to Treat Relapsed/Refractory Multiple Myeloma Patients
Status: Recruiting, Estimated PCD: 2025-12-30
Clinical trial
A Phase 3 Randomized Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma Who Have Received 1 to 3 Prior Lines of Therapy, Including an Anti-CD38 Monoclonal Antibody and Lenalidomide
Status: Recruiting, Estimated PCD: 2025-10-14
Clinical trial
Self-administration of Subcutaneous Elranatamab in the Patients' Homes. An Open Label, Phase Two, Prospective, Non-randomized, Sponsor-initiated Explorative Trial
Status: Not yet recruiting, Estimated PCD: 2025-01-01
Clinical trial
Phase 3 Study Comparing Daratumumab, Lenalidomide, and Dexamethasone (DRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects With Relapsed or Refractory Multiple Myeloma
Status: Active (not recruiting), Estimated PCD: 2016-03-07
Clinical trial
Isa-CAPED MM: Isatuximab, Carfilzomib, Pomalidomide, and Dexamethasone (Isa-KPd) for Patients With Relapsed/Refractory Multiple Myeloma
Status: Recruiting, Estimated PCD: 2029-12-31
Clinical trial
MATCH Treatment Subprotocol N: Phase II Study of PI3K Beta Specific Inhibitor, GSK2636771, in Patients With Tumors With PTEN Mutation or Deletion, With PTEN Expression on IHC
Status: Active (not recruiting), Estimated PCD: 2024-11-30
Product
GSK2636771
Clinical trial
Clinical Trial for the Safety and Efficacy of BCMA CAR-T Cell Therapy for Newly Diagnosed Multiple Myeloma
Status: Recruiting, Estimated PCD: 2024-04-01
Clinical trial
A Phase Ib, Open-Label, Multicenter, Dose-Escalation Study to Evaluate the Safety and Pharmacokinetics of XMAB24306 in Combination With Daratumumab in Patients With Relapsed/Refractory Multiple Myeloma
Status: Recruiting, Estimated PCD: 2026-01-01
Clinical trial
A Modular Phase I/II, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Lmmunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0305 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Relapsed or Refractory Multiple Myeloma
Status: Recruiting, Estimated PCD: 2025-11-11
Product
AZD0305
Clinical trial
A Phase 3 Randomized Study Comparing Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Ciltacabtagene Autoleucel, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against BCMA Versus Bortezomib, Lenalidomide, and Dexamethasone (VRd) Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy
Status: Recruiting, Estimated PCD: 2026-06-11
Clinical trial
CARFILZOMIB IN COMBINATION WITH BENDAMUSTINE AND DEXAMETHASONE IN REFRACTORY OR RELAPSED MULTIPLE MYELOMA - A MULTICENTER PHASE IB/II TRIAL OF THE EUROPEAN MYELOMA NETWORK TRIALIST GROUP (EMNTG)
Status: Completed, Estimated PCD: 2015-09-01
Clinical trial
Phase II Study of Autologous Myeloma-Derived Immunoglobulin Idiotype Conjugated to Keyhole Limpet Hemocyanin Plus Sargramostim (GM-CSF) in Patients With Multiple Myeloma Undergoing Second Autologous Peripheral Blood Stem Cell Transplantation
Status: Completed
Product
Autologous tumor cell vaccine
Product
Keyhole limpet hemocyanin
Drug
sargramostim
Clinical trial
High Dose Ascorbic Acid (HDAA) in Patients With Plasma Cell Disorders
Status: Recruiting, Estimated PCD: 2025-08-31
Clinical trial
An Observational Long-term Follow-up Study of Patients Who Received Prior Caribou Cell Therapy
Status: , Estimated PCD: 2041-12-01
Product
Allogeneic CAR-T
Clinical trial
Phase I/II Open Label Study of Belumosudil Mesylate Alone, and in Combination With Dexamethasone, in Patients With Relapsed/Refractory Multiple Myeloma
Status: Recruiting, Estimated PCD: 2027-08-31
Clinical trial
Phase II Study of Targeting CD28 in Multiple Myeloma With Abatacept (CTLA4-Ig) to Overcome Resistance to Chemotherapy
Status: Active (not recruiting), Estimated PCD: 2022-11-21
Product
Abatacept
Clinical trial
Multicenter Open Label Phase 2 Single Arm Study of Ixazomib, Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma Characterized With Genomic Abnormalities of Adverse Adverse Prognostic
Status: Terminated, Estimated PCD: 2022-12-31
Product
Ixazomib/Pomalidomide/Dexamethasone
Clinical trial
Phase 1 Dose-Escalation and Dose-Expansion Study of the Safety and Efficacy of CS1 CAR-T (WS-CART-CS1) in Subjects With Multiple Myeloma
Status: Not yet recruiting, Estimated PCD: 2029-06-30
Product
WS-CART-CS1
Product
Lymphodepleting chemotherapy
Clinical trial
A Pilot/Feasibility Trial of 64Cu-DOTA-Daratumumab Positron Emission Tomography in Patients With Newly Diagnosed or Relapsed Multiple Myeloma
Status: Completed, Estimated PCD: 2020-01-22
Drug
89Zr-DFO-YS5
Clinical trial
Elotuzumab in Combination With Carfilzomib, Lenalidomide and Dexamethasone (E-KRd) Versus KRd Prior to and Following Auto-SCT in Newly Diagnosed Multipe Myeloma and Subsequent Maintenance With Elotuzumab and Lenalidomide Versus Single-Agent Lenalidomide- A Phase III Study by DSMM
Status: Active (not recruiting), Estimated PCD: 2029-08-01
Clinical trial
A Multicenter, Open Label Study Of Oral Revlimid And Prednisone (Rp) Followed By Oral Revlimid Melphalan And Prednisone (Mpr) In Newly Diagnosed Elderly Multiple Myeloma Patients
Status: Completed, Estimated PCD: 2012-08-01
Product
RP
Clinical trial
Daratumumab, Pomalidomide and Dexamethasone for Del(17p) Positive Relapsed and Relapsed/Refractory Multiple Myeloma Patients [DEDALO]
Status: Active (not recruiting), Estimated PCD: 2024-07-01
Clinical trial
A Randomized Phase II Study of DaRatumumab, Ixazomib, and Dexamethasone vs Daratumumab, Bortezomib (VElcade) and Dexamethasone Followed by Daratumumab-Ixazomib-Dexamethasone in Newly Diagnosed Multiple Myeloma (DeRIVE Study)
Status: Active (not recruiting), Estimated PCD: 2024-07-31
Clinical trial
A Phase 1b/2 Proof-of-Concept Study of the Combination of ACP-196 (Acalabrutinib) and Pembrolizumab in Subjects With Hematologic Malignancies
Status: Active (not recruiting), Estimated PCD: 2020-07-14
Clinical trial
LCI-HEM-MYE-KRdD-001: Phase II Study of Daratumumab Combined With Carfilzomib, Lenalidomide and Dexamethasone in Newly Diagnosed Multiple Myeloma
Status: Active (not recruiting), Estimated PCD: 2023-06-28
Product
Carfilzomib, Lenalidomide, Dexamethasone + Daratumumab
Clinical trial
IIT2017-03-Merin-HaploBFR: Bendamustine, Fludarabine, And Rituximab Conditioning For Haploidentical Stem Cell Transplantation With CD56-Enriched Donor Cell Infusion For Relapsed/Refractory Lymphoma, Multiple Myeloma, and CLL
Status: Active (not recruiting), Estimated PCD: 2021-11-07
Product
CD56-Enriched Donor Lymphocyte Infusion
Clinical trial
A Study of Outpatient Administration of Teclistamab, a BCMA-targeting Bispecific Antibody, in Multiple Myeloma Patients
Status: Recruiting, Estimated PCD: 2025-01-01
Clinical trial
Safety and Efficiency of BCMA CAR-T Cell Therapy in High-risk NDMM Patients With Positive MRD After First-line ASCT: a Prospective, Single-arm, Single-center, Phase II Study.
Status: Recruiting, Estimated PCD: 2025-05-01
Clinical trial
A Phase 3 Randomized Study Comparing Teclistamab in Combination With Daratumumab SC (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma
Status: Active (not recruiting), Estimated PCD: 2025-08-01
Clinical trial
A Phase 2 Study of Nivolumab Combined With Daratumumab With or Without Low-dose Cyclophosphamide in Relapsed/Refractory Multiple Myeloma
Status: Completed, Estimated PCD: 2023-01-25
Product
nivolumab-daratumumab
Product
Nivolumab-Daratumumab
Clinical trial
A Phase 2 Study of PHE885, B-cell Maturation Antigen (BCMA)- Directed CAR-T Cells in Adult Participants With Relapsed and Refractory Multiple Myeloma.
Status: Active (not recruiting), Estimated PCD: 2025-12-16
Clinical trial
Clinical Outcomes and Prognostic Factors in Patients With Multiple Myeloma in Assuit University Hospitals ( Prospective and Retrospective Study)
Status: Not yet recruiting, Estimated PCD: 2025-08-01
Clinical trial
A Phase 1, First-in-Human, Multicenter, Open-Label, Two-Part Dose-Escalation and Cohort Expansion Study of Single-Agent ISB 1342 in Subjects With Previously Treated Multiple Myeloma
Status: Completed, Estimated PCD: 2023-12-15
Product
ISB 1342
Clinical trial
A Phase II Study of Minocycline vs. Placebo to Prevent Treatment Induced Neuropathy in Multiple Myeloma
Status: Completed, Estimated PCD: 2022-08-22
Product
Minocycline
Clinical trial
Comparing the Efficacy and Safety of Autologous Hematopoietic Stem-cell Transplantation Versus Non Transplantation Regimen in Primary Multiple Myeloma Achieved MRD Negativity After Induction: A Multiple Center, Prospective Cohort Study
Status: Recruiting, Estimated PCD: 2028-11-01
Product
Transplant, Autologous
Clinical trial
Comparison of the Effects of Prophylactic Administration of Apixaban on Thrombin Generation in Patients With de Novo Multiple Myeloma and Patients Undergoing a Surgery for Total Knee Replacement
Status: Not yet recruiting, Estimated PCD: 2026-05-30
Clinical trial
Phase 2 Study of Descartes-08 Consolidation Treatment in Patients With High-Risk Multiple Myeloma Who Have Residual Disease After Induction Therapy
Status: Terminated, Estimated PCD: 2022-08-04
Product
Descartes 08
Clinical trial
Phase I Safety and Feasibility Study of Autologous CD8+ T-cells Transiently Expressing a Chimeric Antigen Receptor Directed to B-Cell Maturation Antigen in Patients With Multiple Myeloma
Status: Terminated, Estimated PCD: 2021-04-19
Product
Descartes-08
Clinical trial
A Phase 1b, Multicenter, Open-Label, Study to Investigate the Safety and Efficacy of CLN-619 (Anti-MICA/MICB Antibody) in Patients With Relapsed and Refractory Multiple Myeloma
Status: Not yet recruiting, Estimated PCD: 2026-09-01
Drug
CLN-619
Clinical trial
A Randomized Phase 2 Trial to Evaluate Three Daratumumab Dose Schedules in Smoldering Multiple Myeloma
Status: Active (not recruiting), Estimated PCD: 2023-06-02
Drug
daratumumab
Clinical trial
A Phase 2 Study With Safety Run-In of Marizomib, Pomalidomide, and Dexamethasone For Relapsed and Refractory Multiple Myeloma and CNS Myeloma
Status: Not yet recruiting, Estimated PCD: 2025-12-02
Product
Marizomib
Clinical trial
A Pilot Study of Lenalidomide Alternating With Ipilimumab Post Allogeneic and Autologous Stem Cell Transplantation
Status: Completed, Estimated PCD: 2024-05-03
Drug
Lurbinectedin
Clinical trial
A Phase I/IIa Clinical Trial to Assess Feasibility, Safety and Antitumor Activity of Autologous SLAMF7 CAR-T Cells in Multiple Myeloma
Status: Active (not recruiting), Estimated PCD: 2025-12-01
Product
SLAMF7 CAR-T
Clinical trial
Phase 1 of Exposure Targeted Melphalan Dosing
Status: Recruiting, Estimated PCD: 2026-06-30
Clinical trial
A PHASE 3, MULTICENTRE, RANDOMIZED, CONTROLLED STUDY TO DETERMINE THE EFFICACY AND SAFETY OF LENALIDOMIDE, MELPHALAN AND PREDNISONE (MPR) Versus MELPHALAN (200 mg/m2) FOLLOWED BY STEM CELL TRANSPLANT IN NEWLY DIAGNOSED MULTIPLE MYELOMA SUBJECTS
Status: Active (not recruiting), Estimated PCD: 2022-06-01
Clinical trial
A Real World Study of Equecabtagene Autoleucel in Subjects With Relapsed and Refractory Multiple Myeloma.
Status: Not yet recruiting, Estimated PCD: 2026-08-20
Product
Equecabtagene Autoleucel
Clinical trial
An Attenuated Schedule Dara-RVd Induction for Patients With Newly Diagnosed Multiple Myeloma Who Are Eligible for Autologous Stem Cell Transplantation
Status: Not yet recruiting, Estimated PCD: 2026-05-01
Clinical trial
A Phase 1b Study of Subcutaneous Daratumumab Regimens in Combination With Bispecific T Cell Redirection Antibodies for the Treatment of Subjects With Multiple Myeloma
Status: Active (not recruiting), Estimated PCD: 2024-09-09
Clinical trial
A Phase 3 Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE, Lenalidomide, and Dexamethasone (VRd) in Subjects With Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy
Status: Active (not recruiting), Estimated PCD: 2025-08-29
Clinical trial
A Phase 3b, Multicenter, Open-label, Daratumumab Long-term Extension Study
Status: Recruiting, Estimated PCD: 2026-01-30
Clinical trial
Panobinostat Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant for Patients With Refractory/Relapsed Myeloma
Status: Completed, Estimated PCD: 2024-06-03
Clinical trial
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation - MajesTEC-4
Status: Recruiting, Estimated PCD: 2028-04-01
Clinical trial
An Open-Label, Non-Randomized, Multicenter, Phase II Study to Study the Efficacy of Talquetamab (JNJ-64407564) and Lenalidomide as Post Stem Cell Transplant Maintenance in Multiple Myeloma (OPTIMMAL)
Status: Not yet recruiting, Estimated PCD: 2025-06-01
Clinical trial
A Study of ALT-801 in Patients With Relapsed or Refractory Multiple Myeloma
Status: Terminated, Estimated PCD: 2015-09-09
Product
ALT-801
Clinical trial
A Phase 1b Trial of Teclistamab in Combination With Iberdomide for Relapsed/Refractory Multiple Myeloma
Status: Not yet recruiting, Estimated PCD: 2027-01-30
Abstract
https://www.abstractsonline.com/pp8/#!/20272/presentation/11419
Clinical trial
A Clinical Study to Evaluate the Safety, Tolerance and Efficacy of LCAR-M61S and LCAR-M61D Cell Preparations in Patients With Relapsed/Refractory Multiple Myeloma
Status: Not yet recruiting, Estimated PCD: 2028-08-22
Product
LCAR-M61S
Product
LCAR-M61D
Clinical trial
Prospective Observational Study on the Clinical Efficacy of Teclistamab in Patients With Relapsed and Refractory Multiple Myeloma in Belgium
Status: Not yet recruiting, Estimated PCD: 2027-09-01
Clinical trial
An Open-Label, Multicenter, Phase I Trial Evaluating The Safety And Pharmacokinetics Of Escalating Doses Of RO7297089 In Patients With Relapsed Or Refractory Multiple Myeloma
Status: Completed, Estimated PCD: 2022-02-23
Product
RO7297089
Clinical trial
Phase II Study of the Combination of Daratumumab, Ixazomib, Pomalidomide, and Dexamethasone as Salvage Therapy in Relapsed/Refractory Multiple Myeloma A University of California Hematologic Malignancies Consortium Protocol (UCHMC1809)
Status: Active (not recruiting), Estimated PCD: 2025-03-01
Product
Daratumumab-Hyaluronidase-Fihj
Clinical trial
A RANDOMIZED, MULTICENTER, OPEN LABEL STUDY COMPARING TWO STANDARD TREATMENTS, BORTEZOMIB-MELPHALAN-PREDNISONE (VMP) WITH OR WITHOUT DARATUMUMAB (Dara-VMP) VS LENALIDOMIDE-DEXAMETHASONE (Rd) WITH OR WITHOUT DARATUMUMAB (Dara-Rd) IN AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) INELIGIBLE COMMUNITY POPULATION AFFECTED BY MULTIPLE MYELOMA (MM)
Status: Recruiting, Estimated PCD: 2025-01-03
Clinical trial
A Phase 1 With Extension Cohort, Single Arm, Single Center, Open Label Trial of Belantamab Mafodotin for the Treatment of High-Risk Smoldering Multiple Myeloma (BELLA)
Status: Recruiting, Estimated PCD: 2027-02-02
Clinical trial
Phase 2 Trial of Belantamab Mafodotin Consolidation Treatment in Patients With Multiple Myeloma and MRD Positivity After Autologous Stem Cell Transplantation
Status: Recruiting, Estimated PCD: 2026-09-01
Clinical trial
MATCH Treatment Subprotocol P: Phase II Study of PI3K Beta Specific Inhibitor, GSK2636771, in Patients With Tumors With PTEN Loss by IHC
Status: Active (not recruiting), Estimated PCD: 2024-11-30
Clinical trial
MATCH Treatment Subprotocol Z1E: Larotrectinib (LOXO-101) in Patients With Tumors With NTRK Fusions
Status: Active (not recruiting), Estimated PCD: 2025-03-24
Clinical trial
A Randomized, Double-blind, Placebo-Controlled Phase II Trial of an Allogeneic Myeloma GM-CSF Vaccine With Lenalidomide in Multiple Myeloma Patients in Complete or Near Complete Remission
Status: Active (not recruiting), Estimated PCD: 2024-01-02
Product
GM-CSF
Product
Prevnar13
Clinical trial
A Phase 3 Randomized Study Comparing Talquetamab in Combination With Pomalidomide (Tal-P), Talquetamab in Combination With Teclistamab (Tal-Tec), and Investigator's Choice of Either Elotuzumab, Pomalidomide, and Dexamethasone (EPd) or Pomalidomide, Bortezomib, and Dexamethasone (PVd) in Participants With Relapsed or Refractory Myeloma Who Have Received 1 to 4 Prior Lines of Therapy Including an Anti-CD38 Antibody and Lenalidomide
Status: Recruiting, Estimated PCD: 2026-04-23
Drug
panobinostat
Drug
Trastuzumab
Clinical trial
Exploratory Study Evaluating the Interest of PET to 18F-Fludarabine for the Initial Assessment and End-treatment Evaluation of Patients With Symptomatic Multiple Myeloma in the First Line of Treatment, Not Candidates for Marrow Autograft
Status: Recruiting, Estimated PCD: 2024-09-09
Product
18F-Fludarabine
Product
Talquetamab and Lenalidomide
Clinical trial
A Phase III Randomized, Controlled Study of Equecabtagene Autoleucel Injection in Subjects With Lenalidomide-Refractory R/R Multiple Myeloma
Status: Recruiting, Estimated PCD: 2027-08-01
Clinical trial
A Phase 1, Open-Label Safety, Pharmacokinetic and Efficacy Study of TAS4464 in Patients With Multiple Myeloma or Lymphoma
Status: Terminated, Estimated PCD: 2018-02-01
Product
TAS4464
Clinical trial
The Effect of Novel Treatments in Improving Renal Outcomes Among Patients With Light Chain Cast Nephropathy
Status: Recruiting, Estimated PCD: 2025-06-01
Clinical trial
Measurable Residual Disease-Guided Post-Transplant Elranatamab Maintenance Using Peripheral Blood Clonotypic Mass Spectrometry
Status: Not yet recruiting, Estimated PCD: 2031-09-30
Product
Elrantamab
Clinical trial
An Open-label, Multi-center Phase I Clinical Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of SHR-9539 Injection in Patients With Multiple Myeloma
Status: Not yet recruiting, Estimated PCD: 2027-07-31
Product
SHR-9539